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Abstract 
Liquid extraction surface analysis (LESA) is an ambient ionisation technique which 
allows direct analysis of surfaces coupled with mass spectrometry. LESA mass 
spectrometry has been used successfully to analyse small molecules, but there are a 
limited number of examples where the approach has been applied to protein 
analysis. The work presented here aims to develop novel applications of LESA mass 
spectrometry of proteins.  LESA mass spectrometry was used to analyse intact 
proteins from polymeric membranes. The rationale for these experiments was the 
potential application to analyse proteins electroblotted following polyacrylamide gel 
electrophoresis, i.e., top-down proteomics, and in air monitoring. The subsequent 
focus was dried blood spot (DBS) analysis. An automated LESA based trypsin 
digestion protocol was developed and coupled with liquid chromatography tandem 
mass spectrometry to enable DBS proteomics, i.e., untargeted global protein 
identification via a bottom-up approach.  Approaches for DBS proteomics (in the 
absence of LESA) were explored further using conventional digestion procedures 
coupled with protein depletion. LESA was also applied for targeted analysis of 
proteins from DBS, to determine variants of alpha-1-antitrypsin.  Finally, native LESA 
mass spectrometry was developed to analyse non-covalent complexes from dried 
surfaces. Native LESA mass spectrometry successfully identified the haemoglobin 
tetramer directly from DBS. 
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Chapter 1 : Introduction 
 
 
1.1 Overview  
In the first decade of the 21st century a range of ambient ionisation techniques were 
introduced to mass spectrometry as a means of investigating surface associated analytes. 
Surface analysis made a range of analytically relevant surfaces accessible to mass 
spectrometry. Several ambient ionisation techniques, including liquid extraction surface 
analysis (LESA) [1], are based on electrospray ionisation. Electrospray ionisation and LESA 
are both soft ionisation techniques which makes them ideally suited for ionising non-
volatile macromolecules such as proteins and peptides. The aim of the work contained 
within this thesis is to develop new applications of LESA mass spectrometry in the field of 
protein analysis.  
LESA has previously been successfully used for the analysis of intact haemoglobin 
proteins from DBS [2]. This thesis aims to extend this work and develop novel 
methodology and applications of LESA. The work presented in Chapter 3 focuses on the 
analysis of intact proteins from polyvinylideneflouride (PVDF) membranes, and 
investigation of the possibilities of analysing proteins electroblotted from sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDSPAGE). The work presented in Chapter 4 
investigates the application of LESA for the bottom up proteomics of dried blood spots. 
Bottom-up proteomics of dried blood spots is explored further in Chapter 5, with the 
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emphasis on solution phase chemistry, specifically the incorporation of immunodepletion 
strategies to aid analysis of low abundance proteins in DBS. The work presented in 
Chapter 6 is aimed at targeted analysis of proteins found in DBS, i.e., variants of the 
alpha-1-antitrypsin (A1AT), using LESA. The aim of the work presented in Chapter 7 is to 
develop LESA as a means for investigating non-covalent protein complexes directly from 
surfaces, focussing on tetrameric haemoglobin from DBS. 
 
1.2 Mass spectrometry  
1.2.1 Introduction to mass spectrometry 
 
Mass spectrometry is a powerful tool for the analysis of molecular structure based on 
measuring the mass to charge ratio of ions. There are 3 basic components in mass 
spectrometry. The first stage is the formation of ions from a neutral substance. The next 
stage is mass analysis which separates ions on the basis of their mass-to-charge (m/z) 
ratio before the final stage which is detection of the separated ions.  Mass analysis and 
detection always takes place under a very high vacuum and so too do several ionisation 
techniques [3]. 
The first mass spectrometers were built around a hundred years ago by particle physicists 
studying the electrical conductivity of gases. The very first mass spectrometer was built in 
1912 by J.J. Thomson and his assistant F W Aston [4]. They developed an instrument they 
called the parabola spectrograph [5]. Thomson successfully obtained mass spectra of 
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several different gases and demonstrated that neon is composed of 2 different isotopes. 
The instrument was further improved by Aston who proved that 53 of the known 
elements had multiple isotopes and was later awarded the 1922 Nobel prize in chemistry 
for his efforts [4]. The field of mass spectrometry has changed immensely since then.  It 
changed from largely a physical to chemical analysis technique in the 1940s and became 
an important tool for analysing biological samples in the 1980s [6].  
1.2.2 Ionisation 
Analysis of proteins by mass spectrometry was not possible until the late 1980s when two 
new soft ionisation techniques were developed: electrospray ionisation (ESI) and matrix 
associated laser desorption ionisation (MALDI) [3]. Forming ions from large non-volatile 
macromolecules is perhaps the biggest challenge for an ionisation method [7]. Before the 
introduction of ESI and MALDI, the most established ionisation mechanisms were 
electron ionisation (EI) and chemical ionisation (CI). These mechanisms vaporise a 
substance then bombard it with electrons in EI or reagent gases in CI. Both are able to 
produce ions of volatile species with high vibrational energy states. Ions formed by either 
technique are liable to undergo extensive decomposition and so these techniques are 
unsuitable for most biological samples [3].  As a result of their efforts the inventors of ESI 
and MALDI, John Fenn and Koichi Tanaka were awarded the 2002 Nobel prize in 
chemistry [8]. 
1.2.2.1. Electrospray ionisation 
Electrospray ionisation (ESI) is an electrochemical process which produces gas phase ions 
from solution phase solubilised analytes. It has become the most widely used ionisation 
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method for the analysis of proteins and peptides and is largely responsible for 
advancements in proteomics research during the past few decades. The first report of 
using ESI for protein and peptide analysis was published in 1989,[9] but the ideas have 
been under development since the 1960s by Dole and co workers [10].  The group 
proposed a method for creating ions by using a pressurised gas to spray solutions of 
analytes through a highly charged hypodermic needle tip at atmospheric pressure. The 
effect of this was to disperse the solution into a mist composed of fine droplets. Solvent 
molecules within the droplets would evaporate and leave behind charged gas phase ions. 
Dole used this technique to ionise polystyrene molecules in solutions of acetone and 
benzene. It successfully produced gas phase ions of large polymers and, because the 
mechanism did not rely on bombardment with electrons or harsh chemicals, the ions 
remained intact and did not fragment [10]. Nevertheless the method needed refining and 
it was another 20 years before the idea was taken further. The biggest problem was that 
the process formed highly solvated clusters rather than individual gas phase ions, and the 
technology available lacked the ability to detect them. Mass analysers available in the 
1960s were not sensitive enough to detect the ion currents provided by a low energy 
ionisation mechanism  and lacked the resolution for measuring m/z ratios of multiply 
charged macromolecules [11]. ESI was further refined in the 1980s by John Fenn and co 
workers [9, 12]. Fenn’s method differed from Dole’s in a number of features:  samples 
were sprayed in an aqueous organic mixture, a drying gas was used to desolvate the ions 
and samples were sprayed through a glass capillary with metal electrodes at either end to 
create a potential [12]. The drying gas successfully eliminated the problem of forming 
solvated ion clusters. The gas flowed against the direction of spray which helped desorb 
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the ions from the solvent molecules. The drying gas helped form individual gas phase ions 
rather than solvated ion clusters that were produced in Dole’s method [12, 13]. The 
process is illustrated in Figure 1.1. By the 1980s mass analysers had become more 
sensitive, and the focus of mass spectrometry research had begun to change from 
organic compounds to biological samples and the technique was demonstrated for use in 
protein and peptide analysis [9].  
 
 
Figure 1.1. Illustration of the electrospray ionisation process 
 
There are two mechanisms proposed to explain ion formation during ESI.  Their influence 
appears to depend on the analyte being ionised [14]. Both explain ion formation in a 
similar way, and can be understood by considering the effect that electrical charging has 
upon liquids.  A positive electric potential is applied to the capillary which generates 
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electrical repulsion forces within the liquid [15]. The repulsive forces push the liquid away 
from the capillary and the surface tension at the liquid air boundary of the droplet pulls 
back. When the two forces are equal, a conical shape known as the Taylor cone forms at 
the liquid air boundary [15]. This phenomenon was described by Taylor in 1964 [16]. If 
the electrical charging increases and the repulsion becomes greater than the surface 
tension, small droplets are emitted in a jet from the cone apex. The counter electrode of 
the mass spectrometer is held at a negative potential, which attracts the droplet emitted 
from the capillary and a small current is generated [17]. This process disperses analytes 
from the solution towards the inlet of a mass spectrometer within small highly charged 
droplets.  Charge transfer can be explained by either the charged residue or ion 
evaporation model.  After the charged droplets have left the capillary solvent molecules 
begin to evaporate. As the volume of the droplets decreases the charge density increases. 
Eventually the repulsive forces of the charged droplets rises above the surface tension of 
the liquid and the droplets explode [18]. The point where the surface tension is equal to 
the electrostatic repulsion is known as the Rayleigh limit and is shown in equation 1.1. 
After each droplet explodes several new droplets form and the process repeats producing 
smaller droplets after each fission cycle  [17]. 
 
𝑄𝑅 = 8𝜋(𝜀0𝛾𝑅
3)1 2⁄  
Equation 1.1 The Rayleigh limit, where QR = the number of surface charges of the droplet at the  Rayleigh limit, ε0 = 
the permittivity of the solvent, γ = the surface tension of the solvent and R = the radius of the droplet  [18]. 
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Fission and evaporation of the droplets takes place in both models but the final stages 
are slightly different. The ion evaporation model assumes that the charged droplets 
become so small and the charge density becomes so great that the repulsive forces are 
strong enough to push a charged solute ion out from the droplet [19].  Evaporation of a 
charged ion introduces a desolvated gas phase ion into the vacuum of the instrument 
[20]. Ion evaporation is different to the continual evaporation of neutral solvent 
molecules that forms the small droplets. Ion evaporation takes place when the droplets 
are smaller than 20 nm in diameter [21].  At this point the droplet must contain more 
than one solvent molecule, the electrostatic repulsion must be large enough to push the 
solute molecule out of the droplet and it must be larger than the critical radius of the 
Rayleigh limit to prevent further droplet fission [20].  The charged residue model was 
proposed in Dole’s 1968 paper on ESI and assumes that droplet fission becomes a more 
important factor in ion formation. In this case droplets repeatedly burst and reform, 
becoming so small that they reach a point when the final droplets contain only one 
solvent molecule. The final solvent molecule then evaporates and the charge is retained  
on the non-volatile solute molecule [19]. High molecular weight multiply charged ions are  
ionised by the charged residue model and smaller singly charged species are ionised by 
ion evaporation [14]. 
 
ESI is a very versatile ionisation technique. It is capable of ionising a wide range of 
different compounds of almost any molecular weight [22]. Its most significant application 
has been for the analysis of proteins and peptides which presents a challenge for most 
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other ionisation techniques.  ESI suits protein and peptide analysis for several reasons. It 
is a soft ionisation mechanism that produces intact quasimolecular ions with low internal 
energy  which causes little or no fragmentation [23, 24].  ESI is also capable of producing 
ions from non-volatile and thermally labile species [24]. ESI is unique amongst ionisation 
mechanisms in that it produces multiply charged species of high molecular weight [25].  
Multiply charged peaks  are particularly useful for analysing proteins and peptides as the 
operating m/z ranges of many commercial available mass spectrometers such as ion 
traps, orbitraps and quadrupoles  have upper m/z limits of around 2000 Th[26-28]. 
Proteins and peptides are large molecules so the presence of multiple charges helps bring 
these large ions into the operating ranges of these instruments.   Introducing ions directly 
from the solution phase into the gas phase means that ESI is easily coupled to a liquid 
chromatography system[13]. Proteomics experiments often require analysis of complex 
mixtures of proteins and peptides which require separation before analysis. Liquid 
chromatography can be performed with online ESI mass spectrometry analysis. The liquid 
chromatograph separates the complex mixture into its constituents which then directly 
elute from the column and  are introduced into the mass spectrometer [29]. 
Since ESI was introduced it has become widely-used for the introduction of samples at 
lower flow rates. Fenn’s original technique  used flowrates of around 1-20μl per minute 
[9].  ESI flow rates have now dropped to a few tens of nanolitres per minute which  is 
referred to as nanoelectrospray [30]. Electrospraying samples at lower flow rates has a 
number of advantages: the approach is more sensitive, couples to HPLC more efficiently 
and consumes less sample [30]. Most of the advantages are due to the fact that the 
process forms a smaller Taylor cone which produces smaller droplets in the ESI. Smaller 
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droplets have a greater charge per surface area and require fewer fission cycles to 
produce gas phase ions. Smaller droplets also contain less solvent which are easier to 
desolvate [31].  The smaller Taylor cone means that the ESI can be placed closer to the 
orifice of the mass spectrometer so more of the ions are introduced into the instrument 
[26]. The smaller Taylor cone also reduces the amount solvent entering the instrument 
which is less demanding on the vacuum system [26].  Nanoelectrospray is less sensitive to 
the effects of ion suppression from contaminants and ensures greater charging of the 
analyte molecules than conventional flowrates [32]. 
  
1.2.2.2 Ambient ionisation 
ESI became established as the ionisation method of choice for the analysis of proteins 
and peptides in the 1990s and proteomics became an important field of biomedical 
research. The 21st century saw the development of a range of techniques for sampling 
analytes from the surface of a solid object at ambient conditions, then directly ionising 
and introducing them into a mass spectrometer.  These became known as ambient 
ionisation techniques [33]. The term is slightly misleading:  Many previously existing 
ionisation techniques   such as conventional ESI, atmospheric pressure chemical 
ionisation and atmospheric pressure photo ionisation take place at ambient pressures but 
are not included in this category [34].  What they all have in common is that they directly 
sample a surface at ambient conditions with little or no prior sample preparation. Most 
ambient ionisation techniques incorporated a sampling procedure into a previously 
existing ionisation technique such as ESI or laser  desorption [35]. There are many 
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different variations available and over 40 different ambient ionisation techniques have 
been described [35]. The development of ambient ionisation techniques became very 
popular after the invention of desorption electrospray ionisation (DESI) in 2004 [36]. DESI 
is an ESI based technique. A solvent is electrosprayed towards a surface by use of an 
electric field and nebulising gas.  When the charged droplets strike the surface they 
desorb analytes from the surface which are directed into the inlet of a mass 
spectrometer. DESI can be used to analyse a surface without any sample preparation 
[36]. The technique has been used in analysis of dried blood spots, plant tissues, drugs 
and many other surfaces [37-39]. It was significant in  demonstrating the utility of directly 
sampling surfaces of interest outside the instrument and several other techniques were 
developed to investigate this idea further, including direct analysis in real time in 2005, 
[40] paper spray ionisation in 2009 [41] and LESA.  
 
LESA is a sampling method that is often considered to be an ambient ionisation technique 
[42]. It was launched commercially by Advion Biosciences as one of the modes of function 
on their Triversa Nanomate™ nanoelectrospray platform [1]. The principle behind the 
extraction technique was developed in 2002 by Gary Van Berkel  [43]. It was an ESI based 
process that was originally designed to extract small molecules from thin layer 
chromatography (TLC) plates for analysis by mass spectrometry.  The researchers 
constructed a homemade surface sampling probe composed of two capillary tubes, one 
inside the other. A solvent would be applied to the surface through the outer capillary 
which would be aspirated through the central capillary and interfaced with an ESI source. 
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Depositing the solvent onto the surface of the TLC plate created a wall-less liquid 
microjunction between the surface, the analytes and the probe. The liquid microjunction 
allows passive diffusion of analyte molecules from the surface which could then be 
aspirated into the sampling probe and introduced into the mass spectrometer [43]. The 
process was originally known as the liquid microjunction surface sampling probe (LJM 
SSP). In 2010 the technique was adapted to be merged onto the Triversa Nanomate™ [1]. 
Van Berkel’s original probe used a continuous flow source that would continually apply 
solvent to the surface from one capillary which would then be continually aspirated 
through another. The Triversa Nanomate™ could not accommodate continuous flow as 
its probe consists of a robotic pipettor which could only perform discrete aspiration or 
dispense cycles.  As an alternative a single droplet was aspirated from a solvent reservoir, 
and applied to the surface.  The single droplet formed the liquid micro junction between 
surface sampling probe and the surface, and would be held in contact for a few seconds. 
Analytes would diffuse into the solvent via passive diffusion and after the delay the 
droplet would be re aspirated and directly injected into the mass spectrometer via chip 
based ESI [1]. An outline of the extraction process can be shown in Figure 1.2. 
 
Figure 1.2. Illustration of LESA sampling routine 
 
12 
 
The Triversa Nanomate™ infuses samples via a variant of nanoelectrospray known as chip 
based ESI.  In this process, the glass capillaries used in conventional ESI are replaced with 
a conductive pipette tip and a small chip composed of monolithic silicon. The chip has a 
series of 10 μm nozzles etched into it and act as the ESI emitters[44]. The robotic pipette 
tip filled with the ESI solution is sealed against the chip, a gas and a voltage are applied 
which spray the solution through the micro fabricated nozzles [45]. The chip based ESI is 
similar to conventional ESI, but produces highly stabile ESI currents and easy control of 
ionisation parameters [45]. An image of the chip is shown in fig 1.3. 
 
Figure 1.3 Triversa Nanomate™ ESI chip 
 
  LESA uses a soft ionisation technique that makes it applicable for a wide range of 
analytes including non-volatile macromolecules. Data have been published   on the 
analysis of small organic molecules, lipids, peptides and intact proteins [2, 46-48]. LESA 
makes it possible to analyse a range of substances directly from surfaces in a manner that 
requires no sample preparation. It is non-destructive with the regards to the surface;  it 
does consume the analyte but only a tiny amount is extracted and this often allows 
repeated sampling [2, 49]. LESA has been used successfully in the analysis of tissue 
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sections to monitor drug metabolism in pharmacokinetic studies[46]. After a drug has 
been administered to an animal, different areas of the tissue section can be sampled to 
identify the presence of the drug in different organs. LESA can be used as an alternative 
to whole body  autoradiography, with the added advantage that it requires no sample 
preparation other than sectioning the tissue, it can distinguish the parent drug from its 
metabolites and can provide relative quantification [46, 49]. Applications of LESA have 
also been demonstrated in assessing the safety of foods by Eikel et al. [50]. The group 
used it to identify the presence of pesticides on fruits and vegetables and the method 
could distinguish whether the pesticides were on the surface or within the flesh [50]. 
LESA has been  used for environmental applications, such as identifying the presence of 
brominated flame retardants in waste plastics [51].  Other applications have been 
demonstrated for use in biomedicine such as identifying biomarkers and for diagnostic 
purposes.  Stegemann et al. [47] used LESA as a method for identifying lipids directly from 
the surface of human endarterectomies to identify biomarkers of atherosclerosis. The 
group studied arterial tissue from healthy controls and patients suffering from 
atherosclerosis. They identified 150 different lipids, 25 of which were unique to 
endarterectomies and found that LESA performed as well as direct infusion ESI of tissue 
lipid extracts [47]. Edwards et al. [2]demonstrated an application for the analysis of intact 
haemoglobin proteins from DBS by use of liquid extraction surface analysis. The work was 
the first time intact proteins had been analysed using LESA, and was able to distinguish 
clinically significant haemoglobin variants such as sickle cell disease. The method could 
analyse the proteins directly from the surface of the DBS with no sample preparation in a 
time period as little as 3 minutes per sample [2].   
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1.2.3 Mass analysers 
Three different mass spectrometers were used in the work carried out in this thesis. 
These three were an Orbitrap Velos™ ETD mass spectrometer, a triple stage quadrupole 
(TSQ) Vantage™ mass spectrometer and a Waters Synapt™ Quadrupole-time of flight 
mass spectrometer.  
 
1.2.3.1The Orbitrap mass spectrometer 
In 2005 a new mass spectrometer with a new method of mass analysis was released by 
Thermo Electron. The instrument was known as the orbitrap mass spectrometer and had 
been under development by Alexander Makarov since the mid 1990s and patented in 
1999 [52].  
 
The orbitrap mass spectrometer  uses an electrostatic trapping principle for storing ions. 
It uses image current based detection and Fourier transformations for signal processing 
[53].  The orbitrap cell is a small unit composed of two different electrodes, an inner 
spindle electrode encased within a larger barrel like electrode [53]. An illustration of the 
orbitrap is shown in Figure 1.4.  
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Figure 1.4 Schematic diagram of the orbitrap cell (A) Geometry of trap, (B) Geometry of trap showing axis of 
movemant and charachterstic ion motion 
 
There is a small space between the two electrodes for ion storage and the trap measures 
a diameter of a few centimetres [54].  A potential is applied between the two electrodes 
which generates a static electric field. The central electrode is held at a negative potential 
of around -5 kV and the outer electrodes are held at a ground potential. Ions are injected 
into the trap at a tangent to the spindle electrode and form an orbit around it. The 
motion traps the ions within an electrostatic field which can be described by equation 
1.2.  
 
𝑈(𝑟,𝑧) =
𝑘
2
(𝑧2 −
𝑟2
2
) +
𝑘
2
(𝑅𝑚)
2 ln [
𝑟
𝑅𝑚
] + 𝐶 
Equation 1.2. The electrostatic field of within the orbitrap cell. U = electrostatic potential, r and z are the cylindrical 
co-ordinates z is the distance along axis of the central spindle and r is the radial distance out from the centre of the 
electrode, C is a constant, k is the field curvature and Rm is the characteristic radius [55]. The characteristic radius is 
the radius of an orbit when the field stops attracting ions to the centre of the spindle electrode and begins to repel 
them [56]. 
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The trapping approach was developed in 1923 by K H Kingdon, where it was used as a 
means of storing ions and not as a mass analyser [57].   In the late 1990s when Alexander 
Makarov investigated its potential as a mass analyser and developed a new means of 
mass analysis based on axial harmonic oscillations of ions along the spindle electrode 
during orbit. As the ions orbit the spindle they are free to move up and down its z axis. 
When the oscillation is combined with the rotation of the orbit the ion paths becomes a 
series of complicated spirals. The two types of motion, oscillation up and down the z axis 
of the cell and rotation of ions around the spindle are completely independent of each 
other [55]. The total kinetic energy of an ion at orbit is affected by both types of motion 
but  the frequency of ion oscillations down the z axis is dependent on the ions mass to 
charge ratio. The motion along the z axis can be described as a simple harmonic 
oscillator, a type of motion also present in a swinging pendulum or a load on a spring 
[53].  Equation 1.3 a explains this motion and 1.3 b shows how the mass to charge ratio of 
an ion be calculated from the frequency of axial oscillations.  
 
 
a  𝑧(𝑡) = 𝑧0𝑐𝑜𝑠(𝜔𝑡) + √(2𝐸𝑧/𝑘) 𝑠𝑖𝑛(𝜔𝑡) 
b  𝜔 = √(𝑞/𝑚)𝑘 
Equation 1.3 Axial ion oscillations along the z axis of the orbitrap spindle electrode, (a) equation of motion (b) 
isolation of frequency of oscillations to give the charge to mass ratio of an ion. Where ω= the frequency of axial 
oscillations in radians/ per second Ez = energy characteristic of ion motion along the z axis k is the field curvature of 
the orbitrap cell and q/m = charge per mass ratio of an ion [55]. 
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Mass analysis  is possible because the frequency of axial oscillations along the z axis of 
the trap is dependent upon m/z and not the kinetic energy of the ions  or their conditions 
upon injection into the cell [54].  Once a packet of ions is injected into an orbitrap the 
ions will separate into narrow rings of the same m/z. The rings oscillate in both halves of 
the cell and induce a current in the outer electrodes of the cell known as an image 
current. The image current forms the basis of signal detection in the orbitrap cell [58]. 
The current is then amplified and converted from an analogue to a digital signal which 
displays the intensity of the current against time.  Displaying signal intensity in a temporal 
fashion is known as a transient. The transient is the processed with a fast Fourier 
transform. The fast Fourier transform generates a signal in the frequency domain which 
shows the frequency of the image current. The frequency of the image current is 
proportional to the frequency of axial oscillations of the ions and as shown by equation 
1.3b this frequency is directly proportional to the ions charge per mass ratio which can 
generate a mass spectrum[53]. 
 
Using image currents for detection and Fourier transformations for signal processing 
gives the orbitrap has a high mass resolution and accuracy. Orbitrap mass spectrometers 
have a mass accuracy up to 2 parts per million (ppm) with external calibration and a mass 
resolution of 240,000 for a 768 ms transient at m/z 400 [59].  Previously Fourier 
Transform Ion Cyclotron Resonance (FT ICR) had been the only instruments available for 
high resolution mass spectrometry.  
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Orbitrap mass spectrometers have been used highly effectively in conjunction with other 
mass analysers and a range of hybrid instruments are available. Combining other mass 
analysers in tandem with the orbitrap provides additional options for fragmentation and 
scanning. Linear ion trap-orbitrap hybrids are available with the Orbitrap Velos™ and 
Orbitrap Elite™ [59, 60] The former was the instrument used for the majority of the work 
in this thesis and a schematic diagram is shown in Figure 1.4.   
  
 
Figure 1.5  Schematic diagram of an Orbitrap Velos™ mass spectrometer 
 
The most crucial development in orbitrap mass spectrometry, other than the mass 
analyser itself, was the C trap as a means of introducing ions into the orbitrap. The 
orbitrap mass analyser functions at best when coupled to a pulsed ion source. Makarov’s 
prototype orbitrap mass spectrometer was coupled to a source that generated ions with 
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a pulsed laser so the two coupled well [55].  ESI was the most effective source in 
generating ions of large macromolecules like proteins and peptides which is where the 
resolution of the orbitrap would be most useful. ESI forms ions in a continuous rather 
than a pulsed manner so combining the two was a major challenge. The problem was 
eventually solved by using a radio frequency only quadrupole which was used to store 
ions produced in the spray prior to injecting them into the orbitrap. The ions were 
injected into the trap in a short pulse orthogonally from the spray source and the 
quadrupole. The quadrupole effectively decoupled the orbitrap mass analyser from the 
ESI source. Ions were injected by use of a high voltage electric pulse which lasted only a 
few hundred nanoseconds. The quadrupole had a curved shape similar to that of the 
letter “C” and was coined the C trap [61]. It is a highly successfully means of coupling the 
trap to an ESI source and has been used in every orbitrap mass spectrometer released 
commercially.  
1.2.3.2 Ion trap mass spectrometry 
 The Orbitrap Velos™ mass spectrometer used in the bulk of the work shown here in this 
thesis was a hybrid instrument composed of an orbitrap and a linear ion trap mass 
analyser. The ion trap is composed of a conglomeration of four quadrupolar rod 
electrodes with an end cap at either end. A diagram of the linear ion trap is shown in 
Figure 1.6. Application of a radio frequency waveform to the quadrupolar rods generates 
an electric field that traps ions within the radial (xy) dimension and the electrodes at 
either end trap the ions within the axial (z) dimension by applying a DC voltage [62].  
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Figure 1.6 Schematic diagram and ion of a linear ion trap and axis of motion 
 
The pressure of linear ion traps is often higher than most other mass analysers; a bath 
gas is often added to the trap to help improve ion transmission. Low energy collisions 
help the ions lose kinetic energy so they spend more time in the middle of the trap which 
traps the ions more effectively [63]. The trapping method means that ions have to be 
either injected in or ejected out of the trap. Two of the planar quadruple rods have slits 
cut into them which means that ions can be ejected through the slits in a radial or out the 
ends in an axial fashion [63]. Ejection through either means is mass selective and is 
achieved by applying an AC current to resonate ions of a specific m/z [64]. During axial 
ejection the current is generated between the two planar rods with the slits and when 
performing radial ejection the AC is generated between the planar rods and the end cap.  
Mass selective ejection is the principle of mass analysis. A particular ejection voltage will 
Z 
Y 
X 
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slit 
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only eject ions of a specific m/z from the trap, so to scan a chosen m/z range these 
voltages are ramped to eject a chosen range of m/z values [65]. Once ejected from the 
trap they strike an electron multiplier detector [62] which generates a small current. The 
current is then amplified and the whole mass range can be scanned to generate a mass 
spectrum. 
 
By using mass selective ejection ions can be manipulated in a number of different ways. It 
is possible to eject one specific m/z, eject a range of m/z values or isolate a specific ion 
within the trap and ejecting all other m/z ranges [63]. Fragmentation of the trapped ions 
can be induced by collisions with the bath gas.  Without excitation the collisions are low 
energy and insufficient to yield successful fragmentation. Excitation can be induced in the 
ions by either increasing the strength of the quadrupolar field generated by the planar 
rods or by inducing a small alternating auxiliary voltage between the two end caps.  
Excitation increases ion motion which increases the energy of collisions with the bath gas 
which become great enough to produce unimolecular fragmentation [63, 66]. The ability 
of an ion trap to perform mass selective ejection enables it to perform multiple rounds of 
fragmentation [67]. 
1.2.3.3 Quadrupole mass spectrometry 
Some of the work carried out in chapter 6 was performed on a triple quadrupole mass 
spectrometer. Quadrupoles are common components of many different mass 
spectrometers, where they are used as mass filters, ion guides or mass analysers. They 
were invented in the 1950s by Wolfgang Paul.  A quadrupole is composed of a ring of four 
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hyperbolic rods, each of which has an alternating radiofrequency potential applied to it. 
At any given time two of the rods will be a positive and two will be negative which 
produces a potential difference between the two pairs [68]. An ion path is aimed through 
the centre of the device along the z axis and the radio frequency fields stabilise the 
trajectories of the ions along the x and y axes. The ions passing through the device will be 
momentarily attracted to the rods of the opposite potential, but will be counteracted by 
a repulsive force as soon as the polarities switch. A diagram of a quadrupole is shown in 
Figure 1.7.  Both the attractive and repulsive forces are proportional to the distance from 
the rods which  focus the ions in the centre of the device [68].  
 
Figure 1.7 Schematic diagram and axis of motion of ions in a quadrupole 
 
Z 
Y 
X 
Ion 
Path 
23 
 
 
The field generated by a quadrupole maintains the ions trajectories in the X and Y 
dimension. Unlike the ion trap, motion in the Z dimension is unaffected so quadrupoles 
cannot store ions in any way. The field generated between the rods is shown in equation 
4. 
 
Φ0 =  +(𝑈 − 𝑉 cos 𝜔𝑡)  𝑎𝑛𝑑 − Φ0 =  −(𝑈 − 𝑉𝑐𝑜𝑠𝜔𝑡) 
Equation 4. Quadrupolar field.  Where φ0 is the potential of the rods, ω is the angular frequency of the field in 
radians per second, t is any time point, U is the direct potential between the two rods and V is the zero to peak 
amplitude of the RF voltage [68].   
 
Equation 4 explains how quadrupoles can act as ion guides, but quadrupoles are also 
commonly used as mass filters. Mass to charge selection can be achieved by selectively 
stabilising the x and y trajectories to ions of a certain m/z range. For a given potential, 
only ions of a specific m/z will have a stable trajectory and  be transmitted through the 
device whereas others will be deflected away [6]. When the ions reach the end of the 
device they strike an electron multiplier detector which generates a current. At any one 
voltage only one m/z reaches the detector so in each scan the voltages applied to the 
rods are steadily increased so the full m/z range reaches the detector  [6]. 
 
A quadrupole can be used as a standalone instrument but is often more powerful when 
used in an array of 3 quadrupoles in series known as a triple quadrupole. The triple 
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quadrupole mass spectrometer was first demonstrated in the late 1970s and opened up 
several new options for fragmentation [69]. In this set-up the second quadrupole acts as 
a collision cell and both the first and the third quadrupole can be used to select a specific 
m/z or scan the whole range which are examples of tandem mass spectrometry 
experiments. The triple quadrupole was the first instrument available to put this idea into 
practice. Tandem mass spectrometry experiments available on triple quadrupole mass 
spectrometers include product ion scanning, precursor ion scanning, neutral loss 
scanning, and selected reaction monitoring experiments [68].  
 
 
1.2.3.4 Time of flight mass spectrometry 
The final type of mass spectrometer used for work in this thesis was a quadrupole time of 
flight (QTOF) mass spectrometer. This is a hybrid instrument, composed of a quadrupole 
and a time of flight mass analyser in tandem.  
A time of flight (TOF) mass spectrometer contains a drift tube.  An ion pulse is injected 
into the drift tube The ions receive an acceleration pulse on injection in the tube. The 
tube has a detector such as a microchannel plate at the far end [70]. The applied field is 
constant so all ions no matter what m/z have the same kinetic energy.  According to 
Newtonian mechanics the kinetic energy of a moving object is proportional to its mass 
and velocity, so ions of a different m/z will have a different velocity when the same 
kinetic energy applied.   The acceleration voltage separates out the ions in a spatial 
manner as lower m/z and faster ions will reach the detector first. The time it takes each 
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ion to reach the detector is measured and as the distance of the flight tube is known the 
velocity of the ions can be calculated [68]. The mass to charge ratio of the ion can then be 
calculated by the formula shown in equation 5.  
(𝑚/𝑧)1/2 = (
√2𝑒𝑉𝑠
𝐿
) 𝑡 
 
Equation 5. Measurement of m/z in a time of flight mass spectrometer, where Vs =accelerating potential, L = distance 
of ion path t = flight time [68]. 
 
The first TOF mass spectrometer was described in 1948 [71].  Early instruments had linear 
flight tubes that could be several meters long and had problems with poor resolution.  
They did possess good sensitivity, a fast scanning rate and could analyse ions of almost 
any m/z range. Theoretically there is no upper m/z limit of a TOF mass analyser. TOF mass 
spectrometers have undergone a number of refinements to improve their resolution. 
Early instruments had problems applying a completely uniform acceleration voltage 
across all ions. The ions would receive a range of different kinetic energies from the 
source so when the acceleration pulse was applied, the total kinetic energies of the ions 
would not be identical. Ions of the same m/z could have a different kinetic energy and 
flight time so the peaks in a spectrum would be very broad [70]. A solution is to 
accelerate the ions after a short delay, which is known as delayed extraction. In the delay 
period ions with different kinetic energies separate slightly, so receive different energies 
from the acceleration pulse. The energy applied depends on the ions’ proximity from the 
acceleration electrode and corrects for initial kinetic energies applied by the source. It 
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ensured that the energy distribution of ions is more uniform and peaks became less 
broad [70]. The resolution of a TOF can also be increased by adding a reflectron in the 
drift tube. A reflectron changes the ion path of the drift tube from a linear to a V shape. 
Both the accelerating field and the detector are at the same end of the drift tube and the 
reflectron is placed at the other [72]. Ions are injected into the drift tube are then 
reflected back to the detector by the reflectron which acts as an ion mirror. Reflectrons 
increase the path length without increasing the size of the drift tube. It helps increase 
mass resolution as the ions separate more over a greater path and the reflectron further 
corrects the kinetic energy balance of ions with the same m/z [72]. More energetic and 
faster moving ions spend more time in the reflectron so less energetic ions of the same 
m/z catch up. Instruments can contain multiple reflectrons for this purpose [73]. 
 
Time of flight mass spectrometers are the instruments of choice for pulsed ionisation 
techniques such as laser desorption ionisation and MALDI. Combining a pulsed method of 
mass analysis with a continuous ion source such as ESI is a challenge which was solved by 
use of orthogonal acceleration [74]. In this case the flight tube is set orthogonally to the 
ESI source and the ion beam.  A “pusher” is used which provides an accelerating voltage 
pulse off axis to the ion beam and injects ions into the drift tube. The velocity component 
is independent of that produced to the spray so it is not effected by initial kinetic 
energies formed upon ionisation [74]. The ion pulse last only 10-100 nanoseconds, but a 
new population of ions is not injected until the ions of the highest m/z have reached the 
detector. In this time period the ion beam will begin to fill the orthogonal pusher before 
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they are injected into the flight tube. Waiting for the previous scan to finish does mean 
the instrument has a slower scanning rate compared to conventional TOF mass 
spectrometer [74].  
 
Orthogonal acceleration time of flight mass spectrometers have been used highly 
successfully as hybrid QTOF mass spectrometers. The TOF mass analyser is used in 
tandem with two quadrupoles. The first is used to select a specific m/z which is 
fragmented in the second and then analysed by the TOF [75]. The Waters Synapt™ mass 
spectrometer used in this thesis is an example of such an instrument; however it only 
contains a single quadrupole used in tandem with a travelling wave ion mobility cell as 
shown in Figure 1.8 [76]. Quadrupole time of flight mass spectrometers have proved to 
be highly effective in analysing high m/z ions of native protein complexes [77].  
 
 
Figure 1.8 Schematic diagram of a Waters Synapt™ mass spectrometer 
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1.2.4 Tandem mass spectrometry 
 
ESI mass spectrometry is very useful for obtaining molecular weight information of intact 
proteins and proteolytic peptides. Structural information however can be obtained from 
fragment ions. The process by which a precursor ion is characterised according to its 
fragments is known as tandem mass spectrometry (MS/MS) [6]. There are multiple 
fragmentation methods available including collision induced dissociation and electron 
transfer dissociation. One of the most commonly used MS/MS protocols is product ion 
scanning. In these experiments, a mass spectrum of the precursor ions is acquired. Ions of 
a particular m/z are then fragmented and then a second mass spectrum is acquired from 
which the m/z of the fragments can be determined [78]. 
1.2.4.1 Collision induced dissociation  
 
There are a number of techniques available for fragmenting ions; the most commonly 
used technique is collision induced dissociation (CID). CID is achieved by colliding ions 
with an inert gas such as helium or argon in the mass spectrometer [79].  Increasing the 
kinetic energy of the ions will lead to higher energy collisions and this kinetic energy is 
converted to internal energy in the collision.  In proteomics, research is focused on 
peptide fragmentation. The mechanism behind CID peptide fragmentation has been 
explained by the mobile proton model [80]. The model assumes that the protons on a 
charged peptide are retained on the side chains of basic amino acid residues or the N 
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terminus of the peptide and that fragmentation takes place when the proton is 
transferred to the peptide backbone. Transfer of the proton requires energy, [80]  so CID 
increases the internal energy of ions through collisions as they pass through the mass 
spectrometer [81]. One of the downsides of CID is that the fragmentation pattern is non-
specific: the molecule breaks at the weakest or most labile bond [82]. This can make CID 
difficult for identifying labile post translational modifications, and certain amino acids 
such as proline fragments very differently to others. The presence of proline in a peptide 
tends to favour fragmentation at the N-terminal bond upstream of the proline 
residue[83].   There are a number of positions where a peptide can fragment and a 
system of nomenclature has been described by Roepstorff et al. [84] as shown in figure 
1.9.    
 
Figure 1.9 Nomenclature of peptide fragmentation and possible cleavage points [83] 
 
CID cleaves peptides at the weakest bonds, which are usually the peptide bond between 
the carboxyl group of one amino acid residue, and the amino group of another [85]. 
These fragment ions are termed either b or y ions. In a y ion the charge remains on the 
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fragment which contains the C terminus of the peptide.  The opposite is known as a b ion, 
in which the charge is retained within the N terminal fragment [85]. A population of ions 
will undergo fragmentation at various different points along the peptide, leaving a series 
of b and y fragments containing different number of residues. By finding the difference in 
mass between the peaks in a fragmentation spectrum, it is possible to deduce which 
residues were lost from each fragment and determine the sequence of the peptide. Each 
ion is given a number which counts how many amino acid residues from either the C or N 
Terminus the fragment contains. For example a C terminal fragment retaining 3 amino 
acid residues will be referred to as a y3 ion and a fragment with the N terminus and 3 
residues will be referred to as a b3 ion [85]. 
 
1.2.4.2 Selected reaction monitoring assays 
Selective reaction monitoring assays (SRM) are a specialised tandem mass spectrometry 
experiment available on triple quadrupole mass spectrometers. They are highly sensitive 
scanning methods used for targeted quantification [86].  As they are targeted 
approaches, the precursor mass of the analyte and its subsequent fragmentation pattern 
must be understood prior to analysis. To ensure maximum specificity the first quadrupole 
is tuned to only transmit the precursor m/z of the analyte, which is then fragmented in 
the second quadrupole. The third quadrupole is then tuned to only transmit a specific 
fragment or a few fragments of the analyte. The principle of double m/z scanning 
eliminates unwanted background or interfering ions from the spectrum which means the 
instrument is highly sensitive to the analyte of interest [86]. SRMs are now commonplace 
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techniques  which are used successfully for a range of analytes from small molecules to 
peptides and proteins [87]. A diagram illustrating the process can be seen in figure 1.10. 
 
Figure 1.10 illustration of an SRM scanning method 
 
1.2.5 Native mass spectrometry 
 
Since the early 1990s mass spectrometry has been used as a tool for the analysis of non-
covalent interactions. Analysing non-covalent interactions is possible because ESI is soft 
enough to retain non-covalent interactions after ionisation and this area of research has 
been dubbed native mass spectrometry. The concept was first demonstrated in 1991 
with observation of receptor-ligand, enzyme-substrate and protein-haem interactions 
[88-90]. Since then the field has expanded and many different non-covalent complexes 
have been analysed with mass spectrometry, such as protein cofactor, protein nucleic 
acid and large multi-protein complexes such as intact virus capsids [91, 92]. Native mass 
spectrometry is becoming its own distinct field of research and is beginning to become a 
useful tool in structural biology [93]. Native mass spectrometry can be used to provide 
data on the stoichiometry of a protein and interacting partners in a complex. Mass 
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spectrometry has the added advantage that it can be done with much smaller amounts of 
material and in a much shorter period of time [93]. Native mass spectrometry is often 
combined with ion mobility analysis, which is very powerful tool that can be used to 
calculate  the collision cross sectional area of an ion [94]. The collisional cross section of 
an ion can be used with molecular modelling techniques to calculate the proteins shape, 
and measure the rate of unfolding in a native protein in the gas phase [94, 95].   
Retaining non-covalent interactions after ionisation can be very challenging. The complex 
must be electrosprayed from native conditions, as close to the physiological environment 
as possible [96]. In a typical intact protein mass spectrometry experiment, the protein is 
infused in an aqueous organic mixture at a low pH. These conditions strongly denature 
the protein and expose all residues to the solvent. Basic residues are protonated,  which 
completely disrupts any native interactions [96]. In a native mass spectrometry 
experiment the protein is electrosprayed from an aqueous solution composed only of 
volatile pH buffers such as ammonium acetate. In these conditions the pH is near neutral, 
and the protein will not be denatured. Electrospraying a sample at neutral pH retains 
non-covalent interactions, but only mildly protonates the protein [97]. Proton exchange 
can only take place between highly basic residues such as lysine at the surface of the 
protein. In native conditions the complex is ionised very gently and will have a very low 
number of charges [97]. The m/z ratio of a particular protein in the native state may be 
double that of a typical denaturing experiment which can be challenging given the 
operating ranges of some mass analysers. Many mass spectrometers such as orbitraps 
have an upper m/z limit of 4000 [98]. These instruments offer high resolution but the m/z 
ratios of native complexes are usually above this. TOF mass analysers have become the 
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instruments of choice for analysing native complexes. TOF mass analysers have very high 
upper mass limits and are now available with high resolution. The resolution of a TOF 
mass analyser can now be as high as 50,000 full width half maximum (FWHM) [99] which 
makes them ideal for analysing large ions with high m/z ratios [100]. 
1.3 Proteomics 
 
1.3.1 Overview of proteomics 
Over the last 20 years improvements in mass analysers and the development of soft 
ionisation techniques have changed the focus of mass spectrometry. Early applications of 
mass spectrometry were more focused towards small organic compounds and 
petrochemicals, nowadays it is also a biological tool [5, 101]. The focus on biological 
analytes has given birth to a number of new fields including metabolomics, lipidomics and 
proteomics [102]. Proteomics is the biggest field in mass spectrometry and has become 
particularly significant since the human genome was sequenced in 2001 [103]. The aims 
are to characterise all the proteins expressed by a particular cell at specific times and 
conditions. The term proteome was originally defined to describe all the proteins coded 
for by the genome and is a challenging area of research. The genome can only act as a 
library to tell us which genes can be expressed into proteins and cannot provide any 
information on how cellular function changes at any specific point [104]. The number of 
proteins that can be expressed by an organism is far greater than the number of genes it 
contains. Messenger RNA transcripts may be alternatively spliced, or  modified to give 
many distinct products from a single gene [105]. A cell will not produce all these products 
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at once; the proteome is dynamic [106]. An organism has multiple proteomes, different 
cells and tissues types have their own distinct proteomes and these change with disease, 
environmental conditions, available nutrition and the cycle of cell growth [107]. The field 
requires a completely different method of analysis to genomics.  Proteins cannot be 
amplified in the same way the DNA can by using the polymerase chain reaction [108].  
Proteomics techniques must be highly sensitive, highly specific and be able to cope with a 
large dynamic range of protein concentrations. They must be amenable to multiplexing, 
quantification and be able to identify sites of modification. Mass spectrometry fulfils all of 
these roles and has become the technique of choice in most proteomics research [101]. 
Without mass spectrometry analysis the field would not exist to the extent it does today.   
Most proteomics experiments require the analysis of complex mixtures of proteins, 
perhaps from a cell lysate or biofluid. These samples can contain thousands of different 
proteins [109]. Even with high mass accuracy and automated database searching, it 
becomes important to separate these mixtures of proteins and peptides prior to mass 
spectrometry analysis [109]. For bottom up proteomics, there are two options for protein 
separation, gel based approaches which separate out intact proteins prior to digestion 
and solution based liquid chromatography techniques which can separate mixtures of 
proteolytic peptides [110]. 
1.3.2 Gel electrophoresis  
 
Polyacrylamide gel electrophoresis (PAGE) is a powerful technique for resolving proteins 
and can be carried out in either one or two dimensions.  One dimensional PAGE uses the 
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surfactant sodium dodecyl sulphate to separate proteins on the basis of their molecular 
weight [109].  It is known as SDS PAGE, and is well-established having been  separating 
proteins since the late 1960s [111, 112]. If PAGE is carried out in 2 dimensions the 
proteins are separated out on the basis of their isoelectric point in the first dimension, 
and then by their molecular weights after the addition of sodium dodecyl sulphate (SDS) 
in the second dimension [113]. Both techniques separate proteins in a spatial manner on 
a gel. Two dimensional PAGE separates proteins more successfully than one dimensional 
gel PAGE as it separates proteins out on the basis of two different criteria.  PAGE 
separates a complex mixture of intact proteins into individual spots or bands. The 
proteins can be visualised on a gel by staining with Coomassie blue [113].  Once resolved 
into individual proteins, bands or spots of interest can be cut out for mass spectrometry 
analysis.  The proteins are destained to remove the Coomassie blue and then a 
proteolytic digestion is carried out in the gel.  Proteolytic peptides can then be extracted, 
desalted and analysed via either ESI or MALDI mass spectrometry [114]. The approach 
has been commonly used when combined with MALDI peptide mass finger printing (PMF) 
[115]. 
 
One or 2D gels coupled with mass spectrometry is a useful and low cost means of 
identifying a particular protein of interest from a complex mixture. The downsides are 
that the technology is limited to individual proteins and impractical for the 
characterisations of complex mixtures [116].  Gel electrophoresis is a  low throughput 
technique and in the past decade or so shotgun proteomics techniques have become 
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more popular [116]. Shotgun proteomics relies on performing an online liquid 
chromatography tandem mass spectrometry experiment (LC MS/MS).  
 
1.3.3 Liquid chromatography  
 
ESI ionises analyte directly from the solution phase so as a result it couples to liquid 
chromatography (LC) very effectively [117]. LC or high performance liquid 
chromatography (HPLC) is a widely used laboratory tool for separating mixtures into their 
individual components [118]. There are many different methods available but proteomics 
research typically use reversed phase C18 or reversed phase C4 columns. A sample is 
pumped through a column packed with beads of silica with octadecyl hydrocarbons in 
C18, or butyl groups in C4 chromatography, under a high pressure. The beads are 
immobilised within a capillary and are referred to as the stationary phase [119].  A 
solution known as the mobile phase is pumped through the column.  In reversed phase 
chromatography the mobile phase is typically composed of an aqueous organic mixture 
such as water and acetonitrile [120]. Peptides and proteins bind to the beads of the 
stationary phase. The mobile phase changes composition from a highly aqueous solution 
to become more organic [121]. The composition gradient separates out peptides and 
proteins on the basis of their hydrophobicity. More hydrophilic species will elute from the 
column earlier in more aqueous solutions than more hydrophobic species, which 
separates the analytes in a temporal fashion [121].  In an online LC MS/MS experiment 
the eluted species are directly ionised and introduced into a mass spectrometer [122]. LC 
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MS/MS with shotgun proteomics are commonly used techniques.  In these experiments a 
complex mixture of intact proteins is digested into peptides, yielding a mixture of many 
different peptides before LC MS/MS analysis [122].  An individual peptide may elute from 
the column in a time window of around 20-30 seconds and the mass spectrometer will be 
constantly scanning to detect peptides as they elute from the column [123]. Data 
dependent acquisition is a commonly used mass spectrometry method. The instrument 
performs a survey scan and individual peaks detected in the survey scan are selected for 
subsequent  fragmentation [123]. Shotgun proteomics experiments are useful for 
characterising complex mixtures of proteins. As a result they have become powerful tools 
for the analysis of biofluids and discovering biomarkers of disease [124]. The downsides 
are that LC MS/MS usually requires long run times of over an hour or more which places 
great demands on an instrument’s time. Liquid chromatography alone may not be 
sufficient to fully separate highly complex mixtures such as plasma, salvia and 
cerebrospinal fluid. Multidimensional chromatography experiments are available for 
further separation but this can still be insufficient and separation remains as a limiting 
factor for complex samples [125]. 
1.3.4 Bottom up proteomics 
Mass spectrometry based proteomics experiments are usually based on analysing small 
peptides formed from a proteolytic digests of larger proteins rather than analysing the 
proteins themselves. The analysis of proteolytic peptides is known as bottom up 
proteomics[126]. Analysing intact proteins is far more challenging as most mass analysers 
have insufficient resolving power.  Intact protein analysis is a distinct field in its own right 
known as top down proteomics. Proteolytic peptides are smaller, which enables them to 
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be investigated with low resolution instruments and they are often as unique as the 
proteins they are digested from [127]. A range of proteases are available that cleave the 
peptide backbone of intact proteins at specific amino acid residues [128].   Trypsin is the 
most commonly used protease in proteomics research and cleaves proteins at lysine and 
arginine residues. Others are available however such as Lys-C which cleaves C terminal to 
lysine residues [128, 129]. These proteases are ubiquitous, cleaving almost any protein at 
the same amino acid residues to leave a mixture of peptides that can be used for 
identification.  Trypsin is popular because it has a high rate of activity and most peptides 
it produces are in a size range suitable for mass spectrometric analysis. Trypsin also has 
the advantage in that it cleaves lysines or argines, so all tryptic peptides contain one of 
these two basic amino acid residues which ionise very strongly under ESI [101]. Tryptic 
peptides are on average 8.4 amino acid residues long and up to 97% of all are between 7 
and 35 residues [130].  
 
The simplest type of bottom-up proteomics experiment is protein identification. Both ESI 
and MALDI mass spectrometry are highly effective techniques for peptide analysis. Mass 
spectrometry can be used to measure the precursor m/z ratio of the peptides, or if 
required fragmentation can be induced within the peptide to generate sequence data 
[126]. Either is sufficient to identify the peptide. Proteases cleave proteins at specific 
residues and yield a number of unique peptides. The unique mass of the peptide can be 
measured by mass spectrometry and used to identify the protein from a protein 
database.  The procedure is known as PMF [78] PMF is sufficient to identify proteins but 
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in many cases it is more useful to generate sequence data which can be achieved by 
fragmentation techniques described in section 1.2.4. 
 
After a PMF or a fragmentation spectrum has been obtained the protein must be 
identified. Identification can be very challenging and for this reason a number of search 
algorithms are available for database searching of mass spectrometry data [131]. 
Bioinformatics is now becoming incredibly important in proteomics research. It is crucial 
to have a detailed protein database to efficiently identify proteins. Two of the most 
common algorithms, both of which were used in this thesis, are Mascot and Sequest. 
Sequest was first described in 1994 [132] and Mascot was released a few years later in 
1999 [133]. The two work in slightly different ways. Sequest searches a protein database 
for peptides which match the precursor mass of the observed peptide. Sequest then 
generates a virtual fragmentation spectrum for all peptides that match the precursor 
mass and generates a score for how closely the virtual and observed spectra match. The 
peptide with the closest match to the spectrum is then provided as the identity [134]. 
Mascot is a probability based search tool. The software matches the observed spectra to 
theoretical peptides, and then calculates the probability that these matches arose by 
chance. The data is then filtered out to a significance threshold, for example P<0.05 [133]. 
Since both algorithms were published it has become commonplace to search 
experimental data against a decoy database to estimate the false discovery rate of the 
peptide identifications. In many cases the decoy database is a copy of the original protein 
database with the same number of sequences, each with the same amino acids but with 
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randomised sequences. Data are searched against both the real and decoy databases. 
The experimental data will contain some peptides that are matched by chance, the 
number of which is approximately equal to the number of decoy peptides that match the 
experimental. Decoy databases cannot eliminate false positives; they can only give an 
estimation of how many peptide matches are false but the false discovery rate can be 
used to filter the data to a desired confidence level [135]. 
 
Mass spectrometry can be used for the quantification of proteins as well as identification. 
The most effective methods involve the use of isotopically labelled internal standards 
which behave the same chemically but have a different mass so can be distinguished by 
mass spectrometry. Cell culture based techniques are available in the form of stable 
isotope labelling of amino acids in cell culture (SILAC) experiments, and isobaric labelling 
methods such as isobaric tagging for relative and absolute quantification (ITRAQ) or 
tandem mass tags (TMT) tags are available if cell culture is not an option [136]. Both 
methods allow untargeted quantification of proteins but were not used in this thesis so 
shall not be discussed in any great detail. The most accurate and most sensitive 
quantitative proteomics experiment are multiple reaction monitoring assays (MRM) 
[136]. These are targeted approaches analogous to the selective reaction monitoring 
assays mentioned in section 1.2.4.2.  MRMs and SRMs differ in that an SRM is used to 
detect a single ion whereas an MRM is the use of multiple SRMs to detect several 
different ions [87]. MRMs can be used to quantify a known protein from a mixture.  If the 
sequence of the protein is known, then so too are the proteolytic peptides it yields after 
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digestion. A range of isotopically labelled standards are synthesised with the same 
sequence as the endogenous peptides, but are labelled with stable isotopes to give them 
a different mass. The two react the same chemically and ionise in the same fashion but 
can be distinguished as separate by the mass spectrometer. The internal standard is 
spiked into the sample at a known concentration. One SRM is used to measure the 
intensity of endogenous analyte and the other is used to measure the intensity of the 
internal standard [86]. A calibration curve is generated from a range of standard samples 
with known concentrations of the labelled peptides. The amount of endogenous analyte 
in an unknown sample can be measured from its position on the calibration curve [87]. 
These are very effective tools for the targeted quantification of known proteins. They can 
multiplexed, are highly sensitive and have become popular for quantifying biomarkers in 
complex biofluids such as plasma [137].  
 
1.3.5 Intact protein analysis 
The field of mass spectrometry proteomics is not limited to the analysis of proteolytic 
peptides. The analysis of intact proteins via mass spectrometry is a less commonplace 
technique known as top down proteomics [138]. Top down and bottom up proteomics 
generate different types of data and are used for different purposes. Rather than being a 
tool for the identification or quantification of proteins top down proteomics is more 
commonly used as a tool to characterise particular proteins of interest [127].  Bottom up 
proteomics experiment only identify proteins on the basis of a few short peptide 
sequences. The majority of information about the protein is lost, including information on 
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the molecular weight of the protein and the presence of any modifications [139]. Many 
proteins are covalently modified in various different biological processes and this cannot 
be predicted from the genome. Phosphorylation of proteins is important in many 
signalling events, glycosylation is often important in cell-cell recognition and methylation 
of proteins can be important in regulating gene expression [140]. Post translational 
modifications can be identified by bottom up approaches, but because the approach only 
involves identifying the protein from a few peptides many areas of the protein are not 
covered. The post translational modifications identified by a bottom up approach are 
never complete [141]. In a top down approach the quasimolecular ion can be used to 
provide the molecular weight of the intact protein including any modifications [126]. This 
can then be fragmented to provide sequence data in the same way as peptide 
fragmentation.  Fragmentation is unlikely to take place at every residue along the protein 
backbone, but the approach does not miss large regions in the same way bottom up 
proteomics approaches can [142]. Top down protein analysis provides more extensive 
identifications of post translational modifications than data provided by bottom up 
proteomics techniques. The confidence in protein identifications are also higher than by 
bottom up approaches, due to the fact that molecular weight information is obtained and 
the  sequence coverage of the protein is greater [141]. 
There are a number of factors preventing top down proteomics from becoming adopted 
as a widespread technique. These include sample preparation and fractionation, mass 
spectrometry resolving power and tools for data analysis [139]. Fractionating intact 
proteins in a format that makes them amenable for mass spectrometry analysis can be 
very difficult. The gel electrophoresis available for bottom up proteomics do not work for 
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top down proteomics.  Proteins can be highly resolved but it is almost impossible to 
extract large proteins from a polyacrylamide gel [138]. Reversed phase chromatography 
can be performed on intact proteins, but does not work as well as it does for proteolytic 
peptides. Intact protein chromatography has  a number of drawbacks, intact proteins can 
become irreversibly adsorbed to the beads on a column;  which can lead to carry over 
between different samples and the chromatographic resolution is often poor [139, 143].  
Top down proteomics is also very demanding in terms of instrumentation, particularly in 
mass resolving power. Intact proteins are much larger than tryptic peptides, have a wider 
distribution of charge states and a more complicated isotope spacing pattern. The field 
has been dominated by highly expensive Fourier transform ion cyclotron resonance 
instruments.  The development of the orbitrap mass spectrometer has provided an 
alternative, but it is most applicable for analysing small to medium size proteins [144]. 
Even  high resolution Fourier transform ion cyclotron resonance (FTICR) mass 
spectrometers struggle with very large proteins and have an upper limit to size of 
proteins they can resolve, which are currently around 170 kDa [127]. The bioinformatics 
tools are more limited than those available for bottom up proteomics [145]. There is only 
one commercially available algorithm available for identifying top down spectra, Prosight.  
The algorithm considers the experimentally measured molecular mass of the protein to 
proteins that match it within a specified range. It then considers the fragmentation 
spectrum expected from each of the shortlisted proteins and chooses the closest match 
to the experimental spectrum as the identity [146]. Although  fewer algorithms are 
available  for identifying intact proteins, the matches provided by top down techniques  
tend to be more confident than identifying the protein from bottom up data [141]. 
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1.4 Dried blood spot analysis 
 
One of the most popular applications investigated by groups working with LESA and 
ambient ionisation mass spectrometry has been dried blood spot analysis. DBS are a 
routine blood sampling format used in the clinic. They were initially developed as a 
means of collecting blood samples from newborn babies, but have since been adopted 
for other applications [147]. The paediatrician Robert Guthrie was the first to use blood 
soaked dried paper discs as a sampling tool in 1963 whilst he was working on the disease 
phenylketonuria (PKU) [148]. PKU treatment required a means of diagnosing the disease 
based on testing blood in the first few days of life and required a new sampling method 
that was safe for use on newborn babies. Guthrie’s solution was to acquire the blood 
from a heel prick and apply it directly to small filter paper disc. An image of a DBS is 
shown in figure 1.11 The blood could then be dried for storage and later analysed by 
applying it to bacterial culture plate that identified the disease through a growth 
inhibition assay [148]. The assay identified the disease before symptoms emerge and 
soon became adopted as the basis for many different newborn screening programmes 
[149].  Every child born in a particular population had a DBS taken a few days after birth 
and was tested for PKU.  
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Figure 1.11  A filter paper DBS 
 
1.4.1 DBS as a sampling format 
DBS have become popular in the clinic because they are far easier to work with than 
whole blood.  They are easier to acquire, easier to store and ship, and are safer for the 
laboratory analyst [147]. Whole blood for plasma assays needs to be acquired by a 
specially trained phlebotomist and large volumes need to be acquired by  a fairly invasive 
procedure [150]. Many young children and adults alike find phlebotomy fairly traumatic 
and painful. It must also be done in a clinical setting with anticoagulant and 
centrifugation being required to separate the blood into plasma [151]. Acquiring a DBS, 
however, is much simpler. The blood can be acquired via a finger prick for adults or a heel 
prick for newborns [152]. The person taking the blood requires very little training. It can 
even be taken by the patient themselves and does not need to be done in a clinical 
setting [152]. DBS do not require any special storage conditions. Once the blood is 
applied to the filter paper it is dried in air and they can then be stored at ambient 
conditions or at -20˚C [153]. In comparison whole blood must be separated into plasma 
and transported on dry ice [151].  DBS are stable at ambient conditions and can even be 
transported through standard postal services [153]. Using dried blood also helps reduce 
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the dangers of biohazards for the user. Many different blood borne viruses including HIV 
and hepatitis C are inactivated upon drying [149]. 
 
1.4.2 Analysis of DBS by mass spectrometry 
Newborn DBS screening expanded after the 1960s to include a range of other inborn 
errors of metabolism such as medium chain acyl coenzyme dehydrogenase deficiency 
(MCAD), and maple syrup urine disease (MSUD) [154, 155]. In the 1990s mass 
spectrometry was introduced as a means of analysis.  Diagnosis of inborn errors of 
metabolism required the accurate quantification of a few small amino acids and organic 
acids [156]. The early 1990s had seen the introduction of ESI and the field of 
metabolomics which was a field aimed to characterise small molecules produced by 
biological organisms [157]. ESI combined with triple quadrupole MRMs replaced bacterial 
inhibition assays as a means of analysing small molecule metabolites and diagnosing 
inborn errors of metabolism.  The assay is similar to that of targeted MRMs for 
quantitative proteomics mentioned in section 1.3.4. A small disc (a few millimetres in 
diameter) was cut out of a DBS and the sample eluted in a solvent [158].  SRMs were used 
to measure the intensity of the endogenous metabolite relative to an isotopically labelled 
derivative of the metabolite used as an internal standard. The ratio between the two was 
then used to calculate the absolute concentration of the endogenous metabolite [158]. 
These tests were higher throughput than existing technologies, could be easily 
automated and most importantly could be multiplexed.  A single LC MRM assay could be 
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used for the quantification of several different metabolites and diagnose several different 
diseases in a single test [159]. 
 
1.4.3 Protein analysis of DBS by mass spectrometry 
The potential for using mass spectrometry for analysing metabolites from DBS was 
recognised immediately and has been adopted worldwide the method of choice for 
screening inborn errors of metabolism across the globe [160]. The idea has also been 
used by the pharmaceutical industry. DBS are now often used as an alternative to plasma 
based screening assays in drug metabolism and pharmacokinetic studies [161]. DBS have 
largely remained as a means of small molecule analysis only and very few attempts have 
been made to utilise mass spectrometry to analyse the protein content of DBS [162]. It is 
a particular surprise that the idea has not been explored further, considering the growth 
of proteomics in this time and the focus on plasma as a source for disease biomarkers 
[163]. 
 
1.4.3.1 Targeted analysis of proteins from DBS 
In the few examples where groups have investigated DBS for protein analysis the majority 
of the work has focused on haemoglobin. Haemoglobin is of interest because it is high 
abundance protein and is useful for clinical diagnosis. Newborn DBS programmes screen 
haemoglobin for pathologic variants such as sickle cell disease and thalassemias which 
are a range of disorders caused by  a reduced synthesis of haemoglobin chains [164]. 
These are currently screened for by techniques such as isoelectric focusing and HPLC 
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[165]. A triple quadrupole mass spectrometry method to screen different haemoglobin 
variants was developed by Daniel et al. in 2005, [166] and later the method was applied 
to DBS for providing relative quantification of haemoglobin A2 [167]. In this method a 
small punch was cut out of a DBS and eluted in water under shaking at 37˚C. A small 
aliquot was taken, treated to a short trypsin digestion and analysed with a LC MRM 
approach which was composed of SRMs to detect for the presence of common healthy 
haemoglobin peptides and pathogenic variants [166]. The method was very quick and 
more specific than conventional haemoglobin screening methods, but as only the most 
common variants were added to the MRMs, uncommon variants would be missed. The 
method was later refined by Boemer et al. [168] who successfully developed this further 
and used for the mainstream haemoglobin variant screening programme in Belgium[169].  
Boemer's method worked well on this screening programme, proving to be reliable, 
robust and cost effective [169]. 
 
 
The opportunities in a proteomic analysis of DBS go far beyond that of just haemoglobin 
analysis. Blood is a very rich biofluid composed of thousands of different proteins [170]. 
Prior to the work in this thesis a few groups had investigated targeted MRM approaches 
for the quantification of specific proteins of interest. The first example was in 2008 by De 
Wilde et al. who used MRMs for the quantification of ceruloplasmin [171]. Ceruloplasmin 
is a protein responsible for transporting copper in the blood which can be affected in 
Wilson’s disease. Wilson’s disease is caused by insufficient synthesis of mature 
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ceruloplasmin and a reduction in the amount in the plasma [172]. De Wilde’s method 
aimed to quantify the amount of ceruloplasmin from a DBS. Similar in principle to that of 
Daniels et al. [167], a DBS punch was eluted in solvent and treated to a trypsin digest 
before internal standard peptides were added. The digests were then analysed by a ultra 
high performance liquid chromatography (UHPLC) MRM assay to detect both endogenous 
and internal standard peptides[171]. Similar approaches have been carried out for 
investigations in pharmaceutical drug development studies. Kehler et al. in 2011 sampled 
DBS for quantification of the exendin 1, a 4 kDa peptide, from monkey plasma [173].   
Sleczka et al. [174] investigated the use of a multiple reaction monitoring assay to 
monitor the degradation of mice dosed with therapeutic proteins [174].  In 2013, Cox et 
al. demonstrated a different application: detection of sports enhancing drugs in sporting 
events. Insulin like growth factor  (IGF) is a common doping agent [175]. IGF needs to be 
tested for regularly, even during periods off training and the need to give regular whole 
blood samples is very demanding for the athletes. The authors developed a DBS MRM 
approach as an alternative [175].  
 
One of the great advantages of metabolic DBS analysis is that MRMs can be multiplexed 
to detect for the presence of multiple different analytes [159]. Multiplexed MRMs were 
demonstrated on proteins in 2012 in proof-of-principle experiments by Chambers et al. 
[176]. As seen previously, proteins were eluted from a DBS and digested into peptides. In 
this case the MRM method was used to measure the concentration of 65 peptides from 
60 different proteins. The instrument response showed a linear relationship with 
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endogenous concentration for 40 of the 65 targeted peptides, but many of the 
concentrations measured by the assay did not agree with the established reference 
concentrations [176]. 
1.4.3.2 Untargeted analysis of proteins 
 
In 2011 LESA was used for sampling of DBS to analyse intact haemoglobin proteins.  The 
method could successfully distinguish different haemoglobin variants [2]. The advantages 
of using an untargeted approach for the analysis of haemoglobin variants was a major 
advantage as it could be used to characterise less well understood and even unknown 
variants [177]. LESA sampling meant that the DBS could be analysed directly without any 
sample pre-treatment or preparation. The only downside was that because the technique 
was based on analysing intact proteins, it was demanding in terms of resolution and 
required a high performance orbitrap mass spectrometer for analysis [2]. 
 
1.4.3.3 Future prospects for DBS proteomics 
Research into DBS proteomics is still in its early stages, but there has been a lot of effort 
to characterise the human plasma proteome to identify new biomarkers of disease [163]. 
Plasma is a highly dynamic and complicated biofluid. It is highly affected by disease and 
many clinical assays are based on measuring the amount of a particular protein in the 
plasma[178]. DBS could be used as an alternative sampling format to plasma, but would 
be more convenient in the clinic. DBS analyses face the same challenges as analysis of 
plasma. The number of proteins in plasma and blood is enormous. Over 10,000 different 
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distinct proteins are known to have been identified in plasma so far [179] and some 
speculate that it could contain the entire human proteome at some level [180]. 
Characterising plasma is made particularly difficult by the fact that the concentrations of 
these proteins have a high dynamic range [180]. There are thousands of low abundance 
proteins and a few high abundance proteins that make up most of the total protein in 
plasma. Of the total protein in plasma, 99% is made up of 22 high abundance proteins 
[179].  The presence of high abundance proteins makes it more difficult to analyse the 
proteins that make up the remaining 1% of total protein such as interleukins, cytokines 
and receptor ligands.  Low abundance proteins can be more useful diagnostically and can 
be expressed at the pg/ml level. The difference in concentration between the most and 
least abundant proteins in plasma can be more than 10 orders of magnitude [170]. 
Generating an assay that performs accurately across this range is an incredible challenge 
[181]  and analysing the full proteome of a DBS is likely to be even more difficult  than 
analysing the plasma proteome.  
1.5 Alpha-1-antitrypsin deficiency  
 
The protease inhibitor A1AT was studied in chapter 6 in the investigation of LESA based 
methods for the diagnosis of the disease alpha-1- anti trypsin deficiency. A1AT is a 52 kDa 
glycoprotein which is produced in the liver where it is secreted into the blood plasma.  In 
a healthy human 34 mg for every kg of body mass is made per day. A1AT is one of the 
more abundant plasma proteins at around 20-48 µM in a healthy adult [182]  and has a 
circulating half-life of around six days [183].  It belongs to a family of protease inhibitors 
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known as the serpins, an abbreviation of serine protease inhibitors. The primary 
biological function of the protein is to act as an inhibitor of defensive proteases secreted 
by phagocytes during an immune response. The activity of A1AT is highest against 
neutrophil elastase and acts mostly in the lungs. The lungs receive a constant immune 
challenge due to continual inhalation of airborne particulates and pathogens [184].  The 
immune system responds by recruiting phagocytic cells such as neutrophils into lung 
tissues [185]. Proteases such as elastase are released during phagocytosis and can 
degrade the lung tissues. If left unchecked they can damage alveolar structures [184]. 
A1AT prevents prolonged proteolytic activity by denaturing elastase; elastase binds to 
A1AT at its active site and attempts to cleave the protein. The A1AT protein however 
remains irreversibly bound to the protease and denatures its tertiary structure. The 
inhibition process is suicidal for both proteins but prevents unwanted and prolonged 
proteolysis of self-tissues [186]. The A1AT gene is polymorphic. Several natural variants 
exist to this protein which result in a reduction of synthesis of the protein that can cause 
a pathogenic condition known as alpha-1-anti trypsin deficiency [187].  There are 2 
recognised healthy variants of the protein known as the M variant. One of these variants 
has a valine at the 213 position and the other codes for an alanine [188]. These 
genotypes will result in a normal production and excretion of A1AT so plasma levels will 
be normal between 20 and 50 µM. There are two well understood clinically significant 
mutants which each possess a single nucleotide polymorphism that cause in a decrease in 
the synthesis of the protein. The first is known as S, which is a mutation of the M valine 
(M val) 213 allele with a glutamic acid to valine transition at amino acid 264. The second 
is known as the Z variant and has the most serious implications. It is modification of the 
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M alanine 213 (M ala) allele with has a glutamic acid to lysine transition at the 342 
position [188].  The possession of either of the two alleles results in a decrease in serum 
concentration of A1AT, but the amount can vary. A homozygous MS individual has serum 
A1AT concentration between 20 and 48 µM, which is close to the amount expected in a 
healthy individual. A typical MZ genotype has a concentration between 12 and 35 µM. 
The concentration of A1AT in an SS genotype is normally between 15 and 33 µM whereas 
SZ and ZZ variants are the most serious. An SZ genotype normally results in a 
concentration of A1AT around 8-19 µM and the concentration of a ZZ individual can be as 
low as 2.5-7 µM [189]. Lower serum concentrations result in an increased likelihood of 
clinical problems, but is possible to have a diseased genotype and not suffer any 
symptoms [184]. If left untreated A1AT deficiency can lead to a prolonged attack of lung 
tissues by neutrophil elastase resulting in emphysema and chronic obstructive pulmonary 
disease [190].   Damage can also be done in the liver; A1AT deficiency can be followed by 
cirrhosis or jaundice in children. These problems are caused by the synthesis of the 
protein [189]. Certain variants such as the Pi ZZ variant result in a change to the 3D 
structure of the protein which can aggregate to form a series of A1AT polymers. These 
cannot be secreted by a liver cell and begin to accumulate in the endoplasmic reticulum.  
Accumulation of A1AT polymers can be toxic to the cell which induces apoptosis [189]. 
A1AT deficiency is not a rare disease and frequently goes undiagnosed [191].  It is not 
currently screened for and is usually diagnosed following the presentation of symptoms.  
The means of diagnosis differ from laboratory to laboratory, but rely on multi-step 
processes.  Many laboratories use DBS for sampling [192]. 
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1.6 Aims and objectives 
The overall aim  of the work presented in this thesis was to develop new methods using 
LESA and mass spectrometry for protein analysis and to combine LESA with previously 
existing proteomics techniques.   
 The aim of the work presented in Chapter 3 was to analyse intact proteins from 
PVDF membranes using LESA.  Analysis of PVDF had applications in investigating 
proteins electroblotted from SDS PAGE as a technique for intact protein 
fractionation and as a means for detecting intact proteins from air filters.  
 The work presented in Chapter 4 was aimed at developing the use of LESA for the 
analysis of proteolytic peptides from DBS as a means of untargeted protein 
identification (proteomics). The procedure behind LESA was adapted to 
incorporate a trypsin digestion into the sampling process.   
 The work presented in Chapter 5 further investigated the potentialsof DBS 
proteomics using solution phase chemistry rather than LESA and the use of 
protein depletion to increase the number of proteins that could be identified from 
DBS.   
 The work presented in Chapter 6 focused on targeted analysis of proteins from 
DBS by LESA mass spectrometry to determine alpha-1-antitrypsin variants.   
 The aim of the work presented in Chapter 7 was to investigate the potential of 
using LESA to retain native protein interactions from dried surfaces for mass 
spectrometry analysis and analyse the native haemoglobin tetramer directly from 
DBS.   
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Chapter 2 Materials and Methods 
 
2.1 Materials 
 
Reagents 
All solvents used for mass spectrometry, i.e., water, acetonitrile and methanol were HPLC 
grade obtained from J. T. Baker, (Deventer, The Netherlands). Formic acid (HPLC grade), 
ammonium bicarbonate, dithiothretiol and iodoacetamide were obtained from Sigma 
Aldrich (Gillingham, UK).  Purified lypholised proteins, bovine cytochrome C, bovine alpha 
casein, equine myoglobin, yeast alcohol dehydrogenase and human hemoglobins were 
also obtained from Sigma Aldrich (Gillingham, UK).   Pre cast 4-12% gradient SDS PAGE 
and precast 2-8% native PAGE gels, 4X LDS sample buffer and 20X SDS running buffer 
were obtained from Expedeon (Cambridge, UK). Tris(hydroxylmethyl)aminomethane 
hydrochloride (tris HCl) , tricine, glycine, SDS, reagent grade methanol, Coomassie Plus 
Bradford assay reagent and plain glass microscope slides were obtained from Fisher 
Scientific (Loughborough, UK).  Immobilon P PVDF membranes, reversed phase C18 and 
reversed phase C4 zip tips were obtained from Millipore (Watford, UK). Mass 
spectrometry grade trypsin gold was obtained from Promega (Southampton, UK) Blood 
spot cards were standard NHS blood spot (Guthrie) cards, made from Ahlstrom grade 226 
filter paper (ID Biological Systems Greenville, SC, USA). Customised synthetic peptides 
were made to a purity >70% and purchased from GenicBio (Shanghai, China). Healthy 
adult DBS were acquired from anonymous donors via finger prick. The work was 
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approved by the University of Birmingham STEM ethical review committee ERN 12-
0782A. The blood was applied to standard NHS DBS cards made of Ahlstrom grade 226 
filter paper (ID Biological Systems, Greenville,SC, USA). After blood was spotted onto the 
card, DBS were dried overnight prior to analysis.  DBS from previously screened SZ and ZZ 
genotype alpha-1-antitrypsin deficiency patients were provided by Prof R Stockley,  
Queen Elizabeth Hospital, Lung Function and Sleep department, which was approved by 
STEM ethical review committee LREC 3359. 
 
2.2 Methods 
2.2.1 LESA  
LESA was carried out using the Triversa Nanomate™ nanoelectrospray platform (Advion 
Biosciences Ithaca NY, USA).  The analytical surface was loaded onto a universal LESA 
adapter plate (Advion Biosciences Ithaca NY, USA) and scanned on an Epson perfection 
V300 photo scanner.  The LESA points software was used to plot the exact position of the 
dried sample spot and perform sampling at this precise location. Surface sampling was 
carried out as described in each individual experiment. 
2.2.2 LC MS/MS 
Three liquid chromatography methods were used in the work presented in this thesis. 
Two were used for online analysis with the Orbitrap Velos™ and the third method was 
used online with analysis on the TSQ.  In all cases, the HPLC unit was coupled to the mass 
spectrometer via a Triversa Nanomate™, infusing the samples in positive mode with an 
ionisation voltage of 1.7 kV. 
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Method one was used online with the Orbitrap Velos™ and was composed of a 30 minute 
3.2-44% acetonitrile gradient.  A Dionex Ultimate 3000 was used with an analytical 
column and a trapping column on a 6 port valve. Samples were pumped through a 
Pepmap 100 reversed phase C18 analytical column at a flow rate of 350 nanolitres per 
minute. The trapping column used was a nanoviper pepmap 100, C18 75 μm, samples 
were loaded onto it at a flow rate of 4 μl/minute in 0.1% formic acid.  After loading, the 
valves switched and the analytical gradient was applied starting at 3.2% acetonitrile, 
which increased to 44% over a 30 minute period. The column was then washed by 
increasing the acetonitrile gradient to 90% for 10 minutes before being lowered to 3.2%. 
After a further 10 minutes the valves switched back to load position. The total run time of 
the method was 56 minutes.  
Method two was similar to method one but included an online desalting stage to 
eliminate the need for clean-up with C18 zip tips before analysis.  Samples were loaded 
onto a Pepmap 100, C18 100 μm nanoviper trapping column at a flow rate of 20 
μl/minute in 0.1% formic acid.  Before the valves switched the trap was washed for 5 
minutes in 0.1% formic acid to eliminate salts and contaminants before being switched 
online with the analytical column. The analytical column and the analytical gradient was 
the same as the one used in the first method. The gradient started at 3.2% acetonitrile 
and was increased to 44% over a 30 minute period.  The column was washed in 90% 
acetonitrile for 10 minutes before being reduced back to 3.2%. After a further 10 minutes 
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the valves switched back to load position and remained this way until the end of the run. 
The total run time of the method was 61 minutes, 5 minutes longer than method one. 
Eluents from both methods one and two were infused into the mass spectrometer and 
analysed by a Top 7 CID data dependent acquisition described in section 2.2.3.2.  
 
Method three was used in conjunction with a triple quadrupole MRM method and used a 
Dionex Ultimate 3000 UHPLC unit coupled to a 1:300 splitter. The analytical column was a 
Pepmap 100 reversed phase C18 column, used with a Pepmap 100, C18 100 μm 
nanoviper trapping column. Samples were loaded onto the trapping column at a flow rate 
of 10 μl/minute in 0.1% formic acid. The valve switched and the analytical gradient was 
applied starting at 3.2% acetonitrile, and increased to 44% over a 17 minute period at a 
flow rate of 0.35 µl/min. The column was washed with 90% acetonitrile (ACN) for 10 
minutes, before being reduced to 3.2% ACN for 13 minutes.  Eight minutes later the 
valves switched back to load position. The total time of the method was 40 minutes. The 
eluent was infused into the mass spectrometer and analysed by the SRM method 
described in section 2.2.3.3. 
2.2.3 Mass spectrometry 
Three mass spectrometers were used in this work. The majority of the work was 
performed on an Orbitrap Velos™ ETD mass spectrometer (Thermo Fisher Scientific, 
Bremen, Germany). The work presented in Chapter 6 required the use of a TSQ Vantage™ 
triple quadrupole mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) and 
59 
 
the work presented in Chapter 7 made use of a Synapt™ G2S (Waters Manchester, UK) 
quadrupole-time of flight mass spectrometer.  
 
2.2.3.1. Direct infusion and LESA mass spectrometry 
In direct infusion electrospray, and LESA mode the Orbtirap Velos was operated in 
positive ion mode unless otherwise stated. Samples were infused by the Triversa 
Nanomate™ with an ionisation voltage of 1.7 kV and a gas pressure of 0.3 PSI. Data were 
acquired in the orbitrap with a mass resolution of 100,000 at m/z 400. The maximum 
injection time was 1000 ms with an automatic gain control (AGC) target of 1x106 charges. 
When data was acquired in full scan mode the number of microscans used was either 5, 
30 or 50 as defined in each particular experiment.   
A customised method was used for the detection of β-lactoglobulin in Chapter 3. The 
customised method was 7 minutes long and composed of 5 minutes full scan in the m/z 
region of 600-2000, followed by 1 minute isolation of the +10 charge state of the protein 
(m/z 1837.23) with an isolation window of 10 thomsons (Th), and one minute scanning in 
selected ion monitoring (SIM) mode of m/z 1825-1845 to monitor the same +10 charge 
state. Each scan in this method was made up of 5 microscans.   
When using the Waters Synapt™ G2-S, samples were infused via the Triversa Nanomate™ 
with an ionisation voltage of 1.7 kV and a gas pressure of 1.0 PSI. The instrument was 
used for both direct infusion ESI and LESA analysis. The capillary temperature was set to 
30°C and the cone voltage was 45 V. Samples were acquired in time of flight mode with 
scan time of 2 seconds. 
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2.2.3.2 Data dependent CID 
 
A top 7 data dependent CID method was used in Chapters 4, 5 and 6 for analysis by direct 
infusion ESI and online LC MS. The method comprised 8 scan events beginning with a 
survey scan in the orbitrap cell followed by collision induced dissociation in the ion trap of 
the 7 most abundant peaks identified from the survey scan.  The survey scan was 
acquired at a resolution of 60,000 at m/z 400 with an AGC of 1x106 charges. Ion trap 
fragmentation was carried out with a normalised collision energy of 35% and an AGC 
target of 30,000 charges and a precursor isolation width of 2 Th. Dynamic exclusion was 
applied to prevent any peak with the same m/z from being selected for fragmentation 
within a period of 60 seconds.  Only multiply charged peaks with an intensity greater than 
5000 arbitrary units were selected for fragmentation.  
2.2.3.3 Selective reaction monitoring (SRM) 
SRMs were used to detect targeted peptides from samples analysed through direct 
infusion electrospray ionisation and LC MS method 3 described in section 2.2.2. The mass 
spectrometry method comprised 7 scan events: the first was a full scan in Q3 in the m/z 
range of 50-1500 with a scan time of 1 second. The following 6 scan events were SRMs to 
detect the tryptic peptides covering the 213, 264 and 342 residues of the M Valine 213, 
M Alanine 213, Z and S variants of the alpha-1-antitrypsin protein.  Three transitions were 
used for monitoring each peptide, each with a scan time of 1 second.  Table 2.1 shows 
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which peptides were targeted, the selected precursors, the transitions monitored and the 
collision energies of the fragmentation stage.  
 
 
Peptide Sequence 
Selected   
Precursor m/z 
  
 Transitions 
  
Collision 
energy 
(v) 
MAla 213 DTEEEDFHVDQATTVK [M+3H] 621.94 y9 998.52 y10 1145.59   y11 1260.62  35 
MVal 213 DTEEEDFHVDQVTTVK [M+3H] 631.29 y7 790.43 y8 889.49 y9 1026.55 35 
M264 LQHLENELTHDIITK [M+2H] 902.48 y8 940.54 y9 1069.58   y10 1183.63 33 
S264 LQHLVNELTHDIITK [M+2H] 887.49 y9 1069.58  y10 1183.63 y11 1282.70 33 
M342 AVLTIDEK [M+2H] 444.75 y4 504.26 y5 605.31 y6 718.39 30 
Z342 AVLTIDK [M+2H]380.23 y3 375.22 y4 476.41  y5 589.35 30 
 
Table 2.1 SRM transitions of the 6 peptides required for determining variants of the alpha-1-antitrypsin protein 
 
  
2.2.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) 
SDS PAGE was performed in chapter 3. Proteins solutions for SDS page were dissolved in 
a 50 mM pH 7.5 TrisHCl solution. Twenty microlitre aliquots were loaded onto the gel 
along with 5 µl of 4X LDS sample buffer. Prior to loading the sample was heated to 95˚C 
for 5 minutes and centrifuged at 13,000 rpm for 1 minute. Protein solutions were added 
with a gel loading pipette tip.  Precast 4-12% gradient polyacrylamide gels were 
immersed in TrisHCl/tricine SDS running buffer with 60 mM TrisHCl, 80 mM tricine, 
2.5mM sodium bisulphate and 0.1% SDS. Electrophoresis was run at 180 volts, 50 mA for 
38 minutes.  After electrophoresis, proteins were blotted onto an Immobilon P PVDF 
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membrane. The electroblot apparatus was immersed in a transfer buffer composed of 
192 mM glycine, 25 mM TrisHCl and 10% methanol. Blotting was carried out at 100 volts, 
40 mA and 25 W for 75 minutes.   
2.2.5 Zip tip purification 
Purification by using Zip tips  was performed in chapters 3, 4 and 6. The procedure for 
sample clean-up with reversed phase Zip tips was identical for both C4 and C18 tips. Tips 
were loaded onto a 10 μl pipette which was set at 10 μl. Pure acetonitrile was aspirated 
and dispensed to waste to prepare the tip. This was repeated once.  The tips were rinsed 
through with a wash solution composed of 0.1% Trifluoroacetic acid (TFA) which was 
dispensed to waste. This process was repeated 3 times. Next the proteins or peptides 
were bound to the tips via 7 repeated aspiration and dispense cycles of sample solution. 
The tips were then rinsed by aspirating aliquots of 0.1% TFA and dispensing them to 
waste. This process was also repeated 7 times. After rinsing, the proteins or peptides 
were eluted. This was achieved by aspirating and dispensing 4μl of a 50/0.1% 
acetonitrile/TFA solution in a clean tube. This process was repeated 7 times. After 
elution, samples were dried down in a speedvac running at 60˚C for 30 minutes and 
resuspended in 10 μl 49.4/49.5/1% water/methanol/formic acid for analysis by direct 
infusion electrospray ionisation mass spectrometry or 0.1% formic acid for LC-MS/MS 
analysis.  
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2.2.6 Native PAGE 
Native page was carried out in chapter 3. Proteins solutions for native page were 
dissolved in a 50 mM pH 7.5 Tris-HCl solution. Twenty microlitre aliquots were loaded 
onto the gel along with 5 µl of native PAGE sample buffer. The native PAGE sample buffer 
was composed of 40% glycerol, 4% ficoll 400, 2 mM EDTA, 0.8 M triethanolamine chloride 
pH 7.7 0.025% Commassie blue G250 and 0.025% phenol red. 
 phenol red. Protein solutions were loaded onto precast 2-8% acrylamide gradient gels 
with a gel loading pipette tip.  Gels were immersed in trisHCl/tricine running buffer with 
60 mM TrisHCl and 80 mM  tricine. Electrophoresis was run at 150 V, 50 mA for 90 
minutes.  After electrophoresis, proteins were blotted onto an immobilon P PVDF 
membrane.  The blotting apparatus was immersed in a transfer buffer composed of 192 
mM glycine and 25 mM TrisHCl. Blotting was carried out at 100 V, 40 mA and 25 W for 75 
minutes.   
  
2.2.7 Solution phase digestions 
Where stated that proteins from DBS were digested in solution (see Chapter 5), DBS were 
prepared by a “punch, elute and digest” procedure that is based on the method 
described by Sleczka et al. [174]. A 6 mm disc was cut out of a DBS and transferred to an 
eppendorf tube where the proteins were eluted in 150 μl 50 mM NH4HCO3 on a 
thermomixer shaking at 800 RPM and 40˚C. Protein concentration was determined via a 
Bradford assay. The Bradford assay was carried out by measuring the UV absorbance of 
Coomassie Plus reagent at 595 nm. A standard curve was generated from a series of 
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standards with concentrations of 1.0, 0.8, 0.6, 0.4, 0.2 and 0 mg/ml of bovine serum 
albumin (BSA). Ten microliters of each standard solution was mixed with 200 µl 
coomassie plus reagent and the UV absorbance at 595 nm was measured by 
spectrophotometry. Ten microliters of DBS eluent was also mixed with 200 µl Coomassie 
Plus reagent and the absorbance was measured on the standard curve to calculate the 
protein concentration. An aliquot corresponding to 20 μg of protein was taken from the 
DBS eluent for digestion. This aliquot was diluted tenfold in 50 mM NH4HCO3 and 1 μg of 
trypsin was added to give a 1:20 ratio of enzyme to protein. The sample was incubated on 
a thermo mixer shaking at 800 RPM and 40˚C. The incubation time varied from 30 
minutes to 8 hours and is defined in each experiment. Samples were stored at -20˚C prior 
to analysis. Prior to injection onto the HPLC, samples were diluted by a factor of 200 in 
0.1% formic acid.  
2.2.8 Database searching 
Database searching of data dependent CID was carried out in chapters 4 and 5. Bottom 
up proteomics data were searched against protein databases using the Mascot and 
Sequest algorithms in Proteome Discoverer (versions 1.3 and 1.4). The search parameters 
were as follows. Trypsin was selected as the protease and up to 2 missed cleavages were 
allowed in the digestion. The precursor ion mass accuracy tolerance was 10 ppm, the 
fragment ion mass accuracy tolerance was  of 0.8 Da. Methionine oxidation was included 
as a variable modification and where disulphide bond reduction had been used 
carbamidomethylation of cysteines was included as a static modification. Data were 
searched against the SwissProt human database composed of 20,233 sequences 
(downloaded in December 2012). The false discovery rates of the peptides were 
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calculated with the percolator function of Proteome Discoverer and filtered to a false 
discovery rate of 1%.    
2.2.9 Protein depletion 
Depletion of the top 12 plasma proteins and haemoglobin was carried out on samples 
eluted from DBS in chapter 5. Samples were eluted as described previously in section 
2.2.7. The sample was subsequently depleted of abundant proteins via four methods.  
1. The first method depleted the 12 most abundant plasma proteins with the 
Proteome Purify 12 kit.  The entire 150 μl DBS eluent was mixed with 1 ml 
Immunodepletion resin for 1 hour. The mixture was transferred to a spin column 
and centrifuged at 4600 rpm for 2 minutes. This eluted approximately 500 μl of 
depleted sample from the resin.  
2. The second method depleted DBS of haemoglobin using Hemovoid: Fifty mg 
Hemovoid matrix was weighed out into a spin column, mixed with 250 μl 
Hemovoid binding buffer and vortexed for 5 minutes.  The mixture was 
centrifuged at 3000 rpm for 2 minutes, the flow through was discarded and this 
procedure was then repeated. The 150 µl DBS eluent was added to the resin along 
with 300 μl binding buffer, this mixture was vortexed for 10 minutes and spun for 
4 minutes at 10,000 rpm. The flow through was discarded. Five hundred 
microlitres of Hemovoid wash buffer was vortexed with the sample for 5 minutes 
and then centrifuged at 10,000 rpm for 4 minutes. The flowthrough was discarded 
and this was repeated twice before elution. Three hundred microlitres of elution 
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buffer was added to the sample, which was vortexed for 10 minutes and then 
centrifuged for 4 minutes at 10,000 rpm to elute the depleted proteins.  
3. In the third option Hemovoid was used to deplete haemoglobin followed by the 
top 12 plasma proteins with proteome purify 12. Fifty milligrams of Hemovoid 
matrix was weighed out into a spin column, mixed with 250 μl Hemovoid binding 
buffer and vortexed for 5 minutes.  The mixture was centrifuged at 3000 rpm for 2 
minutes, the flowthrough was discarded and this procedure was then repeated. 
The 150 µl DBS eluent was added to the resin along with 300 μl binding buffer. 
This mixture was vortexed for 10 minutes and centrifuged for 4 minutes at 10,000 
rpm. The flowthrough was discarded. Five hundred microlitres of Hemovoid wash 
buffer was vortexed with the sample for 5 minutes and then centrifuged at 10,000 
rpm for 4 minutes. The flowthrough was discarded and this was repeated twice 
before elution. Three hundred microlitres of elution buffer was added to the 
sample, which was vortexed for 10 minutes and then centrifuged for 4 minutes at 
10,000 rpm to elute the depleted proteins. After the proteins were depleted of 
haemoglobin, the eluted sample was then depleted of the top 12 plasma proteins. 
The sample was mixed with 1 ml proteome purify 12 immunodepletion resin for 1 
hour. The mixture was transferred to a spin column and centrifuged at 4600 rpm 
for 2 minutes.  
4. In the final method the Proteome purify 12 kit was used first, before being 
followed by depletion with Hemovoid. The DBS eluent was mixed with 1 ml 
Immunodepletion resin for 1 hour. The mixture was transferred to a spin column 
and centrifuged at 4600 rpm for 2 minutes. This eluted approximately 500 μl of 
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depleted sample from the resin. Following depletion of the top 12 plasma 
proteins the sample was then depleted of Haemoglobin. Fifty milligrams of 
Hemovoid matrix was weighed out into a spin column, mixed with 250 μl 
Hemovoid binding buffer and vortexed for 5 minutes.  The mixture was 
centrifuged at 3000 rpm for 2 minutes, the flowthrough was discarded and this 
procedure was then repeated. The 150 µl DBS eluent was added to the resin along 
with 300 μl binding buffer, this mixture was vortexed for 10 minutes and 
centrifuged for 4 minutes at 10,000 rpm. The flowthrough was discarded. Five 
hundred microlitres of Hemovoid wash buffer was vortexed with the sample for 5 
minutes and then centrifuged at 10,000 rpm for 4 minutes. The flowthrough was 
discarded and this was repeated twice before elution. Three hundred microlitres 
of elution buffer was added to the sample, which was vortexed for 10 minutes 
and then centrifuged for 4 minutes at 10,000 rpm to elute the depleted proteins.  
After processing, samples were dried down entirely in a speed vac, before a trypsin 
digestion and disulphide bond reduction was carried out as instructed by the 
manufacturer: The dried samples were resuspended in 100 μl 200 mM NH4HCO3. Twenty 
microlitres of 50 mM DTT solution was added to samples which were then incubated at 
60˚C for 45 minutes. One hundred microlitres 22 mM iodoacetamide was added and 
samples were incubated in the dark for 25 minutes. Residual iodoacetamide was then 
quenched with 2.8 μl of DTT and then 2μg of trypsin. Samples were incubated at 40˚C and 
800 RPM. Samples were stored at -20˚C prior to analysis.    
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Chapter 3 : Liquid extraction surface analysis  of intact proteins 
from polyvinylidene fluoride membranes 
 3.1 Introduction 
 
The aim of the work presented in this chapter was to investigate whether LESA can be 
used to extract intact proteins from PVDF membranes. The work was performed for two 
reasons: firstly, to try and develop a new technique for the fractionation of intact 
proteins based on sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS 
PAGE) to be used in top down proteomics research. Proteomics experiments ordinarily 
require the analysis of complex mixtures of proteins that require separation prior to mass 
spectrometry analysis.  Although SDS PAGE is a useful method for separating proteins, 
there are no reliable techniques for extracting intact proteins out of a gel in a format that 
is compatible with mass spectrometry analysis [139].   
Electroblotting is a commonly used molecular biology technique for extracting proteins 
from SDS PAGE gels. PAGE separates out a mixture of proteins into narrow bands which 
are then blotted onto an absorbent PVDF membrane by use of an electric current. 
Blotting immobilises the protein onto the membrane which can then be probed with 
antibodies to identify a particular protein. This process is commonly carried out  during  
Western blotting [193]. The sample format, i.e., protein on PVDF, has previously been 
incompatible with electrospray ionisation analysis because the proteins are immobilised 
on a solid support. These proteins could be accessible for analysis through a surface 
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analysis technique such as LESA and this could become a means for incorporating the 
power of PAGE separation into top down proteomics research.  
In order to achieve this goal, four principles must be demonstrated: 1. Intact proteins 
must be successfully extracted from PVDF membranes. 2. The extraction process must be 
demonstrated on proteins blotted from an SDS PAGE gel. 3. The technique must be able 
to identify unknown proteins. 4. It must be demonstrated to be effective on a range of 
different proteins of different molecular weights. 
 A second potential application of the technique is analysis of proteins from membrane 
filters. The key points of interest here are to determine the most suitable LESA and mass 
spectrometry parameters for optimum sensitivity and consequently to determine the 
sensitivity of the approach. The requirements of this latter application clearly have some 
overlap with those of the former.  
 
3.1 Optimisation of extraction solvent composition 
 
The solvent composition used in the LESA sampling and electrospray process has an 
important effect on the recovery of proteins from the membrane and the subsequent 
ionisation. PVDF membranes are hydrophobic but absorbent to organic solvents. ESI 
solvents are ideally composed of an aqueous organic mixture, but the membrane will 
absorb high concentrations of organic solvents, rendering formation of a liquid 
microjunction in the extraction process impossible.  To deduce appropriate solvent 
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compositions, 5 μl aliquots of solutions with varying methanol and acetonitrile 
compositions were spotted onto a PVDF membrane by manual pipetting to investigate 
whether a liquid microjunction could be formed.  
 
 
 
 
Solvent 
composition microjunction formed Y/N 
  Replicate 1 
Replicate 
2 Replicate 3 
100%  H2O Y Y Y 
10 %   MeOH Y Y Y 
20 %   MeOH Y Y Y 
30 %   MeOH Y Y Y 
40 %   MeOH N N N 
50 %   MeOH N N N 
60 %   MeOH N N N 
70 %   MeOH N N N 
80 %   MeOH N N N 
90 %   MeOH N N N 
100 % MeOH N N N 
 
Table 3.3.1 Formation of liquid microjunctions at different methanol compositions 
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Solvent microjunction formed Y/N 
  
Replicate 
1 
Replicate 
2 
Replicate 
3 
100% H2O Y Y Y 
10 % ACN  Y Y Y 
20 % ACN  Y Y Y 
30 % ACN  N N N 
40 % ACN N N N 
50 % ACN N N N 
60 % ACN N N N 
70 % ACN N N N 
80 % ACN N N N 
90 % ACN N N N 
100 % ACN N N N 
 
Table 3.3.2  formation of liquid microjunctions at different acetonitrile compositions 
 
Tables 3.1 and 3.2 show  that liquid microjunctions with a high organic content could not 
be formed on PVDF membranes.   The maximum organic content of a solution that could 
form a microjunction was 30% methanol, and 20% acetonitrile. Above these limits, the 
applied solutions were absorbed by the membrane. ESI is more efficient with organic 
compositions approaching 50% [13]. Consequently, solutions comprising 30% methanol 
were used for the majority of this work because those solutions were capable of 
maintaining a liquid microjunction on PVDF with a higher organic content than solutions 
containing acetonitrile.  
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3.2 Recovery of intact proteins from PVDF membranes 
 
To investigate whether intact proteins could be recovered from PVDF membranes, a 
range of solutions of lyophilised proteins were spotted onto PVDF and dried before being 
sampled  by LESA.  Experiments were performed on 4 purified proteins, Bovine 
cytochrome C, Equine myoglobin, Bovine alpha casein and Yeast alcohol dehydrogenase. 
These 4 proteins were of molecular weights in the range of 12-33 kDa. Five microlitre 
aliquots of a 10 μM 70/30% water/methanol solution of each protein were dried onto the 
membrane at marked positions, to give a total of 50 pmol of protein in each spot.  Protein 
spots were sampled with LESA by use of the Triversa Nanomate™ coupled to the Orbitrap 
Velos™ mass spectrometer, see Section 2.2.3.1.    The samples were extracted in a solvent 
composed of 69.7/29.3/1% water/methanol/formic acid.   In each extraction process, 
4.5μl of solution was aspirated from the solvent reservoir and 2.5μl was dispensed onto 
the surface of the PVDF with the pipette tip held 1.6 mm above the surface to form a 
liquid microjunction.  The liquid microjunction was held in contact for 2 seconds before 
being aspirated back into the pipette tip. This cycle was repeated twice before the 
samples were infused into the mass spectrometer. Mass spectra shown below were 
acquired for 3 minutes in full scan mode, with each scan being composed of 5 co-added 
microscans.  
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Figure 3.1 LESA mass spectra of intact proteins extracted from PVDF membranes (a) bovine cytochrome C 12.3 kDa, 
(b) equine myoglobin 16.9 kDa, (c) bovine alpha casein 22 kDa (d) yeast alcohol dehydrogenase 33 kDa. 
 
Fig 3.1 shows the mass spectra from four different proteins spots on PVDF. These spectra 
show that proteins up to 22 kDa can be successfully analysed via LESA from PVDF. The 
mass spectrum obtained following LESA of alcohol dehydrogenase (33 kDa) showed peaks 
corresponding to the protein although they were not well-resolved. Peaks corresponding 
to the 22 kDa alpha casein protein were also less well-resolved than myoglobin or 
cytochrome C. These results demonstrate that intact proteins can be successfully 
extracted from PVDF membranes and that it can be used to analyse proteins of different 
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sizes, but this particular instrument could not successfully analyse proteins from a PVDF 
membrane larger than 30 kDa.  
 
Myoglobin was selected as the model protein to investigate compatibility of the LESA 
technique with electroblotting. Prior to blotting the protein from a gel, the sensitivity of 
LESA extraction from PVDF was investigated. A serial dilution of myoglobin solutions were 
prepared with concentrations of   100 μM 10 μM 1 μM, 100 nM 10 nM, 1 nM , 100 pM 10 
pM and 1 pM. Samples were made up  in 70/30% water/methanol and 5 μl aliquots of 
each were deposited onto a PVDF membrane at marked positions.  The samples spread 
over an area of approximatley 0.07 cm2 and were left to dry.  This left a series of spots 
with 500 pmol, 50 pmol 5 pmol, 500 fmol, 50 fmol, 5 fmol, 500 amol 50 amol and  5 amol 
of protein on the surface. Protein spots were analysed by use of the LESA mass 
spectrometry method described above.  
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Figure 3.2 LESA of intact myoglobin from PVDF with different amounts of protein (a) 500 pmol (b) 50 pmol (c) 5 pmol 
(d) 500 fmol 
 
Fig 3.2 shows LESA spectra of myoglobin from PVDF membranes with different amounts 
of protein.  Signals were observed from spots with as little as 5 pmol of protein. A typical 
PVDF membrane can recover around 33% of the protein loaded into a gel [194].  At least 
15 pmol of protein must be loaded into the gel for 5 pmol of protein to be recovered on 
the membrane. Fifteen pmol of myoglobin  is approximately  0.256 μg of protein.  A 
typical Western blot may have around 20-40 μg of a mixture of proteins loaded onto the 
gel [195]. This could be a very complex mixture such as a cell lysate that could possibly 
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contain thousands of proteins [196, 197]. In a very complex sample many low abundance 
proteins will be below this detection limit,[197] but the  5 pmol limit should be sensitive 
enough to detect some of the high abundance proteins, or be useful for less complex 
samples.  
 
3.3 Recovery of intact proteins blotted from SDS PAGE 
 
In section 3.2 it was shown that the sensitivity of LESA extraction of intact proteins from 
PVDF membranes was sufficient for the detection of proteins blotted from a gel. 
Consequently, LESA was used to analyse an electroblot of myoglobin. An SDS PAGE and 
electroblot was carried out as described in section 2.2.4 with 10 μg of protein loaded per 
lane onto a gel. Electroblotted protein samples were analysed by LESA mass spectrometry 
as described in section 3.2. 
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Figure 3.3 LESA mass spectrum obtained from PVDF membrane after electroblotting of myoglobin from an SDS PAGE 
gel.   Ten micrograms of myoglobin was loaded onto the gel.  
 
The mass spectrum in fig 3.3 shows that no signal corresponding to myoglobin was 
observed following LESA of a PVDF membrane blotted from an SDS PAGE gel loaded with 
10 µg of protein. This amount of protein is around 40 fold higher than that needed to 
generate a signal according to levels determined in the experiments of section 3.2. To 
investigate the lack of observed protein signal, further experiments were conducted as 
described below. 
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3.4 Negative ion mode LESA analysis of PVDF membranes 
One reason for the absence of signal observed in the spectrum shown in fig 3.3 could be 
the presence of dodecyl sulphate adducts extracted from the gel along with the protein. 
Sodium dodecyl sulphate is a notorious signal suppressor in ESI mass spectrometry that 
inhibits the ionisation of proteins and peptides.  The presence of SDS on ESI has two 
separate negative effects: Firstly, it is a detergent which reduces the surface tension of a 
solution.  When a solution is charged during the ESI process any surfactants present will 
destabilise the formation of the Taylor cone [198]. Secondly, the surfactant aggregates at 
the liquid air boundary and fewer ESI droplets will be emitted in the desorption process 
of ESI.  In the droplets that are emitted, the surfactant accumulates at the liquid air 
boundary preventing the analytes from reaching the surface.  In ESI, charge transfer from 
solvent to solute takes place at the surface of these droplets and the presence of SDS 
prevents this, thereby inhibiting ionisation [198].   SDS is responsible for providing a 
uniform charge to the proteins that is responsible for the electrophoretic mobility when a 
current is applied.    This mobility is required for resolving proteins during   PAGE and    
drawing extracting the proteins  from the gel during electroblotting, however high 
concentrations of SDS can reduce the binding affinity between the protein and the PVDF 
[194].  The transfer buffers contain methanol to attempt to strip it from the protein. The 
removal may not be entirely complete and some SDS may remain bound to the protein 
[194].  The presence of SDS could explain the absence of signal in section 3.3.   If SDS is 
retained on the membrane and is extracted along with the protein during LESA, it may be 
inhibiting the ionisation of the proteins. To investigate this hypothesis, an electroblot of 
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myoglobin was analysed via negative ion mode LESA mass spectrometry (LESA MS) to 
investigate the presence of dodecyl sulphate ions.   SDS PAGE and electroblotting was 
carried out as described in section 2.2.4 with 10 μg of protein loaded per lane. Samples 
were analysed with LESA parameters as described in section 3.2, with the exception that 
samples were ionised and analysed in negative ion mode. The ionisation voltage was -1.7 
kV and the gas pressure was 0.3 PSI. LESA extraction parameters remained the same as in 
section 3.2 with the exception that the extraction solvent composition was 30/70% 
water/methanol. The solvent did not contain formic acid as samples were being ionised in 
negative ion mode.  
 
Figure 3.4 Negative ion mode LESA mass spectrum obtained from PVDF membrane after electroblotting myoglobin 
from SDS PAGE gel.   Ten micrograms of myoglobin was loaded onto the gel. 
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Dodecyl sulphate anions were detected from myoglobin bands on the PVDF membrane as 
shown on the mass spectrum in fig 3.4. The measured m/z of the dodecyl sulphate peak 
was 265.1482, 1.5 ppm greater than the theoretical m/z of 265.1478. There is no 
indication whether these ions were protein bound adducts or free ions present on the 
membrane surface.  This observation supports the hypothesis that SDS could be 
responsible for suppressing the myoglobin signal in section 3.2.  Future efforts were 
aimed at developing means for eliminating SDS signal suppression.  Eliminating  signal 
suppression could require the incorporation of clean-up stages into the sampling routine. 
Although LESA is an automated process, one of the advantages of the procedure is that it 
is possible to decouple sampling and ionisation. 
 
3.5 Elimination of SDS signal suppression 
 
3.5.1 Reversed phase C4 Zip tips 
 
Reversed phase C4 zip tips are a commercially available approach for desalting intact 
proteins. They are specialised pipette tips with beads of C4 silica immobilised in the tip.  
Peptides and proteins will bind to the tips in aqueous solutions. Salts and detergents will 
not bind in these conditions. After the proteins are bound to the beads, the tips can be 
rinsed with an aqueous solution to eliminate these contaminants before the proteins are 
eluted. Elution is achieved by passing an organic solution through the beads. The 
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advanced user interface section (AUI) of the Chipsoft software used for controlling the 
Triversa Nanomate™ can be used to customise the robotic aspiration and dispense cycles 
of the sampling process.  This feature makes it viable to extract blotted proteins from a 
PVDF membrane using a LESA sampling cycle and place them back into a well of a 
microtitre plate. The samples could then be purified with C4 zip tips manually before final 
analysis by direct infusion ESI.  SDS PAGE and electroblots were carried out as described 
in section 2.2.4 with 10 μg of protein loaded per lane.  An AUI sampling routine was 
written to allow extraction of proteins from the surface of the PVDF before dispensing 
into a well. In this sampling method, a PVDF membrane was placed on the surface of a 
microtitre plate with the myoglobin bands located on the centre of the surface of the 
wells. One well was filled with an extraction solvent and the remaining wells were left 
empty. Eight microlitres of a 69.7/29.3/1% water/methanol/formic acid solution was 
extracted from the solvent reservoir before 7 µl was dispensed onto the surface of a 
PVDF membrane. Larger microjunction volumes were used to account for sample loss 
from dispensing the solution into a well in a microtitre plate after LESA. After a delay of 
approximately 3 seconds, 6.5 µl of sample was reaspirated into the pipette tip and the 
entire solution was deposited back into one of the empty wells of the microtitre plate. 
Samples were then purified by reversed phase C4 Zip tips as described in section 2.2.5. 
After samples were purified by C4 zip tips, they were analysed by direct infusion 
electrospray ionisation, at a gas pressure of 0.3 PSI and an ionisation voltage of 1.7 kV. 
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Figure 3.5 Direct infusion ESI mass spectrum of myoglobin afer surface extraction and zip tipping of a PVDF 
membrane electroblotted from SDS PAGE gel.  Gel was loaded with 10 μg  of myoglobin 
 
Fig 3.5 shows the mass spectrum obtained from using c4 zip tips to purify a sample 
extracted from an electroblot with LESA.   The results show that zip tipping did not 
eliminate signal suppression.  The composition of SDS in the PAGE running buffers is 
approximately 0.1% w/v which is much higher than the concentration of the proteins. 
During page one SDS molecule binds along the protein at every two amino acids [199]. To 
remove all the SDS will be a major challenge. The most likely reason for the failure of this 
treatment appears to be that the zip tipping was could not to remove all the SDS from the 
protein.   Other treatments were investigated to remove the SDS before the surface 
extraction process, as described below. 
83 
 
 
3.5.2 Cetyltrimethyl ammonium bromide 
 
A method  to eliminate the effects of SDS from ESI solutions has recently been presented 
by  Shieh et a. l[200].  In this method the cationic surfactant cetyltrimethyl ammonium 
bromide (CTAB) is added into the ESI solution at a concentration equivalent to the 
concentration of SDS. When in solution, SDS and CTAB form ion pairs which are stronger 
than the interactions between the protein and the SDS. These ion pairs are insoluble in 
aqueous solutions and precipitate out [200]. If CTAB is used for this purpose it must be 
used carefully: it acts as a ESI signal suppressor in its own right and to effectively 
eliminate the SDS it must be used in an equivalent concentration [200].  The 
concentration of SDS within the ESI after LESA is unknown and to reduce the possibility of 
causing signal suppression, CTAB was used to eliminate the SDS from the PVDF 
membrane after the proteins had been electroblotted onto it.  SDS PAGE and 
electroblotting was carried out as described in section 2.2.4. With 10 μg of myoglobin 
loaded per lane. After blotting, the entire PVDF membrane was rinsed in a 1% solution of 
CTAB for 10 minutes which was then dried for 2 hours. The membrane was rinsed in 
methanol for 30 seconds to remove residual CTAB and air dried. Membranes were 
analysed by the LESA mass spectrometry method described in section 3.2.  
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Figure 3.6 LESA mass spectrum of PVDF membrane plotted from an SDS PAGE gel after treatment with CTAB (A) full 
mass spectrum  in the mass range 190- 2000 (B) magnified region of m/z  750-1100 
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Fig 3.6 shows the LESA mass spectrum of a PVDF membrane electroblot rinsed with CTAB 
prior to extraction. Low abundance peaks corresponding to myoglobin were detected.  
These peaks could only be seen under magnification by approximately 770 fold of the m/z 
800-1100 region, see fig 3.6 B. Residual CTAB was observed in the full scan mass 
spectrum, see fig 3.6 A. The signal intensity is too low to carry out fragmentation and  if 
the protein was unknown  it could not be  identified from a mass spectrum of this quality.  
The method was repeated, but this signal could not be reproduced or improved. 
 
3.6 Recovery of intact proteins from PVDF membranes after native PAGE 
 
Considering attempts to eliminate SDS had proved to be unsuccessful, native PAGE was 
investigated as an alternative means of separating proteins prior to electroblotting. 
Native PAGE is an alternative to SDS page that, rather than using a surfactant to denature 
proteins, separates intact proteins on the basis of their native charge or following the 
addition of mild surfactants such as Coomassie blue dyes [201].  Native PAGE lacks the 
molecular weight based separation that is provided by SDS but can still be used to 
separate mixtures of proteins into their individual complexes [201]. Interestingly it may 
also retain non-covalently bound subunits [202]. Native PAGE could eliminate the 
problem of signal suppression and importantly confirm whether the presence of SDS was 
responsible for the non-detection of proteins described above. A native PAGE and 
electroblot was run as described in section 2.2.6, with 100 µg of protein loaded on the 
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gel. Samples were analysed with the LESA MS method described in section 3.2, with the 
exception that samples were analysed by a mass spectrometry method composed of 30 
microscans in the mass range of 450-2000 for 8 minutes.  
 
 
Figure 3.7 LESA mass spectrum of myoglobin extracted from a PVDF membrane blotted from a native gel loaded with 
100 µg of protein. 
Fig 3.7 shows a LESA mass spectrum of a PVDF membrane blotted from native PAGE of 
myoglobin.  No peaks were observed that corresponded with myoglobin. This 
demonstrates the lack of signal observed in previous experiments  was not entirely due to 
signal suppression  from SDS. There are other problems associated with electroblotting 
that may make the technique incompatible for analysis by a surface sampling technique 
such as LESA. Firstly, proteins do not always bind to the surface of the PVDF and may 
become transmitted through the polymeric matrix. A second problem may be that when 
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the proteins do bind to the PVDF, they bind irreversibly [203]. LESA is a surface sampling 
technique, only capable of extracting soluble analytes weakly associated with the surface 
of a substrate. It cannot be used to solubilise strongly bound analytes buried deep within 
the matrix of a solid polymer.   
 
 3.7 Optimisation of extraction parameters for intact protein analysis 
from PVDF membranes 
 
The results described previously show that electroblotting is not a suitable application for 
LESA, so the work presented in the second half of this chapter was aimed at analysing  
intact proteins from PVDF membrane based air filters used in air quality monitoring 
programmes. The remainder of the work presented in this chapter was performed in 
collaboration with Unilever plc.    Initial experiments focussed on optimising the 
extraction conditions for the model protein β lactoglobulin (βlg) from PVDF membranes. 
In section 3.1, signals were observed for the protein myoglobin from membranes spotted 
with as little as 5 pmol of protein over an area of approximately 0.07 cm2. In order to 
improve sensitivity, each of the LESA extraction parameters was optimised.    
3.7.1 Calculation of surface areas and surface protein concentrations 
 
To calculate the surface concentration of protein in a spot, a range of droplets with 
different volumes were measured to show how far they spread on the PVDF.  The 
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droplets were composed of 70/30% water/methanol and were applied to a membrane 
and the diameters of these spots were measured.  The areas of the spots were calculated 
and are shown in table 3.3, this was performed in triplicate.  
 
Volume 
deposited /  
μl Diameter / mm Area / cm2 
  
 Replicate 
1 
Replicate 
2 
Replicate 
3 
Replicate 
1 
Replicate 
2 
Replicate 
3 
5 3 3 3 0.07 0.07 0.07 
4.5 3 3 3.5 0.07 0.07 0.096 
4 3 3 3 0.07 0.07 0.07 
3.5 3 3 3 0.07 0.07 0.07 
3 3 3 2.5 0.07 0.07 0.05 
2.5 2.5 2.5 2.5 0.05 0.05 0.05 
 
Table 3.2 Diameters and areas of sample spots following deposition of droplets of varying volumes onto PVDF 
membranes. 
Table 3.3 shows the areas covered by sample spots of different volumes. A five microlitre 
droplet produces a sample spot of area 0.07 cm2. For protein concentrations of 1 pg/µL, 
the surface concentration of the sample spot will be 70 pmol/ cm2.   
 
3.7.2 Sampling time 
 
The sampling time of a LESA sampling routine can be controlled either by increasing the 
post dispense delay or increasing the number of repeated mix cycles. The post dispense 
delay is the period of time between dispensing the solvent onto the surface of the PVDF 
and re-aspirating it into the pipette tip. A series of 70 pmol/cm2 spots were dried onto a 
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PVDF membrane and sampled by LESA  whilst varying the post dispense delay. 
Experiments were performed in triplicate.  Seven microlitres of a 69.7/29.3/1% 
water/methanol/formic acid was aspirated from the solvent reservoir and 4.5 µl were 
deposited onto the surface of the membrane at a height of 1.6 mm above the surface. 
(Note that a 2.5 μl microjunction was used in the experiments described in sections 3.2-
3.6; however the results shown in section 3.7.1 suggest that a larger microjunction is 
required to fully cover the protein spot).    The delay before aspiration of 5 µl was varied 
between 1 and 11 seconds at 2 second intervals. The aspiration and dispense cycle was 
repeated once before being infused into the mass spectrometer. Samples were analysed 
by a 7 minute mass spectrometry method composed of 5 minutes full scan in the m/z 
region of 600-2000, followed by 1 minute isolation of the +10 charge state of the protein, 
followed by a one minute SIM to monitor the same charge state.  The method is 
described in detail in section 2.2.3.1 and was used throughout all future optimisation 
experiments.  In all cases, each scan was composed of 5 co-added microscans.  The 
optimum conditions were chosen on the basis of the signal to noise ratio of the + 10 
charge state of the protein.   
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SUMMARY 
    Groups Count Sum Average Variance 
1 Second 3 16.62 5.54 8.4196 
3 Seconds  3 104.05 34.683333 261.48243 
5 Seconds 3 182.9 60.966667 1596.7582 
7 Seconds 3 548.562 182.854 61323.779 
9 Seconds 3 126.1 42.033333 100.49923 
11 Seconds 3 181.98 60.66 323.2557 
 
ANOVA 
      Source of Variation SS df MS F P-value F crit 
Between Groups 56714.863 5 11342.973 1.069853 0.42376744 3.105875 
Within Groups 127228.39 12 10602.366 
   
       Total 183943.25 17         
 
Figure 3.8.   Chart showing effect of extraction time on mean signal to noise ratio  of the +10 charge state of βlg 
obtained over 3 replicates and corresponding one way ANOVA. Error bars represent 1 standard deviation.    
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SUMMARY 
    Groups Count Sum Average Variance 
1 Second 3 33.1 11.033333 56.389233 
3 Seconds  3 984.88 328.29333 84522.947 
5 Seconds 3 844.29 281.43 20418.662 
7 Seconds 3 3379.56 1126.52 2535023.8 
9 Seconds 3 6581.41 2193.8033 2800978.3 
11 Seconds 3 10645.16 3548.3867 18004956 
 
ANOVA 
      Source of Variation SS df MS F P-value F crit 
Between Groups 28533853 5 5706770.5 1.4604064 0.27296147 3.105875 
Within Groups 46891912 12 3907659.3 
   
       Total 75425764 17         
 
Figure 3.9 Chart showing effect of extraction time on mean signal to noise ratio  of the +10 charge state of βlg 
obtained from targeted SIM window over 3 replicates and corresponding one way ANOVA. Error bars represent 1 
standard deviation.    
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effect of sampling time did not have a statistically significant effect on the signal to noise 
ratio of either the full scan (p=0.42) or the targeted SIM window (p=0.27)  Both fig 3.8 
and 3.9 show that as the signal to noise ratio increases they error bars also get larger and 
the variance amongst the data also increases.  Despite the results of the ANOVA, figs 3.8 
and 3.9 show that the average signal to noise ratio of the +10 charge state was  greatest  
in the full scan  when the post dispense delay was 7 s  whereas in the SIM mode mass 
spectrum the average signal to noise ratio was greatest when the delay was 11 seconds. 
This difference between the results is likely to be due to the increased influence of 
polymeric contaminants extracted in longer the sampling  times.  Longer extraction times 
will also allow the diffusion of more contaminants from the membrane into the 
extraction solvent along with the protein thus reducing the signal to noise ratio of the 
protein. The targeted SIM-mode analysis eliminates some of this noise and ensures that 
the ions contributing to the AGC target will primarily be protein ions, leading to spectra 
with a higher signal to noise. For known proteins, such as those likely to be analysed in air 
monitoring programmes, targeted mass spectrometry approaches such as the SIM-mode 
analysis are ideal. Despite that the results were not statistically significant the greatest 
average signal to noise ratio acquired with the SIM-mode analysis was found at 11 
seconds so this was used in further experiments.  
 
The sampling time of LESA can also be increased by increasing the number of mix 
(dispense/reaspirate) cycles which also mixes the sample in the pipette tip.     An 
experiment was carried out to determine the optimum number of mix cycles between 0, 
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1 and 2 on a series of 70 pmol/cm2 spots.   Experiments were performed in triplicate, the 
remainder of the sampling routine was the same as described previously with the 
exception that a post-dispense delay of 11 seconds was applied.  
 
SUMMARY 
    Groups Count Sum Average Variance 
0 mixings 3 134.27 44.75667 321.7572 
1 mixings  3 328.84 109.6133 5323.698 
2 mixings 3 232.74 77.58 1079.59 
 
ANOVA 
      Source of Variation SS df MS F P-value F crit 
Between Groups 6309.8929 2 3154.946 1.407402 0.315367 5.143253 
Within Groups 13450.091 6 2241.682 
   
       Total 19759.984 8         
 
Figure 3.10 Chart showing effect of additional mix cycles on mean signal to noise ratio of the +10 charge state of βlg 
obtained over 3 replicates and corresponding one way ANOVA. Error bars represent 1 standard deviation.    
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SUMMARY 
    Groups Count Sum Average Variance 
0 mixings 3 1256.94 418.98 35094.16 
1 mixings  3 2931.28 977.0933 109200.6 
2 mixings 3 1992.75 664.25 56378.76 
 
ANOVA 
      Source of Variation SS df MS F P-value F crit 
Between Groups 469518.82 2 234759.4 3.509572 0.097883 5.143253 
Within Groups 401347.08 6 66891.18 
   
       Total 870865.9 8         
 
Figure 3.11 Chart showing effect of additional mix cycles on mean signal to noise ratio of the +10 charge state of βlg 
obtained from targeted SIM window over 3 replicates and corresponding one way ANOVA. Error bars represent 1 
standard deviation.    
 
The effect of adding additional mix cycles into the LESA sampling routine on the signal to 
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mass spectra and the SIM-mode mass spectra was at its greatest following one repeat 
mix cycle. The one way ANOVAs however show that this effect was not statistically 
significant on either the full scan (p=0.31) or the SIM mode mass spectrum (p=0.09).  As 
mentioned previously, adding mix cycles increases the length of time that the 
microjunction is in contact with the surface of the PVDF and also mixes the sample within 
the pipette tip and mixes the sample in the pipette tip. This resulted in an improved 
signal to noise ratio following the first mix cycles, but adding a second did not provide any 
improvement.  The ANOVA showed this effect was not statistically significant but the 
greatest average signal to noise ratio from this experiment was obtained following one 
mix cycle, which was retained for future experiments.   
 
3.7.3 Liquid microjunction volume 
 
The volume of solvent applied to surface was varied to determine the optimum liquid 
microjunction volume.  Changing the microjunction volume affects the area of PVDF 
being sampled. βlg spots were analysed with a solution composed of  69.3/29.7/1% 
water/methanol/formic acid. Seven microlitres of this solution was aspirated from the 
solvent well and a range of different volumes between 2.5 and 5μl at intervals of 0.5μl 
were applied to the surface of the PVDF. Experiments were performed in triplicate. The 
solution was dispensed at a height of 1.6 mm above the surface. A volume of solvent 
0.5μl greater than that of the amount deposited was then reaspirated into the pipette 
tip. One repeated mix cycle was performed before the solution was infused into the mass 
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spectrometer at a gas pressure of 0.3 PSI and an ionisation voltage of 1.7 kV. All 
experiments were performed in triplicate  
 
SUMMARY 
    Groups Count Sum Average Variance 
2.5μl 3 65.77 21.92333 442.1056 
3μl 3 359.18 119.7267 24621.11 
3.5 μl 3 435.21 145.07 8006.199 
4 μl 3 485.91 161.97 1209.363 
4.5μl 3 328.84 109.6133 5323.698 
5 μl 3 322.16 107.3867 4183.901 
 
ANOVA 
      Source of Variation SS df MS F P-value F crit 
Between Groups 35353.43 5 7070.686 0.968888 0.47433 3.105875 
Within Groups 87572.76 12 7297.73 
   
       Total 122926.2 17         
 
Figure 3.12 Chart showing effect of liquid microjunction extraction volume on mean signal to noise ratio of the +10 
charge state of βlg obtained over 3 replicates and corresponding one way ANOVA. Error bars represent 1 standard 
deviation.    
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SUMMARY 
    Groups Count Sum Average Variance 
2.5μl 3 1106.19 368.73 116228.9 
3μl 3 1017.19 339.0633 51243.77 
3.5 μl 3 4830.24 1610.08 65267.37 
4 μl 3 4884.73 1628.243 57694.5 
4.5μl 3 2931.28 977.0933 109200.6 
5 μl 3 4563.26 1521.087 76027.65 
 
ANOVA 
      Source of Variation SS df MS F P-value F crit 
Between Groups 5524147 5 1104829 13.93629 0.00012 3.105875 
Within Groups 951325.6 12 79277.14 
   
       Total 6475473 17         
 
Figure 3.13  Chart showing effect of liquid microjunction volume on mean signal to noise ratio of the +10 charge state 
of βlg obtained from targeted SIM window over 3 replicates and corresponding one way ANOVA. Error bars 
represent 1 standard deviation.  
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Figs 3.12 and figs 3.13 show the effect of  sampling volume on the signal to noise ratio of 
βlg  on both the full scan and the targeted SIM window. The results of the one way 
ANOVA show that the effect of sampling volume did not have a statistically significant 
effect on the signal obtained from the full scan (p=0.474) but did have a statistically 
significant effect on the targeted SIM approach. The significance of the p value was 
further supported by the fact the F value (13.93) was greater than the F critical (3.10).   
Fig 3.13 shows that the greatest average signal to noise ratio obtained from the SIM 
mode mass spectrum was from liquid microjunctions with a volume of 4 µl.  Larger micro 
junctions may be more successful than smaller microjunctions because there is  a greater 
area of the spot can be sampled so that more protein can diffuse into the microjunction 
during extraction. Smaller microjunctions will also leave some of the solution remaining 
in the tip which never comes into contact with the surface and the protein. The reasons 
as to why the signal to noise ratio decreased with micro junctions with volumes of 4.5 
and 5 µl are less obvious. The reason may be that a 4 µl microjunction was enough to 
sample the whole spot, and that larger microjunctions do not provide any additional 
benefit in sampling.  
 
3.7.4 Liquid microjunction dispension height 
 
The sampling area of a liquid microjunction can  be affected by the height from which the 
microjunction is applied. A droplet can spread further across the surface when applied 
closer to the membrane o spread less when applied further away.  This effect of 
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dispensing a microjunction at a height of 1.2, 1.4 and 1.6 mm was investigated on a series 
of 70 pmol/cm2 spots. The extraction parameters were used as previously, with a 
dispension volume of 4 µl, an aspiration volume of 4.5 µl, a post dispense delay of 11 
seconds and the inclusion of one repeat mix cycle.  In this experiment the pipette 
dispension and aspiration heights were adjusted between 1.2 and 1.6 mm, in 0.2 mm 
intervals. This range was chosen because at 1.8 mm the liquid microjunction was too far 
above the surface for sampling and at 1.0 mm the pipette tip was pushed directly onto 
the surface of the PVDF. The PVDF membrane is a floppy surface that warps slightly when 
applied to the sampling plate, so the microjunction needed to be applied more than 1 
mm above the surface.  Experiments were recorded in triplicate. 
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SUMMARY 
    Groups Count Sum Average Variance 
1.2 mm 3 160.24 53.41333 166.3297 
1.4 mm 3 120411.5 40137.18 4.65E+09 
1.6 mm  3 1916.86 638.9533 610944.2 
 
ANOVA 
      Source of Variation SS df MS F P-value F crit 
Between Groups 3.17E+09 2 1.58E+09 1.020918 0.415325 5.143253 
Within Groups 9.31E+09 6 1.55E+09 
   
       Total 1.25E+10 8         
 
Figure 3.14 Chart showing effect of liquid microjunction dispension height on mean signal to noise ratio of the +10 
charge state of βlg obtained over 3 replicates and corresponding one way ANOVA. Error bars represent 1 standard 
deviation.    
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SUMMARY 
    Groups Count Sum Average Variance 
1.2 mm 3 980.27 326.7567 149091.4 
1.4 mm 1 3 1153.09 384.3633 5642.792 
1.6 mm  3 1022 340.6667 15674.3 
 
ANOVA 
      Source of Variation SS df MS F P-value F crit 
Between Groups 5421.415 2 2710.707 0.047721 0.953758 5.143253 
Within Groups 340816.9 6 56802.82 
   
       Total 346238.3 8         
 
Figure 3.15 Chart showing effect of liquid microjunction dispension height on mean signal to noise ratio of the +10 
charge state of βlg obtained from targeted SIM window over 3 replicates and corresponding one way ANOVA. Error 
bars represent 1 standard deviation.  
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SIM window (p=0.95).  The error bars at an extraction height of 1.4 mm on fig 3.14 are 
very large, which is also reflected by the variance at 1.4 mm as shown in the ANOVA. This 
variance is due to the fact the noise obtained from one of the three replicates was 
unusually low, resulting in an usually high signal to noise ratio. The exact reasons behind 
this are not known but this error was not reflected in the targeted SIM approach. The 
targeted SIM approach is more sensitive and therefore more appropriate for detecting 
small amounts of known proteins.  Although the effect of dispension height did not have 
a statistically significant effect the greatest average signal to noise ratio was obtained 
when the microjunction was dispensed at a height of 1.4 mm which was carried forward 
in future experiments. Applying the liquid microjunction closer to the surface of the 
membrane ensures that it spreads across a larger area, ensuring more of the spot is 
sampled.  This may explain why the signal to noise ratio was higher at 1.4 mm than it was 
at 1.6. There was a small fall in signal to noise ratio when sampling was decreased from  
1.4 to  1.2 mm above the surface of the membrane. This decrease is less easy to explain, 
but may be simply that dispensing the microjunction at 1.4 mm sufficiently covered the 
whole spot and that dispensing the sample below this provided no additional benefit.  
 
3.7.5 Determination of limit of detection limit for LESA analysis of βlg from 
PVDF membranes  
 
Having determined the optimum extraction parameters for LESA surface sampling 
parameters, a PVDF membrane with spots containing a serial dilution of different βlg 
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concentrations was analysed. Concentrations ranged from 1-70 pmol/cm2 at 10 pmol/cm2 
intervals plus additional samples at 45 and 35 pmol/cm2. Samples were analysed by LESA 
using the optimum extraction parameters determined by the experiments above, see 
table 3.3.  Experiments were performed in triplicate. 
 
Sample volume 7 μl 
Dispense volume 4 μl 
Aspiration volume 4.5 μl 
Post dispense delay 11 seconds 
Repeat mix cycles 1 
Aspiration/dispense height 1.4 mm 
 
Table 3.3 Optimum LESA parameters determined by previous experiments 
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Figure 3.16 LESA mass spectra of βlg spots at different concentrations: (A) 70 pmol/cm2 (B) 45 pmol/cm2 (C) 40 
pmol/cm2 (D) 35 pmol/ cm2 
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  Signal to noise ratio of peak 
Sample +15 +14 +13 +12 +11 +10 +10 Isolation +10 SIM 
70 pmol/cm2 1 7.35 7.35 4.78   18.75 66.9 85.74 581.74 
70 pmol/cm2 2 6.33 6.78 5.03   53.29 216.27 4.16 167.66 
70 pmol/cm2 3 7.64 7.52 5.47   17.57 56.27 72.5 3085.05 
60 pmol/cm2 1 6.14 6.61 4.24   10.55 38.28 28.17 2650.8 
60 pmol/cm2 2 2.91 4.14 3.87   331.92 10106.67 - 73.87 
60 pmol/cm2 3 3.65 3.74 2.03   8.6 44.69 - 178.06 
50 pmol/cm2 1 2.78 3.07 2.71   32.63 102.06 - 81.5 
50 pmol/cm2 2 - - - - 5.19 25.6 - 66.34 
50 pmol/cm2 3 2.96 3.43 3.66   422.1 2617.57 - 78.27 
45 pmol/cm2 1 - - - - 4.24 16.44 - 122.93 
45 pmol/cm2 2 - 5.37 6.86 4.49 3.56 18.05 - 54.1 
45 pmol/cm2 3 - 2.77 - - - 10.52 - 47.91 
40 pmol/cm2 1 - - - - - - - - 
40 pmol/cm2 2 3.79 3.81 3.48 - - 20 - 6.68 
40 pmol/cm2 3 - - 1.9 - - 4.48 - - 
35 pmol/cm2 1 - - - - - - - - 
35 pmol/cm2 2 - - - - - - - - 
35 pmol/cm2 3 - - - - - - - - 
30 pmol/cm2 1 - - - - - - - - 
30 pmol/cm2 2 - - - - - - - - 
30 pmol/cm2 3 - - - - - - - - 
20 pmol/cm2 1 - - - - - - - - 
20 pmol/cm2 2 - - - - - - - - 
20 pmol/cm2 3 - - - - - - - - 
10 pmol/cm2 1 - - - - - - - - 
10 pmol/cm2 2 - - - - - - - - 
10 pmol/cm2 3 - - - - - - - - 
1 pmol/cm2 1 - - - - - - - - 
1 pmol/cm2 2 - - - - - - - - 
1 pmol/cm2 3 - - - - - - - - 
 
Table 3.4 Signal to noise ratios of peaks corresponding to β lactoglobulin from protein spots of various 
concentrations Results shown for individual replicates.  
 
Fig 3.16 and table 3.4 show that with the optimised LESA extraction parameters, βlg was 
detected down to a concentration level of 40 pmol/cm2. At this concentration, the 
proteins was only observed in one of three replicates and fig 3.16 C shows that the signal 
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is very weak.  To ensure a consistent and reproducible signal, at least 45 pmol/cm2 is 
needed on the surface.   
 
3.8 Conclusion 
 
The work presented in this chapter demonstrates that the analysis of intact proteins from 
PVDF membranes is possible by use of LESA MS. The initial aim was to develop a new 
approach for the purification of intact proteins from PVDF membranes following 
electroblotting from SDS PAGE. The approach was not able to recover proteins blotted 
from a gel but it was possible to extract intact proteins directly applied to the surface of 
the membrane. Both SDS PAGE and native PAGE,  were attempted which suggests that 
the problem is due to an inherent problem caused during the blotting process rather than 
as a result of signal suppression by SDS anions. The second half of the chapter focused on 
determining the optimum LESA parameters for extracting proteins from membranes and 
investigating the limits of detection, with a view to application in air monitoring. The limit 
of detection for b lactoglobulin was shown to be 40 pmol/cm 2. 
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Chapter 4 Bottom-up proteomics analysis of dried blood spots by 
liquid extraction surface analysis mass spectrometry 
 
4.1 Introduction 
Prior to the work contained in this thesis, LESA had been used effectively for the analysis 
of intact globin proteins from DBS. The technique was demonstrated for use in the clinic 
for determining the presence of newborn haemoglobin variants[2].  The approach 
focused on the analysis of haemoglobins and no other proteins had been identified from 
DBS.  Blood is a complex biofluid composed of thousands of different proteins and a top-
down approach may be unsuitable for identifying other proteins.  As mentioned in 
section 1.3.5 the analysis of intact proteins is usually used as a tool for the 
characterisation of particular proteins of interest and is less successful in untargeted 
protein identification. The aim of the work presented in this chapter was to incorporate a 
bottom-up proteomics strategy for the identification of proteins from DBS by LESA in 
order to identify proteins other than the highly abundant haemoglobins. In doing so, the 
methodology must maintain the automated nature of LESA and reduce any required 
manual intervention as much as possible. Part of this work presented here was published 
as an article in the Journal of the American Society for Mass Spectrometry [204]. 
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4.2 LESA of dried blood and plasma spots.  
 
4.2.1 Dried blood spots 
To confirm that no proteins other than haemoglobin could be detected from a DBS by 
using LESA, the methods described by Edwards et al. [2] were repeated.  Seven 
microlitres of a solution composted of 48.5/48.5/3% methanol/water/ formic acid was 
aspirated from the LESA solvent well, and 6 microlitres were dispensed onto the spot at a 
height of 1.6 mm above the surface. Five microlitres were reaspirated after a delay of 5 
seconds. The aspiration and dispense cycle was repeated once before the solution was 
infused by electrospray into the mass spectrometer. Samples were analysed for a period 
of 8 minutes in full scan mode. Each scan comprised 30 microscans.    
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Figure 4.1 LESA mass spectrum obtained from DBS on filter paper. 
 
The mass spectrum shown in fig 4.1 reveals peaks corresponding to alpha globin, beta 
globin and the free haem peak. No other proteins were identified. Haemoglobin is by far 
the most abundant protein in blood, with a concentration of approximately 130 mg/ml 
for a healthy adult male and 120 mg/ml for a healthy adult female [205].  The 
concentration of haemoglobin is significantly higher than any other protein: the next 
most abundant protein is albumin which has a concentration of 50 mg/ml [206]. The lack 
of signal for any other proteins could be down to two factors: Either the top-down 
method could not cope with the dynamic range between haemoglobin and the next most 
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abundant proteins, or that the remaining proteins are too large to be detected by top-
down methods with the resolution available on the orbitrap.   
 
4.2.2 Dried plasma spots 
To investigate if any other blood proteins could be detected by a top-down technique, a 
dried plasma spot (DPS) was analysed with LESA. Plasma is the liquid portion of the blood 
which is depleted of red blood cells and haemoglobin so its analysis does not face the 
problem of an overwhelming haemoglobin concentration.  Ordinary DBS cards could not 
be used for LESA analysis of plasma. They are suitable for DBS analysis because the blood 
clots to form a matrix on top of the filter paper. Without this matrix, the liquid 
microjunction will be immediately absorbed into the filter paper rendering surface 
sampling impossible.  PVDF was used as an alternative to filter paper for DPS as sampling 
of intact proteins had already been demonstrated on this surface, as described in Chapter 
3.  Twenty microlitre aliquots of plasma were spotted onto PVDF at marked positions, left 
to dry and analysed with LESA using the same method applied for analysis of DBS with 
the exception that the extraction solvent was composed of 69.3/29.7/1% 
water/methanol /formic acid and that each scan was composed of 50 microscans.  
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Figure 4.2 LESA mass spectrum obtained from a dried plasma spot on PVDF. 
The mass spectrum in fig 4.2 shows that no intact proteins could be identified after LESA 
analysis of a dried plasma spot. This result suggests that even if the issue of haemoglobin 
abundance could be overcome, the top down method is not a viable option for 
identifying other proteins from a DBS. 
 
4.3 Bottom-up proteomics 
The results above suggest that top down proteomics is not viable for identifying other 
proteins from DBS, therefore, bottom up proteomics was investigated as an alternative. 
An initial experiment on a DPS was carried out to investigate the potential for protein 
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identification.  Mass spectrometry had been used for the targeted identification of 
particular proteins from DBS previously [171, 174]. In both of these analyses, a small 
punch was cut out of a DBS, the proteins were eluted into solution which was then 
digested with trypsin. A modification of the procedure described in [174] was carried out 
on a DPS. Twenty microlitres of human plasma was spotted onto a filter paper dried 
blood spot card.  After drying, 6 mm punches were cut out and the proteins were eluted 
from the card. Proteins were eluted into 75 μl 50 mM NH4 HCO3 10% methanol for 2 
hours on a thermomixer heated to 40˚C shaking at 800 rpm.  After elution, a Bradford 
assay was carried out to measure the protein concentration.   A 40 μg aliquot of protein 
was taken and 5μg of trypsin was added to create a 1:20 ratio of enzyme to protein. 
Samples were digested for periods of 1 hr and 12 hr. Proteolysis was quenched by the 
addition of 10% formic acid and acetonitrile.  The digests were diluted tenfold in 
49.5/49.5/1% water/methanol/formic acid and directly infused into the mass 
spectrometer. Samples were analysed by a 5 minute direct infusion top 7 CID method 
described in section 2.2.3.2 and database searching was carried out as described in 
section 2.2.8. 
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Figure 4.3 Direct infusion ESI analysis of dried plasma spot digest: (A) 1 h digest ( B) 12 h digest. 
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Multiple proteins were successfully identified by direct infusion analysis of a tryptic 
digestion of a dried plasma spot as shown on fig 4.3.  The full list of proteins identified 
from the 2 digests are shown in appendix 4.1 and 4.2. The proteins identified were mostly 
high abundance plasma proteins such as albumin and immunoglobulins. That result is 
perhaps to be expected as the method relied of direct infusion ESI analysis without HPLC 
separation. This result demonstrates that bottom up protein identification could be 
suitable for identifying other proteins from DBS. Future efforts were aimed at 
incorporating a DBS digestion procedure that is suitable for analysis with LESA.  
 
4.3.1 DBS proteolysis 
There are three possible means of incorporating a digestion stage into the DBS-LESA 
sampling routine. The blood could be digested before it is applied to the card, whilst the 
blood is on the card, or after the proteins have been extracted and before they are 
introduced into the mass spectrometer. The first option of digesting the blood before it is 
applied to the card is not a viable option as it would negate the advantages of DBS 
sampling such as the ability to sample blood straight from a finger prick. To digest the 
blood in this fashion would require the blood to be collected via phlebotomy and 
digested in solution before spotting. In which case there would be no added advantage of 
applying it to the DBS card.   An on card digestion is a viable option as it would maintain 
compatibility with finger prick sampling, but would be difficult to maintain compatibility 
with LESA sampling. Filter paper DBS cards are absorbent so the digestion process must 
proteolytically cleave proteins on the DBS surface but not degrade the clot matrix 
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required for LESA sampling. The final option would be to digest the proteins after the 
sampling process. This option is feasible but would include extra time demands in the 
sampling procedure.  The second and third approaches were attempted on a series of 
DBS with the aim of identifying multiple proteins.  
The two different digestion protocols were carried out manually with the emphasis on 
methods that could subsequently be performed by a robotic sequence carried out on the 
Triversa Nanomate™. 
4.3.2 On card proteolysis 
In this procedure, trypsin solutions were applied to the surface of the DBS which must be 
kept wet to permit proteolysis. The procedure was carried out on DBS placed on a 
heating block at 37˚C. A 20 µl aliquot of methanol was applied to denature the proteins 
prior to digestion. The continual heating meant that applied solvents slowly evaporated. 
After applying the methanol, twenty microliters of 0.5 µg/µl trypsin in 25 mM acetic acid 
and 25 mM NH4HCO3 were applied to the surface of the spot. After 10 minutes, this 
solution had begun to evaporate and an additional 20 µl was added. A further ten 
minutes followed before this solution had dried and from there on 20 µl aliquots of 50 
mM NH4HCO3 were added at 10 minute intervals for a period of 4 hours. After digestion 
the peptides were eluted from the spot. LESA sampling was attempted but the surface 
matrix had been degraded too much to permit the formation of a liquid microjunction.  
The elution process was carried out by cutting out a 5 mm punch and eluting it in 75 μl 
10% methanol for 2 hours on a thermomixer operating at 800 rpm at 40˚C. After elution, 
digestion was inhibited by the addition of 15μl 10% formic acid and 20μl acetonitrile. 
116 
 
 
4.3.3  Surface sampling followed by proteolysis  
In this approach, intact proteins were extracted from the surface of the DBS and 
subsequently digested in solution.  The surface extraction was performed by a hand-held 
pipette.  Seven microliters of a 50 mm NH4HCO3 solution was aspirated into the pipette 
tip and approximately half was applied to the surface of a DBS. The liquid microjunction 
was held in contact with the surface for a period of 5 seconds before reaspiration. The 
sample was placed in an Eppendorf tube and 1 µg of trypsin was added. The mixture was 
incubated in a thermomixer for 1 hour at 37˚C whilst being shaken at  800 RPM. After 1 
hour, the digestion was inhibited by addition of 1.5 µl 10% formic acid and 2 µl 
acetonitrile prior to direct infusion analysis. 
 
Both samples were then treated to a tenfold dilution with 49.5/49.5/1% 
water/methanol/formic acid and analysed by a 5 minute direct infusion top 7 CID method 
described in section 2.2.3.2 and searched as described in section 2.2.8.  
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Figure 4.4 Direct infusion mass spectra obtained following (A) on card digestion of DBS (B) LESA sampling and 
subsequent digestion 
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Fig 4.4 shows that both on-card proteolysis and proteolysis following LESA extraction 
yielded tryptic peptides; however, only alpha globin and beta globin could be identified.  
The mass spectrum obtained following on card digestion shows peaks corresponding to  
undigested intact proteins, with charges of +16, +15 and +14, which can be identified as 
haemoglobin alpha and beta. The limiting factor is likely the high abundance of 
haemoglobin. LC MS/MS was therefore employed as a means of peptide fractionation 
with the aim of identifying more proteins. Digests were prepared as described previously, 
however prior to analysis samples were purified with C18 zip tips as described in section 
2.2.5 and analysed with the LC MS/MS method described in section 2.2.2.    
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Figure 4.5 Total ion current chromatograms showing acetonitrile composition obtained following LC MS/MS analysis 
of DBS digest: (A) on card proteolysis (B) LESA extraction followed by proteolysis 
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Fig 4.5 shows the total ion chromatograms (TICs) of both the on card and the surface 
sampling based digestions.   Sixty eight different proteins were successfully identified 
from the on card digest and 202 proteins were identified from the surface sampling 
based digest. The full list of all the proteins identified can be seen in appendix 4.3 and 
4.4.  The on card digestion identified fewer proteins than the surface sampling and 
solution phase digestion. This digest protocol was also more compatible with LESA 
sampling so was selected for further development. 
 
4.4 Adaption for Automation 
The manual surface sampling and solution phase digestion procedure was adapted for 
execution on the Triversa Nanomate™. There were four features of the manual 
procedure described in section 4.3 that needed to be adapted: surface sampling, 
incubation of the proteolysis mixture, clean-up of the digestion products and finally 
transfer of the samples to the HPLC unit.  The sampling and incubation were performed 
by using a sequence written with the AUI feature of the Triversa Nanomate™.  The whole 
process was performed on a 96 well microtitre plate: DBS were loaded onto the surface 
of a wellplate, with a separate well acting as a solvent reservoir. The digestion/extraction 
solvent was aspirated from the solvent well, a LESA extraction process was performed on 
the DBS surface and the solution containing the intact proteins was then dispensed into 
an empty well which acted as a reaction vessel. The extraction and digestion solvent was 
composed of 50 mM NH4HCO3. In each extraction process 7 μl of solvent was aspirated 
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from the solvent well and 6 μl were applied to the surface of the DBS. Five microlitres 
was reaspirated and the sample was dispensed into the reaction well. After extraction, 
the previous pipette tip was ejected to prevent carryover, before 4.5 μl of 0.1 μg/μl 
trypsin was aspirated from the trypsin well and added to the reaction well for the 
incubation to begin. The sample was mixed once by an aspiration and dispense cycle of 4 
μl. The Triversa Nanomate™ contains a temperature control unit that can heat or cool the 
plate to any desired temperature between 4 and 60°C. In this experiment, the 
temperature control unit was used to heat the plate to 40˚C to incubate the enzyme. In 
the manual procedure described in section 4.3, the sample was digested on a 
thermomixer to mix the sample. This approach would not be a viable option in the 
automated procedure as the Triversa Nanomate™ does not feature a shaker. As an 
alternative, the sample was mixed at regular intervals by performing an aspiration and 
dispense cycle with the pipettor. Performing an aspiration and dispense cycle mixes the 
sample at intermittent periods but does not create the constant agitation that was 
provided in the manual digestion. The aspiration and dispense cycle also proved useful 
because it was noticed that as the plate was being heated the small amounts of solvent in 
the well were prone to evaporation. These mixing stages also allowed additional solvent 
to be added to prevent the sample from drying out. Seven and a half microlitres of 50 
mM NH4HCO3 was added from the solvent well to the reaction wells at 30 minute 
intervals and mixed with an aspiration and dispense cycle of 4 μl.  
Automation of steps 3 and 4 was less simple.  The manual procedure used C18 zip tips to 
remove salts and contaminants produced during the digestion. These contaminants need 
to be removed prior to LC MS analysis, but zip tipping requires manual intervention. To 
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prevent this, an online desalting procedure was incorporated into the LC MS/MS analysis 
(described in detail section 2.2.2). The procedure involved loading the sample onto a 
trapping column that was rinsed through with 0.1% formic acid prior to being switched in 
line with an analytical column. The wash cycle helped remove salts and contaminants 
before the valve switched and the analytical acetonitrile gradient was applied to elute the 
peptides. It is analogous to the effect of zip tipping, but is performed online during the LC 
process to eliminate user intervention. As a result it does however increase LC MS/MS 
analysis time by 5 minutes.  Transferring the plate in step 4 was the only issue that could 
not be overcome. Combining injection into the LC unit via the Triversa Nanomate™ was 
not a viable option. Transferring the plate remained the only manual intervention 
remaining in the procedure. The samples were digested in an automated fashion on the 
Triversa Nanomate™ and then transferred to the HPLC autosampler for analysis.     It can 
be carried out in a batch process where multiple samples are digested in parallel by using 
the nanomate™ and then the plate containing multiple samples can be  transferred to the 
HPLC unit for analysis. To demonstrate multiplexing, the process was performed on a 
series of 3 DBS that were digested in parallel for a period of 1 hour as described above. 
Data was searched as described in section 2.2.8.  A diagram illustrating the sampling 
routine that was developed is shown in fig 4.6 and  is described by a flow chart in fig 4.7.   
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Figure 4.6 Illustration of the digest procedure adapted for LESA sampling (A) the 96 well plate is placed in the 
autosampler of the triversa nanomate™. The temperature control unit heats the plate to 40˚C. A DBS card is loaded 
onto the surface of the well, a solvent well is filled with 50 mM NH4HCO3 and a trypsin well is filled with 0.1 μg/μl 
trypsin. Remaining wells are left blank to act as reaction vessels.  (B) Seven microlitres of solvent is aspirated from 
the solvent well. (C) Six microlitres of solvent is applied to the surface of the DBS forming a liquid microjunction and 
allowing the diffusion of intact proteins from the surface of the spot into the solvent. (D) Five microlitres of solvent 
was reaspirated from the spot and the whole sample was then deposited into one of the reaction wells. (E) After the 
tip has been ejected and replaced 4.5 μl  of 50 mM NH4HCO3 was aspirated from the trypsin well (F) trypsin was 
deposited into sample reaction well and digestion begins. (G). Sample is left to digest for 1 hour, additional 7.5 μl of  
50 mM NH4HCO3 is added to reaction well to account for solvent evaporation at 30 minute intervals (H) sample is 
transferred to HPLC autosampler for LC MS analysis.  
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4.7 Flow chart showing the aspiration and dispense cycles for the digestion of a single DBS 
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Figure 4.8 Total ion current chromatogram showing acetonitrile gradient obtained from LC MS/MS of DBS digest 
prepared by automated LESA sampling and trypsin digest. 
 
Fig 4.8 shows the TIC of an automated digestion of a DBS performed by surface sampling 
and subsequent LESA analysis. The full list of non-redundant proteins identified across 
the 3 replicates is shown in appendix 4.5.  These results demonstrate that the LESA 
coupled with proteolysis can be successfully adapted onto an automated platform.   In 
the 3 replicates used demonstrate the success of the automated digest, 120, 115 and 107 
proteins were identified after LC MS/MS analysis.    Previously reported examples of 
protein analysis of DBS have all been targeted to particular proteins of interest [167, 171, 
174, 176]. The great advantage of this untargeted approach is that the analysis is not 
limited to a few proteins of interest and as demonstrated here, it becomes possible to 
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identify over 100 proteins per LC MS/MS analysis, compared to a previous record of 37 
[176].  
 
 
Figure 4.9 Categorisation of different proteins identified from the DBS.  
 
Fig 4.9 shows the different categories of proteins that were identified from the DBS. The 
analysis identified a number of different types of plasma proteins. Approximately 50% of 
all the proteins identified were plasma proteins. A number proteins originated from 
erythrocytes or platelets.  The analysis also identified various different structural proteins 
and a number of proteins whose cellular origin was unconfirmed. Many proteins are 
known to leak into the plasma from the surrounding tissues.  Tissue leakage takes place 
primarily in the capillary region and these proteins account for some of the less abundant 
Haemoglobins
3% Erythrocyte or 
platelet proteins
14%
Complement 
proteins
7%
Immunoglobulins
8%
Transport proteins
13%
Coagulation factors
4%
Other plasma 
Proteins
19%
Keratins and other 
structural proteins
12%
Enzymes
7%
Other/ unassigned
13%
127 
 
proteins in human plasma [170, 207]. DBS proteomics also faces the challenge that the 
blood is acquired with a finger prick, which releases skin cells onto the card. These 
epithelial cells could be the source for some of the proteins identified in this analysis. The 
least abundant protein identified in this analysis was protein S100 A9. In healthy human 
plasma this protein is expressed at a concentration level of a 0.05 µM [208] which has a 
concentration 4 orders of magnitude less than serum albumin which is the most 
abundant plasma protein. The CID MS/MS spectrum of a peptide from this protein is 
shown in fig 4.10.  
 
Figure 4.10 CID mass spectrum obtained from 2+ ions of peptide DLQNFLK. The peptide is assigned to protein S100 
A9, the least abundant protein identified in this analysis.  
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 The reproducibility of this LESA-based DBS proteomics approach is shown on the Venn 
diagram in fig 4.11. Three replicate analyses resulted in the identification of 120, 115 and 
107 proteins. Sixty four proteins identified were common to all 3 replicates and 
approximately 80 proteins were common to any 2 replicates.   A reproducibility of 64 
proteins out of 120 proteins over 3 replicates may not seem particularly high, however 
poor reproducibility is a common criticism of data dependent acquisition techniques in 
proteomics[123].  
 
 
Figure 4.11 Reproducibility of protein identifications over 3 replicates 
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replicates 
64 proteins 
1-2 overlap 83 
proteins 
23 overlap 81 
proteins 1-3 overlap 81 
proteins 
Unique in 2 22 
proteins 
Unique in 3 12 
proteins 
Unique in 1 25 
proteins 
129 
 
 
4.4.2 Effect of proteolysis times 
The work presented above demonstrated that LESA based bottom-up proteomics of DBS 
can be successfully adapted onto an automated platform, and that the procedure is 
capable of identifying approximately 100 proteins per LC MS/MS run.    
 
An advantage of the method presented here over previously published methods 
analysing proteins from DBS is that the process was highly economical with the amount 
of trypsin used. Previous examples used between 25 and 200 µg to digest each sample 
[167, 171, 174, 176]  whereas this method required only 0.45 µg. This means it becomes 
possible to use high purity proteomics grade trypsin such as trypsin gold at a very low 
cost per sample. 
 
The 1 hour time period used in the digestion is short compared to the digestion times 
used for typical solution phase proteomics experiments. A 1 hour digest fits in well with 
the run time of HPLC.   Longer digestion times would be more demanding in instrument 
time but could possibly result in a greater number of protein identifications. The 
influence of digestion time was investigated in a time course experiment where DBS were 
treated the a digestion routine described in section 4.4, but with incubation periods   of 
30 minutes, 1 hour, 2 hours, 4 hours and 8 hours. This was performed in triplicate and 
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samples were analysed by the LC MS/MS method described in section 2.2.2 and the 
database searching as described in section 2.2.8.   
 
Figure 4.12 total ion current chromatograms showing acetonitrile compositions of LESA based DBS digests across 
different time points (A) 30 minute digest (B) 1 hour digest (C) 2 hour digest (D) 4 hour digest (E) 8 Hour digest 
 
Fig 4.12 shows representative TICs obtained following LC MS/MS analyses of samples 
with different proteolysis times.  The results obtained from the 30 minute, 1 hour and 2 
hour digests shown in fig 4.12 A B and C show peaks corresponding to small amounts of 
intact protein eluting shortly after 30 minutes. As digestion time is increased (Fig 4.12 D 
and E) these peaks disappear as the digestion comes closer to completion.  
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SUMMARY 
   Groups Count Sum Average Variance 
30 mins 3 204 68 124 
1 hour  3 313 104.3333 72.33333 
2 hours 3 286 95.33333 44.33333 
4 hours 3 291 97 9 
 8 hours 3 188 62.66667 274.3333 
 
ANOVA 
      Source of Variation SS df MS F P-value F crit 
Between Groups 4233.733 4 1058.433 10.09955 0.00154 3.47805 
Within Groups 1048 10 104.8 
   
       Total 5281.733 14         
 
Figure 4.13  Average number of proteins identified across 3 replicates for each digestion time point and 
corresponding one way ANOVA. Error bars represent one standard deviation 
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Pairwise t-test  
Pair p 
30 mins-1 hour 0.00145 
30 mins-2 hours 0.00843 
30 mins-4 hours 0.00603 
30 mins-8 hours 0.5377 
1 hour- 2 hours 0.30689 
1 hour- 4 hours 0.40089 
1 hour- 8 hours 0.00055 
2 hours- 4 hours 0.84595 
2 hours- 8 hours 0.00292 
4 hours- 8 hours 0.00212 
 
Figure 4.14 Pairwise t-test of proteins identified from digestion each time point 
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Groups Count Sum Average Variance 
30 mins 3 935 311.6667 2032.333 
1 hour  3 1490 496.6667 6434.333 
2 hours 3 1343 447.6667 849.3333 
4 hours 3 1433 477.6667 4034.333 
 8 hours 3 876 292 3199 
 
ANOVA 
      Source of Variation SS df MS F P-value F crit 
Between Groups 110951.1 4 27737.77 8.380328 0.003107 3.47805 
Within Groups 33098.67 10 3309.867 
   
       Total 144049.7 14         
Figure 4.15 Average number of peptides identified across 3 replicates for each digestion time point and 
corresponding one way ANOVA. Error bars represent one standard deviation   
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Pairwise t-test  
Pair p 
30 mins-1 hour 0.0028 
30 mins-2 hours 0.016 
30 mins-4 hours 0.0054 
30 mins-8 hours 0.6843 
1 hour- 2 hours 0.3215 
1 hour- 4 hours 0.6944 
1 hour- 8 hours 0.0014 
2 hours- 4 hours 0.5374 
2 hours- 8 hours 0.0078 
4 hours- 8 hours 0.0027 
Figure 4.16 Pairwise t-test of peptides identified from each digestion time point 
 
Fig 4.13 shows that digestions of one hour resulted in the greatest number of proteins 
identified across the whole time range. The figure shows that the number of proteins 
identified increases when digestion time increases from 30 minutes to one hour, followed 
by a slow decrease between one and four hours and then decreases further between four 
and eight hours.  The results of the ANOVA prove that the effect of digestion time does 
have a statistically significant effect (p=0.00154) on the number of proteins identified 
following LC MS/MS of the digests.  The significance of the p Value is also reinforced by 
the fact that the F value (F=10.099) is greater than the F Critical of 3.47.  The pairwise t-
test shown in fig 4.14 revealed that there were significant differences between some 
time points and not others. There was no significant difference between 30 minutes and 
8 hours, 1 and 2 hours, 1 and 4 hours and 2 and 4 hours.  The differences between all 
other time points were statistically significant. There was no significant difference 
between the one hour time point and the two or four hour time points despite the fact 
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the one hour digest resulted in the greatest average number of protein identifications.  
Fig 4.15 shows the how the number of peptides identified changes with digestion time. 
Unsurprisingly this follows the trend of the number of proteins identified. The results of 
the ANOVA and the pairwise t-test of the peptide identifications are also similar to that of 
the protein identifications. The ANOVA showed that the digestion time does have a 
statistically significant effect on the number of peptides identified by LC MS/MS. The 
pairwise t-test found the same significant difference between the different time points. 
I.e. there was no significant difference between time points 30 minutes and 8 hours, 1 
and 2 hours, 1 and 4 hours and 2 and 4 hours whereas all other pairs were significantly 
different.  
 
It is perhaps surprising that the number of proteins identified did not increase greatly 
with proteolysis time. The expectation is that a more complete digestion would result in a 
greater number of protein identifications. The fact that it was not is likely due to the 
complexity of the sample. Blood and plasma are incredibly complex samples, composed 
of tens of thousands of different proteins. Without any fractionation beyond liquid 
chromatography, an untargeted shotgun proteomics approach will only be capable of 
identifying the high abundance proteins.  The technique is not sensitive enough to cope 
with the dynamic range present in blood or plasma. If a digestion of a complex sample is 
carried out to completion the number of rare peptides from low abundance proteins will 
become highly saturated by peptides yielded from high abundance proteins. Previous 
groups have reported that for a complex sample, longer digestion times do not 
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necessarily lead to an increase in protein identifications [209].  The decrease in the 
number of proteins identified in the later time point may also be due to the effect of 
proteases present in blood. Blood contains a number of proteases, such as those found in 
the complement system [210] and a large number of clotting factors such as thrombin 
and Factor Xa  [211].  Blood proteases do not cleave proteins ubiquitously at lysine or 
arginine residues in the way that trypsin does [212].  If proteolytic activity is regained 
after drying and after the proteins have been extracted from the DBS, a longer digestion 
time may result in continued proteolysis of endogenous blood proteases may cleave 
proteins at many different residues [212]. This effect may prevent peptides being 
recognisable in a database search.  
4.5 Chapter 4 conclusion 
The work described in this chapter shows that LESA can be used for the successful 
identification of over 100 different proteins from a DBS after the incorporation of an 
automated trypsin digest. It is also the first time in which DBS had been probed with 
untargeted shotgun proteomics by any means at all. Since publishing this work this idea 
has since been explored by others [213].   Untargeted analysis is commonly performed on 
plasma samples to identify new disease biomarkers [163] with the majority of groups 
using multi-dimensional fractionation or immunodepletion techniques to increase protein 
identifications. In comparison to the number of proteins identified by analysing plasma 
with multi-dimensional fractionation the number of proteins identified from this analysis 
of DBS is very small. By using multi-dimensional fractionation of plasma, over a thousand 
proteins can be identified from a plasma sample.  Shen et al. [214] identified 1348 
proteins from a plasma sample by using  strong cation exchange alongside reverse 
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phased LC MS/MS. Without multi-dimensional fractionation the numbers are less 
impressive.  Using reversed phase LC MS/MS analysis only Shen et al. [214] identified 110 
proteins from a plasma sample and haudek et al. [215] identified 204 proteins from 
plasma. This is more comparable to the number of proteins identified from DBS in this 
chapter. There are far fewer examples where mass spectrometry has been used to 
analyse whole blood or DBS. The majority of  groups that have analysed whole blood by 
mass spectrometry have done so to analyse haemoglobin for variant determination [166, 
216, 217] and have not attempted deep level proteome analysis. Hemoglobin analysis can 
even involve analysing intact proteins rather than tryptic digests [216, 217]. Following the 
work carried out in this thesis however chambers et al. [213] have carried out an analysis 
of whole blood by an untargeted bottom up proteomics approach. The group analysed 
whole blood and DBS with an LC MS/MS shotgun proteomics approach.  The authors 
identified an average of 223 proteins from a whole sample and 253 proteins from a DBS 
both over 3 replicates [213]. They did not carry out multi-dimensional fractionation, 
merely reversed phase liquid chromatograph. Their analysis identified a greater number 
of proteins than the numbers of proteins identified from the DBS in this chapter however 
the LC gradient used in the method was longer than that carried out here so did they did 
benefit from improved separation.  
  
 The work carried out in this chapter demonstrates that DBS could be used as an 
alternative platform for biomarker discovery with the added advantages such as ease of 
use that are associated with DBS. The method used here successfully identified a number 
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of proteins that are already used as or are under investigation to be used as  biomarkers 
for clinical assays. These include haemoglobin, cerruloplasmin, alpha-1-anti-trypsin and 
proteins S100 A8 and S100 A9 [166, 171, 184, 218].  Alpha-1-antitrypsin was investigated 
for this purpose in Chapter 6. The surface sampling based digest is highly economical in 
regards to the amount of trypsin required and is applicable for many other surfaces. 
Following on from this work, the approach has been successfully applied for the analysis 
of thin tissue sections [219]. The aim of this thesis is to investigate new applications for 
using LESA in proteomics. Previously applications of LESA in proteomics were limited 
entirely to top down protein analysis. It is a major challenge when success is limited to 
the chance that the sample contains a few proteins that are small enough and abundant 
enough to be identified without proteolytic digestion. A bottom up approach does not 
face the same limitation. Performing a trypsin digestion of a DBS enabled identification of 
proteins with molecular weights in the range 9-515 kDa and endogenous concentrations 
between 600 and 0.05 µM in human plasma.  The method retained the major advantages 
of LESA sampling.  The digestion method was able to analyse a surface with no sample 
preparation in an automated fashion that kept manual user intervention to a minimum. 
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Chapter 5 Bottom up proteomics of dried blood spots: solution 
phase chemistry and immunodepletion 
 
5.0 Introduction 
 
The aim of the work presented in this chapter was to further develop DBS proteomics by 
using solution phase techniques as opposed to the surface sampling based method 
described in Chapter 4. As described in the introduction, other groups have employed a 
“punch and elute” strategy for the analysis of targeted proteins from DBS and even 
untargeted shotgun proteomics since the work in Chapter 4 was published  [213]. 
Untargeted shotgun proteomics of DBS was carried out by Chambers et al. The 
researchers compared proteins identified from whole blood, plasma, serum and 20 µl 
spots of each of the three biofluids dried onto filter paper.  After LC MS/MS analysis, 253 
proteins were successfully identified from DBS. This number is greater than were 
identified by the LESA based digest carried out in Chapter 4, but was obtained following 
use of a longer LC gradient (90 minutes) [213].  In the punch and elute methods, a small 
disk  (typically 2-6 mm) is cut out of a DBS card and the blood sample is eluted into 
solution and digested before LC MS/MS analysis.  The “punch and elute” method was 
investigated here for two reasons: Firstly, to act as a comparison to the LESA-based 
approach described in Chapter 4, and secondly, to investigate the potential of 
immunodepletion as a means for identifying low abundance proteins. The results of 
Chapter 4 demonstrated the successful identification of approximately 120 proteins per 
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LC MS/MS run, however this represents a fraction of the proteins that are present in 
blood.  Blood is an incredibly complex sample that is dominated by a few high abundance 
proteins, as mentioned in section 1.4.3.3 99% of the total protein content comprises just 
22 different proteins and the remaining one percent is composed of several thousand 
[179].   Consequently, many low abundance proteins are undetectable by shotgun 
proteomics techniques in the absence of enrichment techniques. One approach to 
address this challenge is to remove some of the high abundant proteins before digestion, 
thus simplifying the sample and improving detection of lower abundance proteins.  A 
range of immunodepletion kits are available commercially for removing high abundance 
proteins from human plasma. The R&D Systems Proteome Purify 12 kit which targets the 
12 most abundant human plasma proteins, is investigated in this chapter. A separate 
depletion kit, known as Hemovoid that is designed for removing haemoglobin from 
erythrocytes, is also available commercially and was attempted for use on DBS.     
5.1   Proteolysis of blood proteins following punch and elution” from DBS 
samples 
A series of blood samples eluted from DBS were digested in solution as described in 
section 2.2.7.   After elution of the proteins from the DBS, the proteins were digested for 
a range of different time points (30 minutes, 1 hour, 2 hours, 4 hours and 8 hours). These 
timepoints were the same as those described for optimisation of the LESA based digest 
described in section 4.4. The resulting digests were analysed by use of the same LC 
MS/MS method with online desalting as described in section 2.2.2.  This was performed 
in triplicate and representative total ion current chromatograms obtained following 
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analysis of the resulting digests are shown in fig 5.1. The full list of proteins identified for 
the 3 replicates across the various time points is shown in appendix 5.1-5.5. 
 
 
Figure 5.1 Total ion chromatograms showing acetonitrile composition obtained following LC MS/MS analysis of 
samples extracted from DBS (“punch and elute”) and digested for (A) 30 mins (B) 1 hour (C) 2 hours  (D) 4 hours (E) 8 
hours. 
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Figure 5.2 Average number of identifications across 3 replicates for each time point (A) number of proteins identified 
(B) number of peptides identified. Error bars represent 1 standard deviation 
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As shown in fig 5.2, the number of proteins and peptides identified after LC MS/MS 
decreased at digestion times of greater than two hours. The same phenomenon was 
reported in the LESA based digests described in Chapter 4.  This observation, i.e., that the 
number of proteins identified decreases as the digestion comes to completion, may seem 
counter-intuitive.  It is worth bearing in mind that, in a complex sample such as blood, the 
number of different peptides in the digest greatly exceeds the scanning capability of data 
dependent MS/MS analysis, which will target the most abundant peptides in a sample 
[122]. This effect where longer digestion times result in fewer protein identifications has 
been reported previously in the analysis of complex mixtures [209].  That paper also 
reported that the greatest number of proteins is identified with a short digestion of just 1 
hour.  The exact reasons behind this effect are unknown but plausible explanations 
include increased deamidation of proteins in digestion buffers during prolonged 
proteolysis, and the fact that shorter digests can increase the number of peptides with 
one or two missed cleavages which can improve protein identifications [220, 221]. 
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Figure 5.3 Average number of proteins identified across 3 replicates from different digestion times using the LESA 
based digest described in Chapter 4 and a ‘punch and elute’ approach.  Error bars represent 1 standard deviation. 
 
 Fig 5.3 shows that the number of proteins identified from the “punch and elute” digest is 
significantly less than that from the LESA digest for all time points other than 30 minutes.  
Again, this result is counterintuitive; however, it is worth bearing in mind that in the LESA 
based digest, only the surface proteins are extracted from the DBS for digestion whereas  
in the “punch and elute” procedure the whole sample, including all the dried erythrocytes 
and platelets are eluted from the card. The second approach will therefore result in 
samples that are more enriched with cellular proteins such as haemoglobin.  Fig 5.4 
shows that the percentage of peptide spectral matches corresponding to haemoglobin is 
higher in the “punch and elute” approach than it is in the LESA based process. This result 
suggests that the number of identified proteins from the LESA approach is greater than 
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with the “punch and elute” method because the former is less saturated with 
haemoglobin.  
 
Figure 5.4 Percentage of peptide spectral matches corresponding to haemoglobin peptides in DBS digests. Error bars 
represent 1 standard deviation. 
 
The results presented above demonstrate the successful identification of multiple 
proteins from DBS via a “punch and elute” method, although fewer proteins were 
identified than by digesting with LESA. The results demonstrate that DBS proteomics can 
be achieved through more traditional solution phase digestions and could be carried out 
in laboratories that do not have the facilities for surface sampling.  
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5.2 Immunodepletion 
There are many plasma immuno-depletion kits available commercially, which remove the 
most abundant proteins from a sample. The kits can target a range of proteins from  
albumin alone to the top 20 most abundant plasma proteins [222, 223].  
The R&D Systems Proteome Purify 12 kit was used here for the depletion of the high 
abundance plasma proteins. It targets the top 12 most abundant plasma proteins, see 
Table 5.1,which together make up 95% of the total protein in human plasma [224]. 
Alpha-1-acid glycoprotein Alpha-1-antitrypsin 
Alpha-2-Macroglobulin Albumin 
Apolipoprotein A-I Apolipoprotein A-II 
Fibrinogen Haptoglobin 
IgA IgG 
IgM Transferrin 
 
Table 5.1 Proteins targeted by the Proteome Purify 12 kit 
 
The Proteome Purify 12 kit does not target haemoglobin, plasma is depleted of red blood 
cells so it contains very little haemoglobin. A separate depletion kit known as Hemovoid is 
available for haemoglobin depletion. This kit uses a spin column composed of a silica 
enrichment matrix and was originally designed for erythrocyte proteomics [225]. Unlike 
the Proteome Purify 12 kit, Hemovoid does not use antibodies. The silica beads contain a 
range of ionic, hydrophobic, aromatic and polymer ligands. Almost all proteins have an 
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affinity to one of these types of ligand and will bind to the silica beads.  Of all the 
different ligands only a small percentage will have suitable chemistry for an affinity to 
haemoglobin, and these ligands quickly become saturated with haemoglobin when the 
concentration is high.  Other proteins are able to bind to the free ligands which enriches 
the sample in low abundance proteins and eliminates up to 98% of haemoglobin present  
[225]. 
 
 
 Neither of the two depletion kits were investigated for use with the LESA based digest. 
They both require use of centrifugation during sample preparation so are not practicable 
for use in conjunction with LESA.  The two kits were each used in isolation for treatment 
of DBS samples and were subsequently used in tandem.  When used in tandem, the 
plasma proteins could be depleted first followed by the haemoglobin, or vice versa. Both 
approaches were investigated. 
 
5.2.1. Treatment of samples with Plasma Proteome Purify 12 kit 
 
Proteins were eluted from the DBS as described in section 2.2.7 After elution the proteins 
recovered from the DBS were depleted of the top 12 most abundant  plasma proteins as 
described in section 2.2.19. The depleted sample was reduced, alkylated and digested 
with trypsin.  Two proteolysis time points were used: 1 hour and 8 hours.  As described in 
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section 4.1, the 1 hour time proteolysis resulted in the greatest number of protein 
identifications (in the absence of immunodepletion); however, since a more complete 
digest would be less complex after depletion, an 8 hour digest was investigated as well. 
All data were acquired in triplicate. 
 
 
Figure 5.5 Total ion chromatograms showing acetonitrile composition obtained following LC MS/MS analysis of 
samples extracted from DBS and immunodepleted of the top 12 plasma proteins (A) 1 hour digest (B) 8 hour digest 
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Figure 5.6 Average number of proteins identified across 3 replicates after immunodepletion of  the top 12 plasma 
proteins and non-treated DBS digest. Error bars represent 1 standard deviation. 
 
 
Digestion time P Value 
1 hour 0.001 
 
8 hour 0.1 
 
Table 5.2 Two tailed unpaired t-test on number of protein identifications before and after depletion of the top 12 
plasma proteins 
 
Representative total ion chromatograms are  shown in fig 5.5. Fig 5.6 shows that there 
was no major improvement in the number of proteins identified after immunodepletion. 
The full lists of proteins identified after immunodepletion for the two time points are 
shown in appendix 5.6 and 5.7. The number of proteins identified from immunodepleted 
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samples actually decreased in the 1 hour digest and there was only a small and non-
significant (p=0.1) increase in the number of proteins identified from the 8 hour digest.  
There are two factors that could be responsible for this observation. Firstly, the depletion 
kit pulls out the abundant plasma proteins. Across the 3 replicates for the 1 hour digests, 
a total of 8,9 and 9 of the top 12 plasma proteins were not identified from the samples 
and a total of  9 of the top 12 proteins were not identified from each replicate of the 8 
hour digests.  Secondly, problems with non-specific protein removal have been reported 
with plasma depletion kits [224], i.e., removal of proteins other than those targeted for 
by the antibodies in a non-specific manner during the immunodepletion step. 
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Figure 5.7 Average percentage of PSMs over 3 replicates corresponding to peptides originating from haemoglobin 
and the 12 most abundant plasma proteins. Error bars represent 1 standard deviation. 
 
The success of the immunodepletion can be assessed by considering the percentage of 
peptide spectral matches (PSMs)s made up of the top 12 plasma proteins as shown in fig 
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from the 8 hour digest originated from the top 12 plasma proteins. After 
immunodepletion, these values are 10% and 3 % respectively. This result shows that the 
immunodepletion was successful in reducing the amount of high abundant plasma 
proteins; however, there is a concomitant increase in the number of haemoglobin PSMs. 
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shown in Table 5.3. This observation may explain why the number of identified proteins 
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did not increase considerably.  After the high abundance plasma proteins have been 
removed, haemoglobin dominates the digest more so than previously, thus preventing 
detection of the low abundance peptides and further protein identification. 
Digestion time P Value 
1 hour 0.7 
 
8 hour 0.001 
 
Table 5.3 Two tailed unpaired t-test on the percentage of PSMs corresponding to haemoglobin before and after 
depletion of the top 12 plasma proteins. 
 
 
 
5.2.2 Treatment of samples with Hemovoid kit 
In these experiments, samples were depleted by Hemovoid only.  A punch was cut out of 
a DBS and proteins were eluted as described in section 2.2.7. After elution the proteins 
recovered from the DBS were depleted of haemoglobin by using Hemovoid as described 
in section 2.2.9. The depleted sample was reduced, alkylated and digested with trypsin as 
described in section 2.2.9. Samples were digested for 1 hour and 8 hours as above.  Data 
was acquired in triplicate and representative total ion chromatograms obtained following 
LC MS/MS of the peptide digests are shown in fig 5.8.  
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Figure 5.8 Total ion chromatograms showing acetonitrile composition obtained following LC MS/MS of DBS samples 
depleted of haemoglobin (A) 1 hour digest (B) 8 hour digest. 
 
 
Figure 5.9 Average number of proteins identified from DBS samples across 3 replicates after haemoglobin depletion 
and non-treated DBS digest. Error bars represent 1 standard deviation 
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Digestion time P Value 
1 hour 0.00001 
 
8 hour 0.0002 
 
 
Table 5.4 Two tailed unpaired t-test on protein identifications before and after depletion of haemoglobin 
 
Treatment of the samples with Hemovoid successfully resulted in an increase in the 
number of proteins identified from the DBS samples as shown in fig 5.9. The full list of 
proteins identified following haemoglobin depletion are shown in appendix 5.8 and 5.9.  
Treatment with Hemovoid was more successful than with the plasma proteome depletion 
kit (see fig 5.7). After depletion of the top 12 plasma proteins an average of 54 and 48 
proteins were identified from the samples digested for 1 hour and 8 hours respectively, 
whereas haemoglobin depletion resulted in the identification of an average of 143 
proteins for the 1 hour and 147 proteins for the 8 hour digestion time points. 
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Figure 5.10 Average percentage of PSMs over 3 replicates corresponding to peptides originating from haemoglobin 
and the top 12 plasma proteins Error bars represent 1 standard deviation 
 
Hemovoid successfully reduced the concentration of haemoglobin in the sample as 
illustrated in fig 5.10.   The percentage of PSMs corresponding to haemoglobin peptides 
in the 1 hour digest dropped from 52 to 7 % for the 1 hour digest and from 53 to 17% for 
the 8 hour digest.  The remaining amount of haemoglobin after depletion may seem high 
but it should be noted that Hemovoid removes only 98% of the total haemoglobin. 
Considering haemoglobin is such an abundant protein, for a healthy adult male with 
approximately 130 mg/ml of haemoglobin in their blood [205], the remaining 2% would 
leave a concentration of 2.6 mg/ml which would make it the next most abundant protein 
after albumin [208].  Following haemoglobin depletion, fig 5.10 shows that the 
percentage of PSMs corresponding to high abundance plasma proteins increased, as did 
the percentage of PSMs corresponding to the other proteins.  The relative increase in the 
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PSMs from the top 12 plasma proteins is similar to the increase in PSMs from 
haemoglobin following immunodepletion of the abundant plasma proteins.  
 
5.2.3 Combined immunodepletion of abundant plasma proteins and 
haemoglobin depletion 
Workflows combining the two depletion strategies were considered. Proteins were 
eluted from a DBS punch as described in section 2.2.7, and treated by immunodepletion 
followed by haemoglobin depletion, or by haemoglobin depletion followed by 
immunodepletion. 
5.2.3.1 Treatment of samples with Proteome purify 12 and 
subsequent treatment with hemovoid 
After elution the samples recovered from the DBS were immunodepleted of the twelve 
most abundant proteins by use of Proteome Purify 12. The eluent was then depleted of 
haemoglobin by use of hemovid as described in section 2.2.9. The twice-treated sample 
was then treated to a reduction, alkylation and trypsin digest as described in section 
2.2.9. Samples were digested with trypsin for 1 hour and 8 hour and data were acquired 
in triplicate as described previously.  
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Figure 5.11 Total ion chromatograms showing acetonitrile compositions obtained following DBS digestions depleted 
of the top 12 plasma proteins and haemoglobin (A) 1 hour digest (B) 8 hour digest 
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Figure 5.12  Average number of proteins identified across 3 replicates after twice treated and non-treated DBS 
digest. Error bars represent 1 standard deviation 
 
Digestion time P Value 
1 hour 0.17 
 
8 hour 0.0001 
 
 
Table 5.5 Two tailed unpaired t-test on protein identifications before and after depletion of the top 12 plasma 
proteins and haemoglobin. 
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Representative total ion chromatograms obtained following LC MS/MS of the resulting 
peptide digests are shown in fig 5.11. The chart on fig 5.12 showed that performing 
depletion by both kits actually increased the number of proteins identified compared to 
the untreated sample. The full lists of proteins identified after depleting both the top 12 
plasma proteins and haemoglobin are shown in appendix 5.10 and 5.11. This result shows 
that even after the high abundance plasma proteins and haemoglobin have removed 
there was still enough sample for the remaining low abundance proteins to be detected. 
The increase in the number of protein identifications was however smaller than 
performing haemoglobin depletion only. The average  number of identifications from 
using Hemovoid only was 143 for the 1 hour time point and 147 for the 8 hour digest, 
whereas when using the Proteome Purify 12 kit and Hemovoid the average number of 
identifications were 111 and 137 for the 1 hour and 8 hour digests respectively.  
 
Figure 5.13 Average percentage of PSMs over 3 replicates corresponding to peptides originating from the top 12 
plasma proteins and haemoglobin. Error bars represent 1 standard deviation. 
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Fig 5.13 shows how the composition of the PSMs changed according to treatment. The 
percentage of PSMs corresponding to haemoglobin dropped from 52 to 24 for the 1 hour 
digest and from 53 to 22 for the 8 hour digest. This decrease was less than that observed 
when treating with Hemovoid alone. The percentage of PSMs originating from the top 12 
plasma proteins did not vary.  For the samples digested for 1 hour, 25% of all PSMs were 
composed of the top 12 plasma in the untreated samples compared with 25% in the 
depleted samples.  The percentage of PSMs from other proteins increased for both 1 
hour and 8 hour digestions.  
 
5.2.3.2 Treatment of samples with Hemovoid and subsequent 
treatment with Proteome Purify 12 
 
After elution, the samples recovered from the DBS were depleted of haemoglobin by use 
of Hemovoid as described in section 2.2.9. The eluent was then depleted of the high 
abundance plasma proteins by using Proteome Purify 12. The sample was then reduced, 
alkylated and digested as described in section 2.2.9. Samples were digested for 1 hour 
and 8 hours. All data were acquired in triplicate as performed previously.  
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Figure 5.14 Total ion chromatograms showing acetonitrile composition obtained following  DBS digestions depleted 
of haemoglobin and the high abundance plasma proteins (A) 1 hour digest (B) 8 hour digest 
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Figure 5.15 average number of proteins identified across 3 replicates after from twice treated and non-treated DBS 
digests. Error bars represent 1 standard deviation 
 
Digestion time P Value 
1 hour 0.0012 
 
8 hour 0.00005 
 
 
Table 5.6 Two tailed unpaired t-test on protein identifications before and after depletion of haemoglobin and the top 
12 plasma proteins. 
 
 
Representative total ion chromatograms obtained following LC MS/MS of the resulting 
peptide digests are shown in fig 5.14. The chart on fig 5.15 showed that the number of 
proteins identified from samples depleted of haemoglobin followed by high abundance 
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plasma proteins increased compared to the untreated sample. The number of proteins 
identified by depleting haemoglobin followed by the 12 most abundant plasma proteins  
identified more proteins than performing the two rounds of depletion in the opposite 
order as carried out in section 5.2.3.1. The full lists of proteins identified after depleting 
haemoglobin and the top 12 plasma proteins can be seen in appendix 5.12 and 5.13. For 
the sample obtained following an 8 hour digest, the number of proteins identified from 
the combined depletion approach was equal to the number of proteins identified 
following depletion by Hemovoid alone. For the sample obtained following a 1 hour 
digest, fewer proteins were identified following the combined treatment than the 
Hemovoid alone. There was no statistically significant difference in the number of protein 
identifications between using Hemovoid and the two treatments together as shown in 
table 5.7.  
Digestion time P Value 
1 hour 0.06 
 
8 hour 0.95 
 
 
Table 5.7 Two tailed unpaired t-test on protein identifications after depletion of haemoglobin prior to the top 12 
plasma proteins and haemoglobin only.  
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Figure 5.16 Average percentage of PSMs over 3 replicates corresponding to peptides originating from haemoglobin 
and the top 12 plasma proteins. Error bars represent 1 standard deviations 
 
Fig 5.16 shows the composition of PSMS according to treatment.  For the depleted 
samples, only 9% of PSMs from the 1 hour digest sample and 6% of PSMs from the 8 hour 
digest sample originated from haemoglobin.  Of the PSMs that corresponded to the high 
abundance plasma proteins, these made up 23% of the total for the 1 hour digest sample 
and 10% of the total in the 8 hour digest sample. In both cases the remaining peptides 
made up more than 50% of all PSMs.  Whilst this option has provided the most successful 
depletion, the increase in protein identifications was less impressive. The average 
number of proteins identified was 147 for the 8 hour digest and 128 for the 1 hour digest. 
The reason for this is likely to be the same as described when depletion was carried out in 
the opposite order.  There is a finite limit to the initial amount of sample loaded for a 
DBS, and once both the haemoglobin and high abundance plasma proteins have been 
depleted, very little protein is left.   Only 20μl of blood is applied to a DBS and each 6 mm 
punch corresponds to around 7μl of blood.  The same challenge is not faced when 
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depleting plasma: it is possible to begin with larger volumes (up to 100 µl) to account for 
the amount of protein lost [226].   
 
5.3 Conclusion 
 
 
The work presented in this chapter has demonstrated that a proteomics analysis of DBS 
can be achieved not just by LESA sampling methods but also a “punch and elute” 
approach. The LESA sampling method consistently identified more proteins per LC 
MS/MS run than by using the “punch and elute” procedure without depleting the sample 
of its most abundant proteins.  One advantage of analysing DBS via the “punch and elute” 
approach is that it does offer additional options for sample manipulation that would be 
impractical for a surface sampling approach.  A range of different options for the 
depletion of high abundance proteins have been attempted on DBS eluents. Depleting 
the high abundance plasma proteins alone does not increase the number of protein 
identifications. Haemoglobin depletion did increase the number of protein identifications, 
and successfully identified more proteins than using the LESA based digest described in 
Chapter 4. Depleting both haemoglobin and the high abundance plasma proteins does 
not dramatically improve the number of identifications compared to just depleting 
haemoglobin.  In each elution from a DBS only a small amount of blood is recovered, 
corresponding to approximately 7 μl. If both haemoglobin and the high abundance 
plasma proteins are removed from these eluents, then the remaining amount protein is 
166 
 
very small and relatively few extra proteins can be identified.  By incorporating 
immunodepletion the number of proteins identified from the analysis can be increased 
when haemoglobin is removed. Further depletion of the plasma proteins is viable but 
does not necessarily increase the number of protein identifications [226]. 
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Chapter 6 Determination of alpha-1-antitrypsin variants through 
bottom up proteomic analysis of DBS 
6.0 Introduction 
The work presented in this chapter aimed to investigate the use of LESA coupled with 
bottom-up proteomics of dried blood spots for the determination of variants of the 
alpha-1-antitrypsin protein.   As mentioned in section 1.5, A1AT is the most abundant 
protease inhibitor secreted into human plasma. Several variants of this protein exist 
which result in a reduction in synthesis of the protein that leads to a pathological 
condition known as alpha-1- antitrypsin deficiency. Clinical manifestations of the disease 
can result in emphysema, chronic obstructive pulmonary disease and liver failure [227].  
The A1AT protein is highly polymorphic. There are two common healthy variants of the 
A1AT protein which are known as the M variant. The two M variants differ in that one has 
a valine at the 213 position and the other has an alanine residue [188].  There are two 
common clinically significant variants that increase the likelihood of suffering from A1AT 
deficiency, known as S and Z.  The S variant is a mutation of the healthy M valine 213 
(MVal 213) form with a glutamic acid to valine transition at the 264 residue and the Z 
variant is a mutant of the M alanine 213 (MAla 213) form with a glutamic acid to lysine 
transition at residue 342 [188]. Inheriting either an S or Z variant of the protein decreases 
the serum concentration of A1AT of an individual. An individual with an SZ or ZZ genotype 
has a very low serum concentration of A1AT and are likely to suffer from A1AT deficiency 
[189].  The typical concentrations associated with each of the different genotypes can be 
seen in table 6.1.  
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A1AT genotype Serum A1At concentration / µ M 
MM (MVal 213, MAla213 or heterozygous) 20-50 
SM 20-48 
MZ 12-35 
SZ 8-19 
ZZ 2.5-7 
 
Table 6.1 typical Serum concentrations associated with different A1AT genotypes [189]. 
Variants of A1AT are currently diagnosed by using isoelectric focusing. Isoelectric focusing 
measures the electrophoretic mobility of A1AT against a range of laboratory standard 
proteins for each of the common variants [192]. In addition to determining the variant of 
A1AT, quantification of the protein is also required for diagnosis , which is typically 
carried out by nephelometry or radial immune diffusion [192]. In some cases the 
measured concentration of A1AT disagrees with that which would be expected from the 
variant determined by the isoelectric focusing.  In such an event genotyping of the A1AT 
is required for confirmation which can be achieved by PCR or DNA sequencing  [228].  
Mass spectrometry could be used as an alternative approach. Ultimately it could provide 
both quantification of the endogenous A1AT protein and be used to determine the 
different phenotypic variants, similar to methods involving the determination of 
haemoglobin variants previously reported [167, 168]. A report of  a mass spectrometry 
MRM method has been published  to quantify clinically  significant variants of the A1AT 
protein, but the researchers used whole plasma rather than DBS for their analysis [229].   
A method for determining clinically significant variants of A1AT from DBS could be a 
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useful application of the LESA based digest described in Chapter 4. The work in this 
chapter aimed to investigate the potential for of LESA mass spectrometry of DBS for 
determining the different genotypic variants.  
6.1 A1AT coverage 
The most common healthy and clinically significant variants of A1AT MAla 213, MVal 213, 
S and Z differ in 3 different amino acid residues: Ala or Val at position 213, Glu or Val at 
position 264 and Glu or Lys at position 342.   To determine the variant of the A1AT 
protein these 3 regions of interest on the protein must be identified.  Following trypsin 
digestion of the proteins there are 6 different diagnostic peptides across the 4 variants 
(MVal 213, MAla 213, S and Z) that cover these regions.  The sequences and m/z ratios of 
the +2 and +3 charge states of these 6 peptides are shown in table 6.2. Table 6.3 shows 
the diagnostic peptides which would be yielded from a tryptic digestion of each of the 4 
variants. If other A1AT peptides are identified, this will not provide any information on 
which variants are present and detection of them is therefore irrelevant in this context. 
The challenge for a mass spectrometry method for determination of A1AT variants is to 
reliably and consistently identify the 6 diagnostic peptides shown in table 6.2.   
    m/z monoisotopic  
Peptide Sequence [M+2H]2+ [M+3H]3+ 
MAla 213 DTEEEDFHVDQATTVK 946.4314 631.2900 
MVal 213 DTEEEDFHVDQVTTVK 932.4158 621.9462 
M264 LQHLENELTHDIITK 902.4836 601.9914 
S264 LQHLVNELTHDIITK 887.4965 592.0001 
M 342 AVLTIDEK 444.7555 296.8394 
Z342 AVLTIDK 380.2342 253.8252 
Table 6.2 The sequences and theoretical m/z values of the 6 diagnostic peptides required to determine variants of 
A1AT.  
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Variant Peptides yielded 
MAla 213 DTEEEDFHVDQATTVK LQHLENELTHDIITK AVLTIDEK    
MVal 213 DTEEEDFHVDQVTTVK LQHLENELTHDIITK AVLTIDEK    
Heterozygous 
MAla 213,  
MVal 213 
DTEEEDFHVDQVTTVK DTEEEDFHVDQATTVK LQHLENELTHDIITK AVLTIDEK   
S DTEEEDFHVDQVTTVK LQHLVNELTHDIITK AVLTIDEK    
Heterozygous 
S, MVal 213 
DTEEEDFHVDQVTTVK LQHLVNELTHDIITK LQHLENELTHDIITK AVLTIDEK   
Heterozygous 
S, MAla 213 
DTEEEDFHVDQVTTVK DTEEEDFHVDQATTVK LQHLENELTHDIITK LQHLENELTHDIITK AVLTIDEK  
Heterozygous 
S, Z 
DTEEEDFHVDQVTTVK DTEEEDFHVDQATTVK LQHLENELTHDIITK LQHLENELTHDIITK AVLTIDEK AVLTIDK 
Z DTEEEDFHVDQATTVK LQHLENELTHDIITK AVLTIDK    
Heterozygous 
Z, MAla 213, 
DTEEEDFHVDQATTVK LQHLENELTHDIITK AVLTIDK AVLTIDEK   
Heterozygous 
Z, MVal 213, 
DTEEEDFHVDQVTTVK DTEEEDFHVDQATTVK LQHLENELTHDIITK AVLTIDK AVLTIDEK  
 
Table 6.3 Diagnostic peptides yielded from a tryptic digestion of different A1AT variants. 
 
The A1AT protein was detected in the LESA-based DBS proteomics analyses described in 
Chapter 4. See Appendix 4.5.  The likelihood of this method to be able to cover the 3 
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regions was considered by observing the coverage of A1AT detected from a healthy 
individual by the LESA analysis based digest in Chapter 4. A full sequence diagram can be 
shown in appendix 6.2. 
 
 
 
 
  Replicate 
 1 2 3 
MAla 213 - - - 
MVal 213 + + + 
M264 - - + 
S264 - - - 
M342 + + + 
Z342 - - - 
 
Table 6.4 coverage of A1AT of a healthy individual and identifications of diagnostic peptides from DBS digest of 
healthy donor. + = identification of the peptide - = peptide not identified   
 
Table 6.4 shows the coverage of the A1AT protein obtained from a healthy individual over 
3 technical replicates, by means of the LESA based digest described in chapter 4.  Not all 
the expected peptides were identified across all 3 replicates despite the fact that this 
blood was provided by a presumably healthy patient with a presumably healthy A1AT 
concentration at around 20-50 µM [227]. Replicates 1 and 2 were missing the M264 
peptide, but replicate 3 did detect all the 3 peptides that were expected assuming the 
A1AT genotype of the donor was homozygous MVal 213.    
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6.2 Untargeted data dependent LC MS/MS of A1AT deficient 
DBS digests 
 The data acquired in chapter 4 had not successfully detected all the peptides that would 
be expected from a healthy variant of A1AT in all 3 replicates, but it had successfully 
identified 2 of the 3 peptides that were expected from 2 replicates and all 3 of the 
expected peptides from the third.  Therefore the method seemed worth attempting to 
identify variants from DBS of A1AT deficient individuals. The genotypes of these 
individuals were known to be either SZ or ZZ. Three biological replicate DBS were 
prepared by use of the 1 hour LESA based digestion procedure described in section 4.4 
and analysed via the same LC MS/MS method with online desalting and top 7 CID.  Data 
were searched manually for the presence of all the 6 diagnostic peptides and those 
covering the same regions with 1 or 2 missed cleavages. This term refers to larger 
peptides that covered the same regions of the protein (213, 342, or 432) but where the 
digestion had not gone to completion, resulting in a longer peptide with up to two un-
cleaved lysine or arginine residues.  
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Figure 6.1 Representative total ion chromatograms showing acetonitrile composition obtained following LC MS/MS 
analysis of DBS digests from A1AT deficient DBS with (A) SZ and (B) ZZ genotypes. Samples were prepared by a 1 
hour LESA based trypsin digest 
 
 
Sample  Expected 
Peptide SZ1 SZ2  SZ3  ZZ1  ZZ2  ZZ3  SZ ZZ 
MAla 213 -  + + - -  +  + + 
MVal 213 +  + +  - - - + - 
M264 + + + + - - + - 
S264 - - - - - - + + 
M342 + + + - - - + + 
Z342 - - - - - - + - 
 
Table 6.5 Identification of diagnostic peptides from A1AT deficient DBS digests and theoretical sample showing the 
peptides that would be expected to be identified from the two genotypes. + = identification of the peptide - = no 
identification of the peptide   
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Table 6.5 shows which peptides were identified from the samples.  Not all the peptides  
that were expected to be produced by digestion of these variants were identified. More 
of the expected peptides were identified from the SZ variants than the ZZ variants. This is 
to be expected as the serum concentration of A1AT is higher in a SZ individual than it is in 
a ZZ. A trypsin digestion of A1AT from an SZ genotype should be expected to yield all 6 of 
the diagnostic peptides. From the DBS of the SZ individuals, 4 of the 6 expected peptides 
were identified in 2 replicates and 3 of the 6 peptides were detected in the other.   
Digestion of a ZZ genotype should yield the MAla 213 peptide, the M264 peptide and the 
Z342 peptide. The data from this experiment only resulted in the identification of the 
M264 peptide from one replicate, the MAla 213 peptide from the other and none of the 6 
diagnostic peptides from the final.  Other A1AT peptides were detected  so the protein 
can be identified from the sample, but as mentioned previously this cannot provide any 
information on which variants are present. Appendix 6.2 shows the full sequence 
coverage of A1AT obtained for each replicate.  Determinination of protein variants by 
data dependent LC MS/MS of a tryptic digest faces a number of challenges. The method 
fragments the most abundant  peptides observed in the survey scan and in  a complex 
sample like blood the  number of peptides present in the sample exceeds the scanning 
capabilities of the instrument [122].   Lower abundant peptides will not be selected for 
fragmentation. When comparing the data from this experiment to the data in section 6.1, 
it becomes clear that the identification of the diagnostic peptides is becoming less 
successful as the concentration of the protein drops from the healthy donors, to the SZ 
genotypes and then on to the ZZ individuals.   Untargeted data dependent acquisition 
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favours identification of abundant proteins,   and   because it could not successfully 
determine the genotypes of A1AT deficient individuals, targeted approaches were 
deemed more suitable and selected for further development.  
 
6.3 Targeted data dependent LC MS/MS through inclusion lists 
 In a data dependent LC MS/MS experiment, an inclusion list can be used to select ions of 
specific m/z values for fragmentation prior to other ions regardless of their relative 
abundance peaks.  An inclusion list was used here to attempt to identify A1AT variants 
from DBS digests of A1AT deficient individuals.   Samples were digested as described in 
section 6.1, and then analysed with the same LC parameters but a different MS/MS 
method. The mass spectrometry method comprised a full mass spectrum survey scan in 
the orbitrap, which was followed by up to 7 fragmentation events in the ion trap in the 
event that any precursor m/z from a series of peptides added to an inclusion list were 
detected. The inclusion list was composed of the m/z values shown in table 6.2 and 
additional peptides covering the same regions with 1 or 2 missed cleavages.  The full list 
of m/z values added to the inclusion list can be found in table 6.6. Data were acquired in 
duplicate.   
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  Sequence [M+2H]2+ [M+3H]3+ 
MAla 213 GKWERPFEVKDTEEEDFHVDQATTVK 1560.749 1040.835145 
  WERPFEVKDTEEEDFHVDQATTVK 1468.191 979.12967 
  WERPFEVKDTEEEDFHVDQATTVKVPMMK 1761.339 1174.56204 
  DTEEEDFHVDQATTVK 932.4158 621.946282 
  DTEEEDFHVDQATTVKVPMMK 1225.564 817.378652 
  DTEEEDFHVDQATTVKVPMMKR 1303.615 869.412355 
MVal 213 GKWERPFEVKDTEEEDFHVDQVTTVK 1574.765 1050.178912 
  WERPFEVKDTEEEDFHVDQVTTVK 1482.207 988.473437 
   WERPFEVKDTEEEDFHVDQVTTVKVPMMK 1775.355 1183.905807 
  DTEEEDFHVDQVTTVK 946.4314 631.290048 
  DTEEEDFHVDQVTTVKVPMMK 1239.58 826.722418 
  DTEEEDFHVDQVTTVKVPMMKR 1317.631 878.756122 
M264 YLGNATAIFFLPDEGKLQHLENELTHDIITK 1770.922 1180.950621 
  LQHLENELTHDIITK 902.4836 601.991497 
  LQHLENELTHDIITKFLENEDR 1354.188 903.127712 
  LQHLENELTHDIITKFLENEDRR 1432.238 955.161416 
  YLGNATAIFFLPDEGKLQHLENELTHDIITKFLENEDR   1482.086836 
  LSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDIITK   1533.483762 
S264 YLGNATAIFFLPDEGKLQHLVNELTHDIITK 1755.935 1170.959228 
  LSSWVLLMKYLGNATAIFFLPDEGKLQHLVNELTHDIITK   1523.492369 
  LQHLVNELTHDIITK 887.4965 592.000104 
  LQHLVNELTHDIITKFLENEDR 1339.201 893.136319 
  LQHLVNELTHDIITKFLENEDRR 1417.251 945.170023 
  YLGNATAIFFLPDEGKLQHLVNELTHDIITKFLENEDR   1472.095443 
M342 LSKAVHKAVLTIDEK 826.4907 551.329562 
  AVHKAVLTIDEK 662.3852 441.925877 
  AVHKAVLTIDEKGTEAAGAMFLEAIPMSIPPEVK 1782.446 1188.633247 
  AVLTIDEK 444.7555 296.839409 
   AVLTIDEKGTEAAGAMFLEAIPMSIPPEVK 1564.817 1043.54678 
  AVLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVFLMIEQNTK   1655.866667 
Z342 AVLTIDKKGTEAAGAMFLEAIPMSIPPEVK 1564.343 1043.230903 
  AVLTIDKK 444.2817 296.523532 
  AVHKAVLTIDKK 661.9114 441.61 
  AVHKAVLTIDK 597.8639 398.911679 
  LSKAVHKAVLTIDIK 818.5114 546.010052 
  AVLTIDK 380.2342 253.825211 
 
Table 6.6 m/z values added to an inclusion list to identify the 6 diagnostic peptides required for determining A1AT 
variants.  
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Figure 6.2 Representative total ion chromatograms showing acetonitrile composition obtained following LC MS/MS 
analysis, incorporating the inclusion list described in table 6.6, of DBS digests from A1AT deficient individuals from 
(A) SZ and (B) ZZ A1AT genotypes. 
 
 
Sample  Expected 
Peptide SZ1 SZ2  ZZ1  ZZ2  SZ ZZ 
MAla 213 -  + - + + + 
MVal 213 - + - - + - 
S264 - - - - + - 
M264 - - - - + + 
M342 - + - - + - 
Z342 - - - - + + 
 
Table 6.7 Identification of diagnostic peptides from A1AT deficient DBS digests by LC MS/MS analysis with an 
inclusion list. + = identification of the peptide - = no identification of the peptide   
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Table 6.7 shows that the peptides necessary for diagnosis of the variant were not 
identified by LC MS/MS analysis incorporating an inclusion list.  More peptides were 
detected from the SZ variant than the ZZ, which is to be expected due to the higher 
serum concentrations of A1AT associated with the SZ genotype. The mass spectrometer 
was only fragmenting the targeted diagnostic peptides and not others, so when none of 
the targeted peptides were detected, the protein could not be identified. As discussed 
above, one issue preventing the detection of the other peptides may be the lack of 
sensitivity. An individual with a ZZ phenotype may have as little as 2.5 µM of A1AT in their 
serum. Only 20 µl of blood is applied to a DBS, which would amount to 50 pmol of protein 
in the whole spot in a ZZ individual. LESA only samples a small area of the DBS surface 
and as the extraction efficiency is likely to be low anyway, the total amount of A1AT 
protein in the digest is likely to be very low indeed. To improve detection of the 
diagnostic peptides, a more sensitive and selective means of analysis was needed. 
 
6.4 Multiple reaction monitoring analysis for determining 
A1AT variants 
 
  SRM assays and the analogous multiple reaction monitoring assays are considered to be 
the most sensitive mass spectrometry techniques and can be targeted to individual 
analytes.  SRMs are more commonly used for quantification than identification, but it is 
possible to directly measure the abundance of specific peptides to determine their 
presence.   An LC MRM method is a viable option for determining A1AT variants by using 
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with 6 different SRMs to detect each of the six diagnostic peptides shown in table 6.2. 
Presence of the diagnostic peptide in the digest would be indicated by a signal in the SRM 
targeted to the peptide and absence of the peptide would be indicated by absence of 
signal. The approach  is similar to the method described by Chen et al. [229] with the 
exception that SRMs were used to measure the intensity of endogenous peptides only 
and not the amount relative to isotopically labelled internal standard peptides spiked into 
the sample. 
 
6.4.1. Analysis of synthetic peptides through direct infusion MRM analysis 
Prior to analysing DBS samples from A1AT deficient individuals, the SRM methods were 
validated by direct infusion electrospray ionisation of the targeted peptides.  Synthetic 
analogues of each of the 6 diagnostic peptides shown in table 6.2 were analysed 
individually, along with one sample composed of a mixture of all 6 peptides and another 
sample in which the six peptides were spiked into a proteolytic digest standard. The 
digest standard comprised a tryptic digest of a mixture of six proteins (cytochrome C, 
lysozyme, alcohol dehydrogenase, serum albumin, apotransferrin and β galactosidase) at 
a concentration of 50 fmol/µl.  The individual peptides were made up in a 0.1% formic 
acid solution to a concentration of 1 mg/ml and in the mixtures, each peptide was at a 
concentration of 0.1 mg/ml. Both these concentrations were significantly higher than 
those expected in a DBS digest of an A1AT deficient individual. The concentration of A1AT 
in the serum of a ZZ individual is 527 fold lower than the concentration of the peptide 
used in this experiment, but this experiment was designed to validate the SRMs only. Ten 
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μl aliquots of each sample were purified with C18 zip tips as described in section 2.2.5 
prior to analysis. After drying down, samples were resuspended in 49.95/49.95/0.1% 
water/ acetonitrile/ formic acid and samples were analysed by direct infusion with an 
MRM method composed of 3 transitions for each of the 6 diagnostic peptides. The 
precursor masses and the three transitions used to detect each peptide are shown in 
table 6.8, and the method is fully described in section 2.2.3.3.   
Peptide Sequence 
Selected   
Precursor m/z 
  
 Transitions 
  
Collision 
energy 
(v) 
MAla 213 DTEEEDFHVDQATTVK [M+3H] 621.94 y9 998.52 y10 1145.59   y11 1260.62  35 
MVal 213 DTEEEDFHVDQVTTVK [M+3H] 631.29 y7 790.43 y8 889.49 y9 1026.55 35 
M264 LQHLENELTHDIITK [M+2H] 902.48 y8 940.54 y9 1069.58   y10 1183.63 33 
S264 LQHLVNELTHDIITK [M+2H] 887.49 y9 1069.58  y10 1183.63 y11 1282.70 33 
M342 AVLTIDEK [M+2H] 444.75 y4 504.26 y5 605.31 y6 718.39 30 
Z342 AVLTIDK [M+2H]380.23 y3 375.22 y4 476.41  y5 589.35 30 
 
Table 6.8 Precursor ion masses and the 3 transitions monitored in the MRM assay for detection of the 6 diagnostic 
peptides. 
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Figure 6.3  Ion counts for each diagnostic peptide measured by direct infusion electrospray MRM. 
 
Fig 6.3 shows the ion counts of each of the SRMs for each different peptide.  When 
infusing the individual peptides, signal was detected by the correct SRM to show the 
peptide was present, which is demonstrated by the spectra in fig 6.4.   Interference was 
encountered in some samples. In certain cases signals were observed for peptides that 
were not present in the sample.  For example infusing the Z342 peptide shows a signal for 
the M342 peptide, and infusing the S264 peptide also showed a signal for the M342.  Fig 
6.5 demonstrates this interference.     
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Figure 6.4 SRM spectra showing detection of synthetic peptides. (A) MAla 213 SRM showing signal for MAla 213 
peptide. (B) MVal 213 SRM showing signal for MVal 213 peptide (C) M264 SRM showing signal for M264 peptide (D) 
S264 SRM showing signal for S264 peptide (E) M342 SRM showing signal for M342 peptides (F) Z342 SRM showing 
signal for Z342 peptide.  
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Figure 6.5 interfering peaks observed by direct infusion SRM assay, (A) transition monitoring presence of the M342 
peptide whilst infusing the Z342 peptide. Interfering peaks are shown with ion counts of 130 and 91. (B) Transition 
monitoring the M342 peptide whilst infusing the S264 peptide. Spectrum shows an interfering peak with an ion 
count of 1784 
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The data provided by direct infusion electrospray MRM analysis may not be robust 
enough to indicate the presence of variants in an unknown sample.  A better means of 
analysis may be to compare the intensity of each SRM relative to the intensity of the SRM 
measured in a blank sample, see Fig 6.6.  
 
Figure 6.6 Relative intensities of diagnostic peptides compared to blank samples, measured detected by direct 
infusion MRM.   
 
Fig 6.6 shows the ion counts of each of the SRMs from each sample compared to the ion 
counts measured by the SRMs when infusing blank solvent.   The ion counts of SRMs of 
the M264, S264 and M342 were over 40,000 fold higher than the signal measured for the 
blank sample, indicating that these SRMs are very sensitive to their targeted peptides.   
The ion counts of the MVal 213, MAla 213 and Z342 SRMs were over 1000 fold higher 
than the ion counts measured from the blank sample, but were less sensitive to their 
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targeted peptides than the SRMs for the M264, S264 and M342 peptide. Lack of 
sensitivity of the SRM could be a problem for detecting the low abundance peptides from 
the blood of A1AT deficient individuals. Comparing the signal measured by an SRM to a 
blank sample did help avoid problems of interference.  
6.4.2 LC MRM analysis of DBS digests 
 
 Liquid chromatography concentrates low abundance species from a mixture into a short 
chromatographic time window, which could help improve the sensitivity of the MRM 
assay used in section 6.4.1. An LC MRM method was used to attempt to determine the 
variants of the A1AT protein from a series of DBS digests from A1AT deficient individuals 
and healthy donors to act as controls. Three different biological replicates were used for 
each genotype of the A1AT deficient variants, and the control samples were technical 
replicates from the same donor. The exact genotype of the healthy control was not 
known. Samples were digested as described in section 6.1 and analysed by the LC method 
described in section 2.2.2 and the mass spectrometry MRM method described in section 
2.2.3.3. The LC MS/MS method did not include an online desalting stage so samples were 
purified with C18 zip tips as described in section 2.2.5 prior to analysis.   
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Figure 6.7 Ion counts of each of the 6 diagnostic peptides measured by LC MRM analysis from DBS digests of healthy 
controls and A1AT deficient individuals. 
 
Fig 6.7 shows that the LC MRM method did not detect the peptides that would be 
expected to be present in -either the variant or the healthy control samples. The control 
blood samples show strong signals for the MVal 213 and M342 peptides but no others 
and signals for all the A1AT deficiency samples are very weak.   The ion counts of the 
SRMs were then compared to those measured from blank samples, shown in fig 6.8. 
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Figure 6.8 Relative intensities of diagnostic peptides compared to blank samples measured from DBS digest of 
healthy controls and A1AT deficient individuals by LC MRM assay.   
 
 Comparing the intensities of the diagnostic peptides from DBS digests relative to the 
blank samples cannot determine which variants of A1AT are present in the blood. The 
most intense signal was an M342 peptide detected from a healthy control, which was 
only 10.53 fold higher than the ion count measured from a blank sample. This signal is 
not strong enough signal to reliably confirm the presence of the peptide in the digest. In 
comparison, the ion counts measured from the synthetic peptides were all over 1000 fold 
more intense than those acquired from the blank samples. Additionally the results 
suggest that the Z342 and S264 peptides were also present in the control patients, which 
is unlikely to be the case.  Signals for the healthy controls had a greater intensity relative 
to blank than any of the diseased variants.  The increase in signal intensity in healthy 
controls does suggest that the instrument response increases in concordance with the 
concentration of the protein. The results suggests that the SRMs were not sensitive 
0
2
4
6
8
10
12
Intensity of 
peptide relative to 
blank
Sample
LC SRM intensities of DBS digests
M val 213
M ala 213
M264
S 264
M342
Z 342
SRM
188 
 
enough to detect the correct diagnostic peptides from DBS digests of healthy controls, so 
it would be unable to determine the variant of A1AT from a diseased individual.  SRM 
analysis of the variant samples did not identify the correct peptides that would be 
expected from their genotypes.  The ZZ variants did show a small signal for the Z342 
peptide, but also showed signals corresponding to the S264 peptides and the M342 
peptides as well. Neither the S264 nor M342 peptides would be expected to be present in 
a ZZ genotype individual.  The SZ type individuals would be expected to show that all 6 
diagnostic peptides were present. Fig 7.6 suggests that all peptides other than the MAla 
213 peptides were present. The ion counts for the observed peptides were approximately 
two fold greater than the ion counts measured from a blank sample, so the presence of 
these peptides cannot be reliably confirmed from this data.  
 
6.5 Chapter 6 conclusion  
 
Several different methods have been attempted for to determine genotypic variant of the 
A1AT protein from DBS.  The methods attempted included untargeted data dependent LC 
MS/MS, targeted data dependent LC MS/MS and targeted LC MRMs. None of these 
methods were able to determine which variant of A1AT was present from a DBS.  
Determining the variant of a proteins is a challenge for a bottom up proteomics 
technique, it requires 3 different regions of the protein to be consistently and 
reproducibly identified. The amount of A1AT expressed by a deficient individual can be as 
low as 2.5 μM, and identifying 3 regions of a protein at such a low concentration in a 
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mixture as complex as blood was difficult.    The coverage of A1AT could be improved by 
incorporating a depletion strategy as demonstrated in section 5.3. By using hemovoid to 
deplete the haemoglobin proteins, the analysis was more sensitive to the high abundant 
plasma proteins which could be investigated to increase the coverage of A1AT and 
determine the variants.     
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Chapter 7 Analysis of non-covalent protein complexes by liquid 
extraction surface analysis mass spectrometry 
 
The work presented in the final chapter of this thesis was aimed at demonstrating the use 
of LESA for analysing non-covalent protein complexes from dried surfaces.  The field of 
native mass spectrometry is becoming a commonplace technique for the analysis of non-
covalent complexes.  Native mass spectrometry has been carried out using solution phase 
ESI which was discussed in detail in section 1.2.5.   Prior to this work, no ambient 
ionisation techniques have been applied to the analysis of protein complexes directly 
from surfaces. Zhang et al. investigated paper spray ionisation, but the group have not 
been able to analyse surface associated analytes. The method was only capable of 
analysing complexes prepared in solution [230].  LESA is a possible tool for native mass 
spectrometry because, unlike some other ambient ionisation techniques it forms ions by 
conventional electrospray ionisation which is soft enough to retain fragile interactions.    
Solution phase native mass spectrometry is not normally used to analyse surface 
associated proteins so the additional challenge for a LESA approach is that the technique 
must be able to retain interactions from dried proteins. Drying a protein denatures its 
tertiary structure and disrupts non-covalent interactions [231].  In order for these non-
covalent complexes to be retained into the gas phase they must either be strong enough 
to survive in the drying process or reform upon sampling with LESA.  Much of the work 
shown in this chapter has been accepted for publication as an article for the Journal of 
the American Society for Mass Spectrometry [232]. 
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7.1 Protein standards 
A range of lypholised protein standards dried onto surfaces were analysed.  The 
standards comprised two small well-defined proteins: equine skeletal muscle myoglobin 
and human haemoglobin. Myoglobin forms a non-covalent complex with a prosthetic 
haem cofactor and haemoglobin is comprised of a non-covalent protein heterotetramer 
composed of 2 alpha and 2 beta subunits each of which is non-covalently bound to a 
haem group. The crystal structures of these proteins can be seen in fig 7.1.  
 
Figure 7.1 Crystal structures of (A) equine myoglobin obtained at 1.45 Å resolution, generated using PQS software 
[233]  (B) human haemoglobin tetramer obtained at  1.8 Å resolution, generated using PISA software [234] Both 
Images Courtesy of Protein Data Bank 
 
 
   Proteins were dried onto a surface and then analysed with LESA mass spectrometry. 
LESA analyses were validated against direct infusion ESI.  Glass microscope slides and 
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PVDF membranes were used as model surfaces as LESA MS of intact proteins had 
previously been demonstrated from these surfaces as shown in chapter 3. Five microlitre 
aliquots of a 100 μM aqueous solution of each protein was spotted onto the surface, 
leaving 500 pmol of protein. The spots were left to dry for 4 hours before analysis. Unless 
otherwise stated the extraction solvent was composed of 10 mM NH4AC, pH balanced to 
6.8. In direct infusion ESI, each protein was electrosprayed at a concentration of 10 μM in 
10 mM NH4AC (pH 6.8).  Mass spectrometry analysis was performed on two different 
instruments: the Thermo Fisher Orbitrap Velos™ and the Waters Synapt™ G2-S.  In the 
LESA extraction process, 7 μl of solvent was extracted from the solvent well,  4 µl were 
then deposited from a height of 1.6 mm onto the surface (Orbitrap) or from 0.6 mm 
above the surface (Synapt™). After a delay of 3 seconds, 4.5 μl was reaspirated. The cycle 
was repeated once before being infused into the mass spectrometer. Samples were 
analysed in full scan mode on both instruments as described in section 2.2.3.1. Data were 
acquired for a period of 5 minutes on the Synapt™ and 10 minutes (each scan was 
comprised of 50 microscans) on the Orbitrap Velos™.  
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7.1.1 Myoglobin  
 
Figure 7.2 Direct infusion native ESI mass spectrum of equine skeletal muscle myoglobin magnification of the +8 
charge state of the myoglobin-heme complex obtained on  (a) Orbitrap Velos™ (B) Synapt™ G2 S. 
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Fig 7.2 shows the native mass spectra of myoglobin when analysed by direct infusion ESI. 
The holomyoglobin complex was retained in the gas phase in both instruments, and the + 
8 charge state was the most abundant peak in both cases. The mass spectrum recorded 
on the Orbitrap Velos™ shows peaks corresponding to holomyoglobin in the +9, +8 and 
+7 charge states at m/z 1952.80, 2196.77, and 2510.45 respectively. The theoretical m/z 
for the the +9, +8 and +7 charge states are 1952.87, 2196.85 and 2510.54 (each m/z both 
theoretical and measured corresponds to the most abundant isotope). The mass 
spectrum recorded on the Orbitrap Velos™ also showed evidence of dimerization of 
myoglobin, with peaks at m/z 2703.15 and 2928.82.   Mass spectra showing evidence of 
the formation of myoglobin dimers have been reported elsewhere  [221].  The dimers are 
likely to be an artefact of the ESI process as myoglobin only exists as a monomer in its 
native environment [220].  The mass spectrum recorded on the Waters Synapt™ showed 
peaks corresponding to the + 9, +8 +7 and +6 charge states of the holomyoglobin complex 
at m/z 1952.70, 2196.48, 2509.68 and 2927.00. The theoretical m/z for 9+, +8, +7 and and 
+6 charge states are 1952.87, 2196.85, 2510.54 and 2928.80. Once again each m/z 
corresponds to the most abundant isotope.  The different isotopologues could not be 
distinguished from the mass spectra acquired using the Synapt™, unlike those acquired 
using the Orbitrap Velos™. Sodium adducts were observed in addition to the protonated 
species on both instruments. The presence of sodiated peaks are a common problem in 
native mass spectrometry. Non-specific cation adducts form alongside the protonated 
species during ESI [235].  
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Figure 7.3 Native LESA mass spectrum of equine myoglobin and magnification of the +8 Charge state of the 
myoglobin-heme complex obtained from glass microscope slide acquired on the Orbitrap Velos™  
The holomyoglobin complex was observed following native LESA sampling of a glass 
microscope slide as seen in the mass spectrum shown in fig 7.3. The holomyoglobin 
complex was observed in the + 9, +8 and + 7 charge states at m/zs 1952.78, 2196.75 and 
2510.42. The theoretical m/z of these charge states were 1952.87, 2196.85, 2510.54 and 
as previously all of which refer to the most abundant isotope. The mass spectrum shows 
polymeric contaminants in the low m/z range and the protein peaks show evidence of 
sodiated adducts, but otherwise appear very similar to when analysed by direct infusion.  
Sodium adducts and other cationated species of the complex appear often when 
analysing non-covalent complexes. This is a result of the electrospray conditions [235]. 
This takes place during ion evaporation, where the concentration of salts can accumulate 
at the liquid air boundary of the charged droplets in an ESI source. The salts are the liable 
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to undergo ion paring with the recently formed protein ions [236]. The dimer artefact 
was absent from the native LESA MS analysis of myoglobin on glass.  
 
 
 
Figure 7.4 Native LESA mass spectrum of equine myoglobin and magnification of the +8 charge state of the 
myoglobin-heme complex obtained from PVDF membrane acquired on the Orbitrap Velos™ 
LESA mass spectrometry of the intact myoglobin complex was less successful from PVDF 
than from glass, see Fig 7.4. The LESA mass spectrum shows peaks corresponding to 
apomyoglobin and a peak corresponding to the haem group at m/z 616.17. The most 
intense peaks were the sodiated forms of the holomyoglobin complex, which was 
observed in the +8 and + 7 charge states at m/zs 2199.51 and 2513.58. The protonated 
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species was also observed in the + 9 charge state at m/z 1952.79, but was less intense 
than the + 8 charge state of the sodiated adduct.  The results suggest that PVDF is less 
suitable for native LESA mass spectrometry than the glass microscope slide. PVDF is a 
very hydrophobic surface which can denature proteins as a result of interactions between 
the hydrophobic amino acid residues and the surface [237]. There were also more sodium 
adducts detected. The monosodiated species was more abundant than the protonated 
adducts of the + 8 and + 7 charge state.  Whilst not as successful as the analysis from 
glass microscopes slides, this mass spectrum demonstrates that non-covalent complexes 
can be extracted from different types of surface.  
 
 
Figure 7.5 Native LESA mass spectrum of equine myoglobin and magnification of the +8 charge state of the 
myoglobin-heme complex obtained from glass microscope slide acquired on the Synapt™ G2S 
 
Fig 7.5 shows the LESA mass spectrum of myoglobin acquired from the glass microscope 
slide using the Synapt™. This mass spectrum is very similar to that acquired from the 
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Orbitrap Velos™, see fig 7.3. The holomyoglobin complex was observed in the +9, +8  +7, 
+6  charge states at m/z 2927.06, 2509.66, 2196.88 and 1952.80. The theoretical m/z of 
these peaks are 2928.80, 2510.54, 2196.85 and 1952.87. The holomyogoblin species were 
by far the most abundant peaks, but there is evidence of denaturation as well.  The 
charge state distribution of the holomyoglobin has shifted slightly towards lower charge 
states when compared to the mass spectrum obtained on the Orbitrap Velos™. The most 
abundant peak in the mass spectrum obtained on the Orbitrap Velos™ (fig 7.3) was the 
+8 peak, followed closely by the + 9 and with only a small peak corresponding to the +7 
charge state. On the Synapt™, the +8 charge state was the most abundant followed by 
the +7 and then the + 6. The variation in the charge state distribution is likely to be due to 
the difference in the temperature of the ion transfer tube of the two instruments. The 
Orbitrap’s ion transfer tube is heated to 250°C whereas the Synapt’s™ is 30°C. Higher 
capillary temperatures lead to more efficient desolvation of the protein complex during 
ESI which can lead to more efficient protonation and the production of higher charge 
states [97, 238, 239]. 
199 
 
 
 
Figure 7.6 Native LESA mass spectrum of equine myoglobin and magnification of the +8 charge state of the 
myoglobin-heme complex obtained from PVDF membrane slide acquired on the Synapt™ G2S 
  
Fig 7.6 shows the native LESA mass spectrum obtained from myoglobin spots on PVDF 
using the Synapt™. It is clear there has been significant denaturation of the complex.   
The extent of denaturation was greater than that seen with the Orbitrap Velos™, see fig 
7.4. The holomyoglobin complex was observed in the + 8 and +7 charge states  m/z 
2197.14 and 2510.42. Theoretical m/z values were 2196.85 and 2150.54.  The 
holomyoglobin species were less intense than peaks corresponding to apomyoglobin. 
There is a Gaussian-like distribution of charge states between m/z 1000- 1700 which is a 
similar appearance to that expected with a fully denatured protein The most abundant 
peaks were the + 7 and +8 charge states of  apomyoglobin at m/z of 2422.32 and 2120.43 
(theoretical m/z 2422.62 and 2119.91). This denaturation is likely to be induced by the 
200 
 
surface, as discussed above, as the instrument was capable of detecting the 
holomyoglobin complex from glass and by direct infusion electrospray.  
7.1.2 Haemoglobin 
 
In its native state, haemoglobin forms a heterotetramer composed of two alpha-globin 
subunits and two beta-globin sub units each non-covalently bound to a haem group, see 
fig 7.1 (B). Haemoglobin samples were analysed in the same way as myoglobin, beginning 
with analysis by direct infusion electrospray.  
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Figure 7.7 Direct infusion ESI native mass spectra of human haemoglobin obtained on (a) Orbitrap Velos™ and 
magnification of the +12 charge state of the αβ2H dimer (B) Synapt™ G2 S and magnification of the +11 charge state 
of the αβ2H dimer 
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Haemoglobin species Observed charge 
states 
Observed m/z  
(most abundant 
isotope) 
Calculated m/z 
(most abundant 
isotope) 
αβ2H +12, +11 2686, 2930 2686, 2930 
αβH +12, +11 2637, 2877 2635, 2874 
αH +9, +8,  +7, 1750, 1968, 2249 1750, 1968, 2249 
βH +9, +8 1832, 2061 1832, 2061 
β +18 -+10 884, 936, 994, 1060 
1136, 1223 1325, 
1446, 1590 
882, 934, 1058, 
1134, 1221, 
1323, 1443, 1587 
Table 7.1 Haemoglobin species detected by the Orbitrap Velos™ mass spectrometer following direct infusion 
electrospray of haemoglobin standards in ammonium acetate. 
Species Observed Charge 
states 
Observed m/z’s 
(most abundant 
isotope) 
Calculated m/z 
(most abundant 
isotope) 
(αβ)2 4H +16, +15, +14  4031, 4298, 4605, 4029, 4298, 4604 
αβ2H +11 ,+10, +9 3576, 3220, 2928 3581, 3223, 2930 
αβH +11 ,+10, +9 2875,  3511, 3162 2874, 3513, 3161 
αH +8,  +7, +6  1968,  2249, 2623 1968, 2249, 2624 
β +16 -10 1061, 1136, 1224, 
1325, 1446,-1590 
1058, 1134, 1221, 
1323, 1443, 1587 
Table 7.2 species acquired on the Waters Synapt™ from direct infusion analysis of haemoglobin standards 
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Haemoglobin complexes were successfully detected following from direct infusion 
electrospray of the protein standard as shown in fig 7.7. Peak assignments are shown in 
tables 7.1 and 7.2. The mass spectrum obtained on the orbitrap reveals the presence of 
(αβ)2H and haem-deficient  (αβ)H dimers. Three different monomers were detected: αH, 
βH    and additionally a β only subunit. The spectrum showed the beta subunit had 
undergone an oxidation. Haemoglobin tetramers were not detected. The mass spectrum 
acquired using the Synapt™ revealed the same peaks as observed using the orbitrap but 
without the presence of the intact βH monomer and low abundance peaks that could be 
due to the presence of the intact tetramers. These peaks are at the baseline level and 
cannot be assigned with great confidence. Having successfully obtained multi-protein 
haemoglobin complexes through direct infusion electrospray, standards were analysed 
with native LESA mass spectrometry.  
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Figure 7.8 Native LESA mass spectrum of human haemoglobin and magnification of the +12 charge state of the αβ2H 
dimer obtained from glass microscope slide acquired on the Orbitrap Velos™ 
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Species Observed Charge 
states 
Observed m/z (most 
abundant isotope) 
Calculated m/z 
(most abundant 
isotope) 
αβ2H +12, +11 2686, 2930 2686, 2930 
αβH +12, +11 2637, 2877 2635, 2874 
αH +9, +8,  +7, 1750, 1968, 2249 1750, 1968, 2249 
βH +9, +8 1832, 2061 1832, 2061 
β +18 -10 884, 936, 994, 1060, 
1136, 1224, 1325, 
1446, 1590 
882, 934, 992, 
1058, 1134, 1221, 
1323, 1443, 1587 
Table 7.3 Species acquired on the Orbitrap Velos™ from LESA of haemoglobin standards from glass microscope slides 
 
 
As described above, glass microscope slides were the most suitable substrate for native 
LESA mass spectrometry of myoglobin. The native LESA mass spectrum of haemoglobin 
corroborates that finding, see fig 7.8 and table 7.3. The same complexes observed by 
direct infusion ESI were also observed following native LESA from glass:  (αβ)2H, haem 
deficient  (αβ)H dimers, and three types of monomer. The same 3 types of monomer,  αH 
βH and the oxidised apo beta monomer were seen  as well. The presence of dimers is 
particularly significant as it demonstrates that multi-protein complexes can be reanalysed 
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from a surface after drying. Salt adducts were present, as seen in the case of myoglobin. 
No tetramers were observed in this mass spectrum, but this is unsurprising considering 
they were absent when electrosprayed by direct infusion (see fig 7.7). Having been 
demonstrated on glass, native LESA mass spectrometry of haemoglobin was repeated on 
PDVF. 
 
 
Figure 7.9 Native LESA mass spectrum of human haemoglobin and magnification of the +12 charge state of the αβ2H 
dimer obtained from PVDF membrane acquired on the Orbitrap Velos™  
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Species Observed Charge 
states 
Observed m/z’s 
(most abundant 
isotope) 
Calculated m/z 
(most abundant 
isotope) 
αβ2H +12, +11 2686, 2930 2686, 2930 
αβH +12, +11 2637, 2877 2635, 2874 
αH +9, +8,  +7, 1750, 1968, 2249 1750, 1968, 2249 
βH +9, +8 1832, 2061 1832, 2061 
β +18 -10 884, 936, 994, 1060, 
1136, 1223, 1325, 
1446, 1590 
882, 934, 992, 
1058, 1134, 1221, 
1323, 1443, 1587,  
Table 7.4 Species acquired on the Orbitrap Velos™ from LESA of haemoglobin standards from PVDF membrane 
 
The native LESA mass spectrum of haemoglobin standard from PVDF (fig 7.9 and table 
7.4) shows the presence of the same complexes as that obtained from glass (fig 7.8). 
Myoglobin was denatured when applied to PVDF, but the effect on haemoglobin has not 
been as great. Dimers were successfully detected although they are less intense than 
those obtained from glass. Dimers were present in +12 and +11 charge states as both 
(αβ)2H  and haem deficient (αβ)H dimers.  Monomers observed in this mass spectrum 
included αH, βH and the apo beta monomer.  
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Figure 7.10 Native LESA mass spectrum of human haemoglobin and magnification of the +11 charge state of the αβ2H 
dimer obtained from glass microscope slide acquired on the Synapt™ 
 
 
 
Species Observed Charge 
states 
Observed m/z 
(most abundant 
isotope) 
Calculated m/z 
(most abundant 
isotope) 
(αβ)2 4H +16, +15, +14 4046, 4309, 4614 4029, 4297, 4604 
αβ2H +11 ,+10, +9 2934, 3234, 3596, 2930, 3223, 3581  
αβH +11 ,+10, +9   2875, 3162, 3511, 2874, 3161, 3513 
αH +8,  +7, +6  1968,  2249, 2623 1968, 2249, 2624 
β +16 -10 1061, 1136,-1224, 
1325, 1446, 1590 
1058, 1134, 1221, 
1323, 1443, 1587, 
Table 7.5 species acquired on the Waters Synapt™ from LESA of haemoglobin standards from glass microscope slide 
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Fig 7.10 shows a mass spectrum obtained following native LESA of a haemoglobin spot on 
a glass microscope slide acquired on the Synapt™. The mass spectrum shows peaks 
corresponding to the intact tetramer in addition to the dimers and monomers. Although 
of low abundance, these peaks are more intense than observed in the mass spectrum 
acquired from solution (fig 7.7).   The dominant peaks in this mass spectrum 
corresponded to the β monomers.   Intact αH monomers were observed but  βH 
monomers were not whereas both  were obtained with the Orbitrap Velos™.   
Heterodimers were present as both (αβ)2H  and haem deficient (αβ)H dimers, which is 
similar to the spectrum acquired with the orbitrap. The Synapt™ was not able to 
distinguish the isotopic spacing of the peaks, unlike the orbitrap.  
 
 
Figure 7.11 Native LESA mass spectrum of human haemoglobin and magnification of the + 11 charge state of the αβ2H 
dimer obtained from PVDF membrane acquired on the Synapt™ 
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Species Observed Charge 
states 
Observed m/z 
(most abundant 
isotope) 
Calculated m/z 
(most abundant 
isotope) 
αβ2H +11 ,+10, +9 2930, 3220, 3576,  2930, 3223, 3581 
αβH +11 ,+10, +9  2872, 3161, 3520, 2874, 3161, 3513, 
αH +8,  +7, +6 , +12-9 1312, 1432, 1575, 
1750, 1968,  2249, 
2623,  
 1312, 1432, 
1575, 1750, 1968,  
2249, 2624 
Table 7.6 species acquired on the Waters Synapt™ from LESA of haemoglobin standards from glass microscope slide 
 
The haemoglobin standard was analysed by native LESA from a PVDF membrane. The 
resulting mass spectrum is shown on fig 7.11. No peaks corresponding to the intact 
tetramer were observed.  The dominant peak was an αH monomer.  Peaks corresponding 
to dimers were observed as both the (αβ)2H and haem deficient (αβ)H forms but were less 
intense than those observed in the mass spectrum obtained from glass. These results are 
consistent with reports that a hydrophobic surface can act as a denaturant. 
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7.2 Dried blood spots 
After non-covalent complexes had been successfully analysed from dried purified 
proteins by native LESA mass spectrometry, the next step was to apply the approach to a 
sample of biological interest. DBS were chosen due to the successful results obtained 
after analysing haemoglobin standards, and because analysing haemoglobin tetramers 
could be of clinical interest for investigating disorders affecting haemoglobin synthesis.   
Work presented in previous PhD thesis from this group had attempted using LESA 
orbitrap mass spectrometry for this purpose detecting haemoglobin dimers from DBS, 
but not tetramers [240]. The remainder of this chapter focuses on native LESA mass 
spectrometry from DBS.   
7.2.3 Orbitrap analysis  
In order to determine whether detection of haemoglobin tetramers was possible by use 
of the orbitrap, diluted whole blood samples were analysed. By using whole blood, the 
challenges of drying and coagulation are avoided. The upper m/z limit is 4000 Th and 
previously published examples where the native haemoglobin tetramer have been 
detected have peaks close to or above this limit [230, 241]. Human whole blood has been 
used to analyse haemoglobin tetramers previously [242]. In that work, human whole 
blood was acquired via finger prick, diluted by a factor of X 500 in ammonium acetate, 
and analysed via direct infusion ESI.   
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Figure 7.12 Direct infusion native ESI mass spectrum of whole blood diluted x500 in 10 mM ammonium acetate 
acquired on the Orbitrap Velos™ 
 
Fig  7.12 shows the mass spectrum obtained following direct infusion ESI of whole blood 
diluted by 500 in  10 mM ammonium acetate. The dominant peaks correspond to the 
(αβ)2H dimer. In addition, there are peaks corresponding to αH and βH monomers and a 
low abundance poorly-resolved peak at m/z 3795 corresponding to a tetramer in the + 17 
charge state. The ions at m/z 3795 were isolated (isolation width 50 Th) in an attempt to 
improve resolution.  
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Figure 7.13 Isolation of 3795 peak following direct infusion native mass ESI analysis of whole blood diluted X500 in 10 
mM ammonium acetate acquired on the Orbitrap Velos™  
 
The mass spectrum obtained following peak isolation is shown in fig 7.13. The measured 
m/z was 3792.22, (theoretical m/z is 3792.33 , Δ 22.8 ppm) just and the charge state was 
determined to be +17 so can be confirmed to be a haemoglobin tetramer.  Isolation could 
be used as a means for targeted identification of the haemoglobin tetramer from DBS.   
A series of DBS were analysed by this approach using LESA mass spectrometry. Surface 
sampling was carried out as described in section 7.1.  Samples were analysed first via a 
full scan mass spectrum, followed by isolation centred at m/z 3792.22 with a 50 Th 
window and a normalised collision energy of 0%.  
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Figure 7.14 Native LESA mass spectrometry of DBS:  (A) Full scan mass spectrum  (B) Isolation m/z 3792.22   
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LESA analysis of DBS on the orbitrap did not result in the successful detection of the 
native human haemoglobin tetramer.  The full scan mass spectrum shown in fig 7.14 A is 
of very low intensity: the dimers could not successfully be resolved. There were peaks 
corresponding to the αH monomer, but this was the only non-covalent complex that could 
confidently be identified. Apo beta monomers were also present. The isolation of the m/z 
3792.22 peak was also unsuccessful because there was no peak present in the full scan.   
 
7.2.4 Q-TOF analysis 
Haemoglobin tetramers had not successfully been obtained from DBS via LESA mass 
spectrometry on the orbitrap, so the Synapt™ mass spectrometer was used as an 
alternative. As mentioned in section 1.2.5, TOF mass spectrometers are the most 
common mass analysers used for the analysis of non-covalent protein complexes. The 
Synapt™ is more likely to be able to detect fragile multi-protein complexes than the 
orbitrap: Its inlet capillary is capable of operating at lower temperatures which are less 
likely to disrupt fragile interactions and the upper mass limit is higher, allowing the 
analysis of higher m/z ions.   
DBS were acquired in full scan TOF mode as described in section 2.2.3.1 and acquired for 
a period of 5 minutes. Problems occurred with formation of liquid microjunctions. When 
the solvent was applied to the surface, it was followed by the collapse of the 
microjunction and absorption of the solvent into the DBS. When this took place, spots 
were left to dry for 5 minutes before the same area was resampled using the same 
method described in section 7.1 but with only one dispension and aspiration cycle. Two 
216 
 
different solvent systems were used in the LESA analyses. The first was composed of a 10 
mM NH4AC solution, pH balanced to 6.8, and the second was also composed of a 10 mM 
NH4AC solution, balanced to pH 6.8, but with the addition of 5% methanol.  
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Figure 7.15 Native LESA mass spectrum obtained from DBS and magnification of the +14 charge state of the αβ24H 
tetramer acquired using the Synapt™ G2S. (A) 10 mM NH4AC extraction solvent (B) 10 mM NH4AC 5% methanol 
extraction solvent 
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Species Observed Charge 
states 
Observed m/z 
(most abundant 
isotope) 
Calculate m/z 
(most abundant 
isotope) 
(αβ)2 4H 16, 15, 14 4065, 4338, 4652  4029, 4297, 4604 
αβ)2H +11 ,+10, +9 2929, 3222, 3612 2930, 3223, 3581 
αβH +11 ,+10, +9  2876, 3163, 3514 2874, 3161, 3514 
αH +8,  +7, +6  1968,  2249, 2623, 
1312-1750 
1968, 2249, 2624 
β +16-+10 1060, 1136, 1224, 
1325, 1446, 1590 
992, 1058, 1134, 
1221, 1323, 1443, 
1587 
Table 7.7 Species acquired on the Waters Synapt™ after LESA of DBS with 10 mM NH4AC 
Species Observed Charge 
states 
Observed M/z’s Calculate m/z 
(most abundant) 
(αβ)2 4H 16, 15, 14 4069, 4345, 4662 4029, 4297, 4604 
αβ2H +11 ,+10, +9 2929 3247, 3623 2930, 3223, 3581 
αβH +11 ,  2876 2874, 3161, 3514 
αH +8,  +7, +6   1968,  2249, 2623 1968, 2249, 2624 
Β +16-+10 1060, 1136, 1223, 
1325, 1446, 1590 
992, 1058, 1134, 
1221, 1323, 1443, 
1587 
Table 7.8 Species acquired on the Waters Synapt™ after LESA of DBS with 10 mM NH4Ac and 5% MeOH 
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Haemoglobin tetramers were detected from DBS following native LESA mass 
spectrometry on the Synapt™ mass spectrometer using both solvent conditions. 
Tetramers were observed in the +16, +15 and +14 charge states. The tetramer peaks 
were less intense than those corresponding to the dimers and monomer but significantly 
more intense than those observed from the purified protein on glass microscope slides 
shown in fig 7.10. The tetramer peaks were very broad (~ 100 Th) which is similar to 
previously reported examples[230, 241]. Broadening of the peaks is likely to be due to 
insufficient desolvation of the complex, and aggregations of salts. The temperature of the 
Synapt’s™ ion transfer tube is set at 30°C, compared with 250°C for the orbitrap. Lower 
temperatures prevent dissociation of unstable interactions which may be why it is 
possible to obtain tetramers on the Synapt™. Lower temperatures can lead to the 
retention of interactions between the solvent and the protein into the gas phase resulting 
in peak broadening. Higher temperatures would result in narrower peaks but may make it 
impossible to retain the tetramer into the gas phase.  Salts can be another problem: Salts 
form adducts along with the protonated form of the protein, as seen in previous spectra. 
Here the different adducts could not be distinguished from the tetramer due to the 
limited resolving power. The resolving power of TOF mass analysers are not great enough 
to distinguish different adducts for a native protein complex with a mass higher than 65 
kDa [243].  Salts are an unavoidable issue when analysing DBS. Blood contains a 
physiologically high concentration of salts.  The most concentrated endogenous salt is 
sodium at between 135-145 mM in a healthy individual [244]. Peaks corresponding to 
tetramers were more intense when analysed in a solution composed of 5% methanol. 
Adding small amounts of organic solvents in native mass spectrometry can improve 
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ionisation efficiency,[245] but in this case it could also help improve protein extraction 
and solubility. 
 
7.3 Chapter 7 conclusions  
 
This work presented in this chapter demonstrates the successful use of LESA mass 
spectrometry for the analysis of non-covalent complexes from proteins dried onto 
surfaces.  Multi-protein and protein-cofactor complexes were observed in the gas phase 
following native LESA sampling with a spectral quality similar to that obtained following 
direct infusion ESI. Two different mass spectrometers were used to analyse these non-
covalent complexes, a high resolution orbitrap mass spectrometer and a high resolution 
QTOF. Both w--ere capable of analysing non-covalent interactions, but the QTOF mass 
spectrometer was better able to transmit larger complexes of higher m/z ratios.   This 
was work was some of the first demonstrating the analysis of non-covalent interactions 
from a surface by an mass spectrometry surface sampling tool, but this concept has since 
been explored by others. LESA has recently been used to sample native protein 
complexes from thin tissue sections [246].  
 
In this chapter the haemoglobin tetramer was observed from a DBS, which is of particular 
interest as the approach could be of use for investigating disorders affecting 
haemoglobin. Certain disorders such as thalassemias result in abnormal haemoglobin 
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subunit stochiometries [247]. Thalassemias can result in larger amounts of haemoglobin 
A2, haemoglobin   H or haemoglobin Barts [248]. Haemoglobin A2 is  a tetramer 
composed of two alpha chains and two delta-globin chains, haemoglobin H is made up of 
four delta globin chains  and  haemoglobin Barts is a tetramer composed of  four gamma 
haemoglobin chains[248, 249]. If the healthy haemoglobin tetramer can be identified 
then it may be possible to identify others too and native LESA mass spectrometry could 
be used to these tetramers directly from a DBS without any additional sample 
preparation. 
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Chapter 8 Conclusions 
 
The work carried out in this thesis has shown a number of new applications for LESA mass 
spectrometry in proteomics research. Prior to beginning this work, there had only been a 
few published examples of using LESA for proteomics analysis and the majority of 
applications were aimed at the analysis of small molecules, such as lipids, pesticides and 
drugs. This work in this thesis demonstrates the development of new methods and 
substrates showing that LESA is a useful tool for analysing proteins from surfaces.   
 
The work presented in Chapter 3 was carried out to attempt to improve fractionation 
techniques available for top down proteomics, by using LESA to extract intact proteins 
blotted onto PVDF membranes from SDS PAGE gels. LESA could not be used for the 
analysis of proteins blotted from gels but it was possible to reanalyse proteins after they 
have been directly deposited onto PVDF. The ability to analyse intact proteins from PVDF 
led to formation of an external collaboration and proved to be useful in for analysing 
proteins in air filters. 
The most successful part of this PhD was presented in Chapter 4 in which untargeted 
bottom up proteomics analysis of DBS by use of LESA coupled with automated proteolysis 
was demonstrated. Until this work was undertaken, applications of LESA in proteomics 
were restricted to the analysis of intact proteins. Top down protein analysis can be very 
limiting: many proteins are too large to be detected without any proteolytic digestion and 
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it is most effective at detecting the most abundant proteins in a sample. In a complex 
sample, the majority of proteins will not be accessible to top down analysis. Incorporating 
a trypsin digestion into the LESA sampling routine made it possible to greatly increase the 
number of proteins that can be identified from a DBS via LESA.  It was possible to identify 
over 100 proteins through an LC MS/MS analysis of a DBS digest whereas using a LESA 
top down proteomics approach had only ever resulted in the identification of 
haemoglobin proteins. The research also unexpectedly demonstrated a new approach for 
analysing DBS that had never been investigated in any detail: proteomics. This approach 
could be of major advantage in the clinic as DBS could be used as a convenient source for 
many different protein biomarkers. The work demonstrated that these protein 
biomarkers are accessible to mass spectrometric analysis. DBS could become as a 
sampling format to rival plasma in identifying new biomarkers which is a major focus of 
research in proteomics. It is surprising that until now the DBS had not even been 
considered as an alternative.   
   
The idea of pursuing a proteomics analysis of DBS were further explored in Chapter 5 by 
considering more established means of sample preparation. Proteins were eluted from 
punches cut out of DBS and digested in solution. If DBS were to be used as an alternative 
to plasma the majority of laboratories would be unlikely to use LESA sampling and would 
most likely use the “punch and elute” approach. Data from Chapter 5 showed that the 
“punch and elute” approach was a viable option for identifying proteins from a DBS, but 
less successful than the LESA based digest. Solution phase digests were amenable to 
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enrichment of low abundance proteins by immunodepletion. Sample complexity is a 
major challenge when analysing blood and plasma and the number of proteins identified 
was improved by removing the higher abundance proteins.  Several different options 
were attempted but the most successful appeared to be removing haemoglobin only. 
Care is needed when depleting DBS. DBS contain only a small amount of protein, and 
even though there are many different types, if too much protein is pulled out by 
immunodepletion, there may very little of the low abundance proteins available for 
detection.  
 
The work presented in Chapter 6 aimed to demonstrate the clinical use of the LESA based 
trypsin digest developed in Chapter 4 by determining variants of the alpha-1-antityrypsin 
protein. This was unsuccessful. The different variants linked to disease result in a 
significant reduction in synthesis of the protein which becomes difficult to characterise at 
low concentrations. The results did demonstrate, however, that the LESA based trypsin 
digest can be analysed by a variety of different mass spectrometry methods. It can be 
analysed by targeted approaches which could be particularly important for clinical 
applications. 
 
The work presented in the final chapter demonstrated the application of LESA to analyse 
non-covalent complexes from proteins dried onto surfaces, overcoming the challenge of 
denaturation upon drying. The work presented in this chapter saw protein cofactor and 
multi-protein interactions retained into the gas phase from a dried surface. Most exciting 
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of all the spectra obtained were those where a haemoglobin tetramer had been 
recovered directly from a dried blood spot, exactly how it exists in its native state. This 
was all achieved without performing any sample preparation or pre-treatment.   
 
Future work 
 
Much of the work carried out in this thesis could be investigated further. The LESA based 
digest described in Chapter 4 could be applied to a range of different samples and not 
just DBS. It has already been used successfully for the analysis of thin tissue sections 
[219]. Similar approaches have been published, where LESA has been used to identifying 
proteins from tryptic peptides originating from tissues but were not able to couple 
sampling and digestion so had to perform them in a multi-step process. Applications have 
been demonstrated for analysing meat surfaces in the authentication of foods and 
discovering  biomarkers from cancerous tissue [250, 251]. Montowska et al. [250] 
focused on analysing meat surface and developed a method by which a meat sample 
were digested in solution and then printed onto a surface and dried prior to re-analysis 
with LESA. Wisztorski [251] used a similar approach for identifying of cancer biomarkers 
from ovarian tissue, their method involved performing an on tissue digest with a chemical 
inkjet printer, which was then followed up by LESA sampling to extract the peptides, solid 
phase extraction for clean-up and then finally LC MS/MS.  By using the method described 
in Chapter 4 the sample preparation performed in these two multi-step methods could 
be carried out in a single stage. Chapter 4 demonstrated that LESA sampling can be 
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incorporated alongside sample processing by using the Triversa Nanomate™ as a liquid 
handling robot. Only a trypsin digest has been experimented with in detail so far, but it 
would be interesting to see if other processing stages could be incorporated as well. 
Other processing stages could include a disulphide bond reduction, immunodepletion 
such as that carried out in Chapter 5, or even sample clean-up such as zip tipping. 
 
In terms of advancing the field of DBS analysis, there are a number of options for taking 
this work further. A new range of specialised DBS cards incorporating membrane 
filtration have been released. These contain specialised filters that filter out red blood 
cells from the plasma during the blood spotting and drying process, leaving a sample that 
is more similar to a dried plasma spot [252, 253]. These spots could be an interesting 
sample to analyse from a proteomics perspective as it would be a less complicated 
sample than a standard DBS but still retain the advantages associated with fingerprick 
sampling.  These samples would also be interesting to analyse with immunodepletion 
methods such as those described in Chapter 5.   
The immunodepletion methods used in Chapter 5 were interesting in showing that 
identification of low abundance proteins could be improved by sample enrichment. 
Removing the high abundance proteins was a viable option, but an alternative could be to 
pull out specific proteins of interest for analysis. This approach has been applied to 
plasma samples, such as the stable isotope standards and capture by anti-peptide 
antibodies (SISCAPA) assays [254]. This would be a targeted means of analysis, but it can 
be multiplexed and crucially can be used for the detection of very low abundance 
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proteins such as the interleukins and cytokines [254] and have been experimented for 
use on DBS [255].  
 
A1AT variants could not be characterised by LESA based DBS digestions, however there 
are a number of additional options that could be attempted. The failure was 
hypothesised to be due to low concentrations of the A1AT protein rendering it 
impractical for detailed characterisation by bottom up proteomics techniques. Chapter 5 
did demonstrate that depletion of haemoglobin proteins does increase the detection of 
some of the less abundant plasma proteins. If haemoglobin depletion were carried out on 
an A1AT deficient DBS then it may enrich the A1AT protein enough for bottom up 
characterisation and variant determination.  
 
Chapter 7 also raises a number of new possibilities. The native haemoglobin tetramer was 
detected from LESA sampling of DBS. This method could be of interest in sampling DBS 
from patients suffering from thallasemias and could be used for detecting abnormal 
haemoglobin stoichiometries. The results in this chapter also showed LESA analysis of 
non-covalent complexes from purified proteins.  Protein nucleic acid complexes were not 
investigated in this work, but are commonly used in research on native mass 
spectrometry. It would be interesting to investigate if these interactions could be 
analysed using LESA.  A final avenue of research would be to combine LESA sampling with 
the travelling wave ion mobility spectrometry that is available on the Synapt™. If used 
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effectively it can be used as a structural tool to calculate the collision cross section of an 
ion, and could reveal the extent of denaturation proteins undergo when drying. 
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Appendix 4 
 
 
 
 
 
 
Appendix 4.1. Proteins identified from direct infusion ESI mass spectrometry of dried plasma spot digested for 1 
hour. 
 
 
 
 
 
 
 
Appendix 4.2 Proteins identified from direct infusion ESI mass spectrometry of dried plasma spot digested for 12 
hours. 
 
Protein Description Total 
Coverage 
Unique 
peptides 
Mascot 
Score 
Sequest 
Score 
Ig kappa chain C region  49.06 % 2 98.30  48.65  
Serum albumin  32.18 % 25 1969.35  323.34  
Apolipoprotein A-II  21.00 % 2 
 
4.01  
Uncharacterized protein C7orf13  20.37 % 1 
 
0.00  
Apolipoprotein A-I  16.48 % 4 409.85  33.26  
Ig gamma-1 chain C region 10.91 % 3 58.63  25.90  
Ig lambda-2 chain C regions  9.43 % 1 65.62  16.62  
Alpha-1-antitrypsin  7.89 % 3 
 
32.17  
Alpha-1-acid glycoprotein 1  7.46 % 1 
 
0.00  
Haptoglobin  3.94 % 2 34.43  7.95  
Hemicentin-2  2.92 % 1 
 
0.00  
Metal transporter CNNM1  2.80 % 1 
 
4.28  
Fibrinogen alpha chain  1.96 % 1 90.95  28.55  
Serotransferrin  1.72 % 1 
 
3.16  
Protein Description Total 
Coverage 
Unique 
peptides 
Mascot 
Score 
Sequest 
Score 
Ig kappa chain C region  49.06 % 2 269.85  40.06  
Serum albumin  32.68 % 24 1886.53  249.15  
Ig lambda-2 chain C regions  27.36 % 2 36.53  6.72  
Apolipoprotein A-I  26.97 % 6 584.63  51.49  
Ig gamma-1 chain C region  26.67 % 4 267.51  37.74  
Ig gamma-4 chain C region  17.13 % 1 124.58  16.39  
Alpha-1-antitrypsin  16.51 % 5 54.50  34.19  
Apolipoprotein A-II  11.00 % 1 
 
2.44  
Fibrinogen beta chain  7.72 % 1 
 
3.32  
Heterogeneous nuclear ribonucleoprotein L  7.64 % 1 23.53  
 
ATP-binding cassette sub-family G member 
5  
6.78 % 1 
 
0.00  
Haptoglobin  5.91 % 3 65.29  9.83  
Isoform Gamma-A of Fibrinogen gamma 
chain  
5.26 % 1 
 
0.00  
28S ribosomal protein S5, mitochondrial  3.49 % 1 
 
1.74  
Coiled-coil domain-containing protein 54  3.35 % 1 
 
1.85  
Roundabout homolog 2  2.98 % 1 
 
1.99  
Serotransferrin  1.72 % 1 
 
2.87  
Fibrinogen alpha chain  1.50 % 1 29.06  2.78  
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Protein Description Total 
Coverage 
Unique 
peptides 
Mascot 
Score 
Sequest 
Score 
Hemoglobin subunit delta  99.32 % 20 2645.90  176.47  
Hemoglobin subunit beta  99.32 % 29 6942.99  649.81  
Hemoglobin subunit alpha  99.30 % 27 4062.92  505.25  
Apolipoprotein A-I  67.42 % 20 714.65  68.89  
Ig kappa chain C region  66.98 % 6 316.99  25.96  
Carbonic anhydrase 1  62.45 % 13 813.29  79.76  
Carbonic anhydrase 2  44.23 % 8 271.74  24.38  
Flavin reductase (NADPH)  41.75 % 5 183.80  15.63  
Alpha-1-antitrypsin  37.80 % 11 265.69  29.31  
Peroxiredoxin- 36.36 % 8 343.73  29.35  
Serum albumin  31.86 % 22 829.90  68.46  
Protein S100-A6  31.11 % 1 45.61  2.93  
Alpha-synuclein  27.14 % 2 101.94  6.53  
Glyceraldehyde-3-phosphate 
dehydrogenase  
21.49 % 5 99.94  3.06  
Catalase  21.06 % 8 208.81  19.52  
Apolipoprotein C-III  19.19 % 2 132.87  12.13  
Ig lambda-7 chain C region  18.87 % 2 85.57  7.66  
Actin, cytoplasmic 1  17.07 % 5 74.59  8.26  
Fibrinogen gamma chain  16.56 % 4 131.40  17.45  
Transthyretin  15.65 % 1 41.02  3.11  
Granulysin  15.12 % 1 
 
0.00  
Hemoglobin subunit gamma-2  14.97 % 2 748.88  40.83  
N-glycosylase/DNA lyase  14.21 % 1 
 
0.00  
Leucine-rich repeat-containing protein 55  14.15 % 1 
 
0.00  
Fibrinogen beta chain  13.44 % 5 106.56  14.77  
Apolipoprotein C-I  13.25 % 1 25.22  3.10  
Serotransferrin  12.75 % 8 272.09  33.29  
Ig gamma-1 chain C region  12.73 % 3 110.13  9.70  
Ig alpha-1 chain C region  12.18 % 4 139.07  8.75  
Apolipoprotein F  12.01 % 1 
 
0.00  
Ig mu chain C region  11.95 % 5 140.44  15.99  
Band 3 anion transport protein  11.31 % 6 224.24  22.59  
Acyl-coenzyme A thioesterase 1  10.45 % 1 
 
0.00  
Olfactory receptor 2F1 [ 9.15 % 1 
 
0.00  
Fibrinogen alpha chain  9.01 % 6 254.17  22.99  
Protein Smaug homolog 1  8.12 % 1 
 
0.00  
Isoform 6 of Osteoclast-associated 
immunoglobulin-like receptor  
7.94 % 1 
 
2.65  
Peptidyl-prolyl cis-trans isomerase  7.88 % 1 25.76  2.83  
Complement C3 7.58 % 9 261.27  24.08  
Isoform 2 of Tetratricopeptide repeat 
protein 8  
7.20 % 1 
 
0.00  
Alpha-2-macroglobulin  6.65 % 6 178.99  11.90  
Insulinoma-associated protein 1  6.27 % 1 
 
0.00  
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Protein Description Total 
Coverage 
Unique 
peptides 
Mascot 
Score 
Sequest 
Score 
Ig gamma-2 chain C region  5.83 % 2 57.11  2.33  
Alpha-1B-glycoprotein  5.66 % 2 33.02  2.34  
Apolipoprotein A-IV  5.56 % 2 89.53  4.98  
Alpha-2-HS-glycoprotein 5.45 % 1 71.91  5.17  
Serum amyloid P-component  4.48 % 1 42.89  2.31  
Isoform 2 of Cingulin  3.89 % 1 
 
0.00  
Uncharacterized protein C7orf63  3.40 % 1 27.02  
 
Complement C4-B alpha chain  3.36 % 1 
 
1.66  
Haptoglobin  3.20 % 1 47.06  3.64  
Serine/threonine-protein kinase MRCK 
alpha (Fragment)  
3.11 % 1 
 
2.02  
Spectrin beta chain, erythrocytic  2.90 % 5 96.77  9.27  
L-lactate dehydrogenase B chain  2.69 % 1 67.51  2.11  
Spectrin alpha chain, erythrocytic 1  2.44 % 5 88.18  12.27  
Kininogen-1  2.30 % 1 
 
1.69  
T-box transcription factor TBX18  2.30 % 1 
 
0.00  
Ankyrin-1  2.18 % 2 34.54  3.70  
Solute carrier family 2, facilitated glucose 
transporter member 1  
2.03 % 1 58.50  2.79  
Alpha-1-antichymotrypsin  1.65 % 1 22.67  1.61  
35 kDa inter-alpha-trypsin inhibitor heavy 
chain H4 (Fragment)  
1.53 % 1 
 
0.00  
Putative uncharacterized protein C12orf63  1.36 % 1 
 
0.00  
Inter-alpha-trypsin inhibitor heavy chain H1  1.32 % 1 55.99  2.48  
DNA-binding protein RFX5  1.22 % 1 
 
0.00  
Isoform 2 of Protein TANC1  0.63 % 1 
 
0.00  
Isoform 2 of Histone-lysine N-
methyltransferase, H3 lysine-36 and H4 
lysine-20 specific  
0.58 % 1 
 
0.00  
Apolipoprotein B-100  0.55 % 2 61.07  2.55  
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Protein Description Total Coverage Unique 
peptides 
Mascot 
Score 
Sequest 
Score 
Hemoglobin subunit alpha  74.65 % 16 737.74  124.29  
Hemoglobin subunit beta  69.39 % 7 1059.32  96.86  
Transthyretin  59.86 % 7 123.41  31.63  
Hemoglobin subunit delta  57.82 % 3 724.67  55.26  
Carbonic anhydrase 1  54.02 % 9 233.00  24.65  
Ig kappa chain C region  49.06 % 3 68.52  13.82  
Apolipoprotein A-I  42.32 % 13 416.75  40.70  
Hemoglobin subunit gamma-1  39.46 % 3 317.79  23.11  
Glyceraldehyde-3-phosphate dehydrogenase  37.31 % 5 147.81  25.76  
Alpha-1-antitrypsin  34.45 % 13 337.62  37.11  
ADP-ribosylation factor-like protein 6-interacting protein 1  31.82 % 1 
 
2.53  
Flavin reductase (NADPH)  30.58 % 3 20.69  0.00  
Actin, cytoplasmic 1  29.87 % 8 95.47  26.41  
Apolipoprotein C-III  27.27 % 2 78.81  4.71  
Apolipoprotein C-I  26.51 % 2 
 
2.37  
Complement C3 25.56 % 27 668.82  86.91  
Serum albumin  25.29 % 18 543.74  59.86  
Dermcidin  24.55 % 3 65.30  8.40  
14-3-3 protein zeta/delta  23.67 % 3 77.82  14.37  
dCTP pyrophosphatase 1  23.53 % 2 35.17  5.86  
Peroxiredoxin-2  23.23 % 5 122.02  12.76  
Profilin  22.73 % 1 
 
0.00  
Ig gamma-1 chain C region  22.42 % 3 98.02  13.93  
Fibrinogen beta chain  22.20 % 8 89.79  13.44  
Fibrinogen gamma chain  22.08 % 7 199.59  26.20  
Heat shock 70 kDa protein 1A/1B  20.75 % 6 106.68  18.04  
RAC-alpha serine/threonine-protein kinase (Fragment)  20.00 % 1 
 
0.00  
Complement component 1 Q subcomponent-binding protein, 
mitochondrial  
19.86 % 2 79.42  3.98  
14-3-3 protein epsilon  19.22 % 2 95.47  18.75  
Alpha-2-macroglobulin  19.20 % 18 489.04  59.80  
Mitochondrial fission 1 protein  19.08 % 1 39.32  2.89  
Isoform 2 of COP9 signalosome complex subunit] 18.75 % 1 
 
0.00  
Apolipoprotein A-IV  18.69 % 5 120.28  15.36  
Ceruloplasmin  18.59 % 11 220.05  37.29  
Carbonic anhydrase 2  18.46 % 3 124.89  14.09  
Hemopexin  18.40 % 7 157.52  19.30  
Alpha-1B-glycoprotein  18.18 % 4 117.28  7.77  
Protein FAM98B   17.82 % 1 
 
2.31  
Phosphoglycerate mutase 1  17.72 % 2 44.94  11.89  
60 kDa heat shock protein, mitochondrial  17.63 % 5 195.46  16.92  
Abhydrolase domain-containing protein 10, mitochondrial  17.56 % 1 
 
0.00  
Peroxiredoxin-6  16.96 % 2 46.12  2.56  
Heat shock cognate 71 kDa protein  16.87 % 4 109.98  23.70  
Inter-alpha-trypsin inhibitor heavy chain H2  16.70 % 9 159.11  29.79  
L-lactate dehydrogenase B chain 16.47 % 3 105.69  14.11  
Nuclear autoantigenic sperm protein (Fragment)  16.00 % 1 
 
3.48  
Glutathione reductase, mitochondrial (Fragment) 15.86 % 1 
 
2.24  
Alpha-synuclein  15.71 % 1 37.24  3.27  
Heat shock protein HSP 90-beta  15.61 % 2 158.68  16.11  
V-type proton ATPase subunit D (Fragment)  15.03 % 1 
 
0.00  
Eukaryotic translation initiation factor 5A-1  14.94 % 1 28.22  2.76  
Isoform 2 of Acidic leucine-rich nuclear phosphoprotein 32 
family member B  
14.87 % 1 
 
2.46  
Ig kappa chain V-III region SIE 14.68 % 1 74.61  3.20  
Fibrinogen alpha chain  14.67 % 10 269.47  36.33  
Angiotensinogen  14.64 % 4 163.04  11.73  
Keratin, type I cytoskeletal 10  14.55 % 5 59.90  13.84  
Alpha-trypsin chain 2 (Fragment)  14.08 % 1 
 
2.02  
Clusterin  14.03 % 4 73.11  9.43  
26S proteasome non-ATPase regulatory subunit 13 (Fragment)  13.57 % 1  0.00  
Stress-induced-phosphoprotein 1  13.56 % 1  0.00  
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Protein Description Total Coverage Unique 
peptides 
Mascot 
Score 
Sequest 
Score 
Elongation factor 1-gamma  12.81 % 3 23.10  5.13  
Spliceosome RNA helicase DDX39B (Fragment)  12.77 % 1 
 
0.00  
39S ribosomal protein L12, mitochondrial  12.12 % 1 20.86  2.52  
Protein SET  12.08 % 1 
 
0.00  
L-lactate dehydrogenase A chain  12.05 % 2 72.78  12.99  
Translin (Fragment)  11.89 % 1 
 
0.00  
Vesicle-fusing ATPase (Fragment)  11.80 % 1 
 
2.62  
Platelet basic protein  11.72 % 1 35.76  3.14  
Acidic leucine-rich nuclear phosphoprotein 32 family member A  11.65 % 1 23.85  2.44  
Poly(rC)-binding protein 2 (Fragment)  11.41 % 1 
 
2.40  
Protein S100-A9  11.40 % 1 
 
2.73  
Heat shock protein HSP 90-alpha  10.66 % 1 276.57  24.98  
Eukaryotic translation initiation factor 3 subunit H (Fragment)  10.64 % 1 
 
2.06  
T-complex protein 1 subunit beta  10.47 % 3 96.42  13.68  
DNA damage-binding protein 1 (Fragment)  10.44 % 1 
 
4.99  
Keratin, type II cytoskeletal 1  10.40 % 5 137.78  14.85  
Inosine-5'-monophosphate dehydrogenase 2 (Fragment)  10.39 % 1 
 
0.00  
Ig alpha-1 chain C region  10.20 % 3 68.27  4.47  
60S ribosomal protein L10a  10.14 % 1 23.43  0.00  
Ig gamma-3 chain C region  10.08 % 1 70.11  6.69  
Stress-70 protein, mitochondrial  10.01 % 2 85.76  14.59  
Apolipoprotein A-II  10.00 % 1 55.27  2.49  
Heterogeneous nuclear ribonucleoprotein U (Fragment)  9.92 % 1 
 
5.69  
T-complex protein 1 subunit alpha  9.89 % 2 116.36  6.30  
HBS1-like protein (Fragment)  9.88 % 1 
 
0.00  
ADP/ATP translocase 2  9.73 % 1 
 
2.09  
Inter-alpha-trypsin inhibitor heavy chain H4  9.68 % 7 159.84  22.13  
Inter-alpha-trypsin inhibitor heavy chain H1  9.44 % 5 54.35  12.42  
Gelsolin  9.34 % 4 109.25  15.69  
Coatomer subunit epsilon  9.09 % 1 22.82  2.07  
Methylosome protein 50 (Fragment)  8.93 % 1 
 
0.00  
Fructose-2,6-bisphosphatase TIGAR  8.52 % 1 0.00  
 
Histidine-rich glycoprotein  8.38 % 3 29.93  2.03  
Fructose-bisphosphate aldolase A  8.24 % 1 27.43  2.55  
Complement C4-A  8.03 % 8 238.00  
 
Serotransferrin  8.02 % 5 96.14  13.80  
Tubulin alpha-4A chain  7.81 % 2 61.83  2.83  
Alcohol dehydrogenase class-3  7.49 % 1 
 
0.00  
Transcription factor SOX-17  7.49 % 1 
 
0.00  
Complement factor B  7.46 % 4 67.34  9.80  
Alpha-2-HS-glycoprotein  7.36 % 2 60.27  9.43  
Proteasome subunit alpha type-6  7.32 % 1 20.17  2.10  
Alpha- and gamma-adaptin-binding protein p34  7.30 % 1 26.83  3.08  
Exportin-2  7.21 % 3 26.14  2.10  
Nucleosome assembly protein 1-like 4  7.20 % 1 39.02  3.56  
T-complex protein 1 subunit zeta  7.16 % 2 41.57  5.23  
2-hydroxyacyl-CoA lyase 1  7.12 % 1 
 
2.03  
Isoform 4 of Apoptosis-inducing factor 1, mitochondrial  7.10 % 1 
 
0.00  
Ig gamma-2 chain C region  7.06 % 1 53.32  4.00  
Serpin H1  6.94 % 1 23.58  2.33  
Endoplasmin  6.85 % 2 23.50  3.20  
T-complex protein 1 subunit eta  6.81 % 2 27.86  2.65  
Adenylyl cyclase-associated protein 1  6.74 % 2 65.10  6.86  
X-ray repair cross-complementing protein 5  6.69 % 2 109.18  20.55  
Tubulin-specific chaperone D  6.64 % 1 
 
0.00  
Acetyl-CoA acetyltransferase, cytosolic  6.55 % 1 28.67  2.28  
Phosphoribosylformylglycinamidine synthase  6.29 % 2 
 
0.00  
Tropomodulin-3  6.25 % 1 20.44  2.12  
Importin subunit alpha-1  6.24 % 1 36.69  5.35  
Ig mu chain C region  6.19 % 3 46.65  1.84  
Haptoglobin  6.16 % 2 63.28  4.89  
Importin subunit beta-1  6.16 % 2 33.14  2.04  
cAMP-dependent protein kinase catalytic subunit alpha  5.98 % 1 24.04  0.00  
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Protein Description Total Coverage Unique 
peptides 
Mascot 
Score 
Sequest 
Score 
Tetranectin 5.94 % 1 94.71  3.19  
Complement component C8 beta chain  5.75 % 2 35.32  6.22  
Apoptosis inhibitor 5  5.53 % 1 24.85  2.06  
Vitamin D-binding protein  5.49 % 2 38.55  7.62  
Trifunctional enzyme subunit beta, mitochondrial  5.49 % 1 35.91  5.78  
Copine-3  5.40 % 1 34.09  2.97  
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit 2  
5.39 % 1 41.11  2.62  
Elongation factor 2  5.36 % 2 116.88  16.59  
Mitogen-activated protein kinase 3  5.01 % 1 29.38  2.90  
General transcription factor 3C polypeptide 5  5.01 % 1 0.00  2.13  
Serum amyloid P-component  4.93 % 1 
 
2.16  
Leucine-rich alpha-2-glycoprotein  4.85 % 1 
 
0.00  
26S proteasome non-ATPase regulatory subunit 2  4.83 % 1 
 
0.00  
Eukaryotic peptide chain release factor subunit 1  4.81 % 1 121.07  13.63  
Eukaryotic translation initiation factor 3 subunit M  4.81 % 1 27.27  2.25  
Monofunctional C1-tetrahydrofolate synthase, mitochondrial  4.70 % 2 53.82  4.12  
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
48 kDa subunit 
4.61 % 1 22.93  5.46  
Hypoxanthine-guanine phosphoribosyltransferase  4.59 % 1 
 
1.99  
ATP synthase subunit beta, mitochondrial  4.54 % 1 72.26  2.47  
Splicing factor 3A subunit 3  4.46 % 1 
 
0.00  
Alanine--tRNA ligase, cytoplasmic  4.24 % 2 33.92  7.98  
Eukaryotic initiation factor 4A-I  4.19 % 1 288.73  39.25  
Transketolase  4.17 % 1 27.09  0.00  
Fatty acid synthase  4.10 % 5 53.23  8.84  
T-complex protein 1 subunit epsilon  4.02 % 1 
 
0.00  
Glucose-6-phosphate isomerase  3.94 % 1 
 
0.00  
SUMO-activating enzyme subunit 2  3.91 % 1 
 
2.78  
Phosphoglycerate kinase 1  3.84 % 1 32.25  2.87  
Squalene monooxygenase  3.83 % 1 23.56  5.09  
Cystathionine beta-synthase  3.81 % 1 34.85  4.57  
Dihydrolipoyl dehydrogenase, mitochondrial  3.73 % 1 63.18  11.55  
Heat shock 70 kDa protein 6  3.73 % 1 49.56  7.50  
Puromycin-sensitive aminopeptidase  3.67 % 1 
 
2.10  
ATP-citrate synthase  3.63 % 2 118.81  16.62  
Heterogeneous nuclear ribonucleoprotein K  3.46 % 1 47.22  2.35  
Plasma protease C1 inhibitor  3.40 % 1 32.42  0.00  
DNA replication licensing factor MCM6  3.29 % 1 26.07  2.09  
Elongation factor 1-alpha 1  3.25 % 1 23.23  2.66  
Alpha-enolase  3.23 % 1 82.39  3.74  
Citrate synthase, mitochondrial  3.22 % 1 44.25  3.88  
Epidermal growth factor receptor kinase substrate 8  3.20 % 1 
 
0.00  
Complement component C8 beta chain  5.75 % 1 42.75  2.88  
Catalase 3.04% 1 26.84  0.00  
Pyruvate kinase PKM  3.01 % 1 130.33  8.78  
tRNA-splicing ligase RtcB  2.97 % 1 
 
2.73  
Probable phospholipid-transporting ATPase VD  2.88 % 1 
 
0.00  
Peroxisomal multifunctional enzyme type 2  2.85 % 1 70.46  5.07  
Ubiquitin carboxyl-terminal hydrolase 5  2.80 % 1 24.93  4.98  
C-1-tetrahydrofolate synthase, cytoplasmic  2.78 % 1 44.08  10.64  
78 kDa glucose-regulated protein  2.75 % 1 89.83  4.31  
Importin-9  2.69 % 1 
 
0.00  
Alpha-1-antichymotrypsin  2.60 % 1 55.35  3.50  
Exportin-T  2.60 % 1 
 
2.55  
Insulin-like growth factor-binding protein complex acid labile 
subunit  
2.48 % 1 55.87  4.09  
Neutral alpha-glucosidase AB  2.44 % 1 57.91  3.53  
Microtubule-associated protein 4  2.34 % 1 20.13  5.50  
Complement C1s subcomponent  2.33 % 1 47.04  9.58  
Afamin  2.17 % 1 
 
2.22  
Coatomer subunit beta  2.10 % 1 97.14  6.95  
Filamin-B  1.96 % 2 33.23  7.62  
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Protein KIAA0368  1.90 % 1 
 
0.00  
N-alpha-acetyltransferase 15, NatA auxiliary subunit  1.85 % 1 25.05  5.97  
Importin-5  1.73 % 1 79.90  9.58  
Apolipoprotein B-100  1.71 % 5 176.50  18.15  
Eukaryotic translation initiation factor 5B  1.64 % 1 78.59  5.50  
Band 3 anion transport protein  1.43 % 1 49.60  3.05  
Kininogen-1  1.40 % 1 33.98  0.00  
DNA-dependent protein kinase catalytic subunit  1.17 % 2 
 
4.51  
Filamin-A  1.02 % 1 23.70  2.59  
E3 ubiquitin-protein ligase HUWE1 (Fragment)  0.56 % 1 
 
4.10  
Kinesin-like protein KIF1C  0.54 % 1 
 
0.00  
Cytoplasmic dynein 1 heavy chain 1  0.50 % 1 
 
0.00  
Spectrin beta chain, erythrocytic  0.47 % 1 28.21  0.00  
Heterogeneous nuclear ribonucleoprotein U (Fragment)  9.92 % 1  5.69  
T-complex protein 1 subunit alpha  9.89 % 2 116.36  6.30  
HBS1-like protein (Fragment)  9.88 % 1  0.00  
ADP/ATP translocase 2  9.73 % 1  2.09  
Inter-alpha-trypsin inhibitor heavy chain H4  9.68 % 7 159.84  22.13  
Inter-alpha-trypsin inhibitor heavy chain H1  9.44 % 5 54.35  12.42  
Gelsolin  9.34 % 4 109.25  15.69  
Coatomer subunit epsilon  9.09 % 1 22.82  2.07  
Methylosome protein 50 (Fragment)  8.93 % 1  0.00  
Fructose-2,6-bisphosphatase TIGAR  8.52 % 1 0.00   
Histidine-rich glycoprotein  8.38 % 3 29.93  2.03  
Fructose-bisphosphate aldolase A  8.24 % 1 27.43  2.55  
Complement C4-A  8.03 % 8 238.00   
Serotransferrin  8.02 % 5 96.14  13.80  
Tubulin alpha-4A chain  7.81 % 2 61.83  2.83  
Alcohol dehydrogenase class-3  7.49 % 1  0.00  
Transcription factor SOX-17  7.49 % 1  0.00  
Complement factor B  7.46 % 4 67.34  9.80  
Alpha-2-HS-glycoprotein  7.36 % 2 60.27  9.43  
Proteasome subunit alpha type-6  7.32 % 1 20.17  2.10  
Alpha- and gamma-adaptin-binding protein p34  7.30 % 1 26.83  3.08  
Exportin-2  7.21 % 3 26.14  2.10  
Nucleosome assembly protein 1-like 4  7.20 % 1 39.02  3.56  
T-complex protein 1 subunit zeta  7.16 % 2 41.57  5.23  
2-hydroxyacyl-CoA lyase 1  7.12 % 1  2.03  
Isoform 4 of Apoptosis-inducing factor 1, mitochondrial  7.10 % 1  0.00  
Ig gamma-2 chain C region  7.06 % 1 53.32  4.00  
Serpin H1  6.94 % 1 23.58  2.33  
Endoplasmin  6.85 % 2 23.50  3.20  
T-complex protein 1 subunit eta  6.81 % 2 27.86  2.65  
Adenylyl cyclase-associated protein 1  6.74 % 2 65.10  6.86  
X-ray repair cross-complementing protein 5  6.69 % 2 109.18  20.55  
Complement component C8 beta chain  5.75 % 2 35.32  6.22  
Apoptosis inhibitor 5  5.53 % 1 24.85  2.06  
Vitamin D-binding protein  5.49 % 2 38.55  7.62  
Trifunctional enzyme subunit beta, mitochondrial  5.49 % 1 35.91  5.78  
Copine-3  5.40 % 1 34.09  2.97  
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit 2  
5.39 % 1 41.11  2.62  
Elongation factor 2  5.36 % 2 116.88  16.59  
Mitogen-activated protein kinase 3  5.01 % 1 29.38  2.90  
General transcription factor 3C polypeptide 5  5.01 % 1 0.00  2.13  
Serum amyloid P-component  4.93 % 1  2.16  
Leucine-rich alpha-2-glycoprotein  4.85 % 1  0.00  
26S proteasome non-ATPase regulatory subunit 2  4.83 % 1  0.00  
Eukaryotic peptide chain release factor subunit 1  4.81 % 1 121.07  13.63  
Eukaryotic translation initiation factor 3 subunit M  4.81 % 1 27.27  2.25  
Monofunctional C1-tetrahydrofolate synthase, mitochondrial  4.70 % 2 53.82  4.12  
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
48 kDa subunit 
4.61 % 1 22.93  5.46  
Hypoxanthine-guanine phosphoribosyltransferase  4.59 % 1  1.99  
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Protein Description Total Coverage Unique 
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ATP synthase subunit beta, mitochondrial  4.54 % 1 72.26  2.47  
Splicing factor 3A subunit 3  4.46 % 1  0.00  
Alanine--tRNA ligase, cytoplasmic  4.24 % 2 33.92  7.98  
Eukaryotic initiation factor 4A-I  4.19 % 1 288.73  39.25  
Transketolase  4.17 % 1 27.09  0.00  
Fatty acid synthase  4.10 % 5 53.23  8.84  
T-complex protein 1 subunit epsilon  4.02 % 1  0.00  
Glucose-6-phosphate isomerase  3.94 % 1  0.00  
SUMO-activating enzyme subunit 2  3.91 % 1  2.78  
Phosphoglycerate kinase 1  3.84 % 1 32.25  2.87  
Squalene monooxygenase  3.83 % 1 23.56  5.09  
Cystathionine beta-synthase  3.81 % 1 34.85  4.57  
Dihydrolipoyl dehydrogenase, mitochondrial  3.73 % 1 63.18  11.55  
Heat shock 70 kDa protein 6  3.73 % 1 49.56  7.50  
Puromycin-sensitive aminopeptidase  3.67 % 1  2.10  
ATP-citrate synthase  3.63 % 2 118.81  16.62  
Heterogeneous nuclear ribonucleoprotein K  3.46 % 1 47.22  2.35  
Plasma protease C1 inhibitor  3.40 % 1 32.42  0.00  
DNA replication licensing factor MCM6  3.29 % 1 26.07  2.09  
Elongation factor 1-alpha 1  3.25 % 1 23.23  2.66  
Alpha-enolase  3.23 % 1 82.39  3.74  
Citrate synthase, mitochondrial  3.22 % 1 44.25  3.88  
Epidermal growth factor receptor kinase substrate 8  3.20 % 1  0.00  
Complement component C8 beta chain  5.75 % 1 42.75  2.88  
Catalase 3.04% 1 26.84  0.00  
Pyruvate kinase PKM  3.01 % 1 130.33  8.78  
tRNA-splicing ligase RtcB  2.97 % 1  2.73  
Probable phospholipid-transporting ATPase VD  2.88 % 1  0.00  
Peroxisomal multifunctional enzyme type 2  2.85 % 1 70.46  5.07  
Ubiquitin carboxyl-terminal hydrolase 5  2.80 % 1 24.93  4.98  
C-1-tetrahydrofolate synthase, cytoplasmic  2.78 % 1 44.08  10.64  
78 kDa glucose-regulated protein  2.75 % 1 89.83  4.31  
Importin-9  2.69 % 1  0.00  
Alpha-1-antichymotrypsin  2.60 % 1 55.35  3.50  
Exportin-T  2.60 % 1  2.55  
Insulin-like growth factor-binding protein complex acid labile 
subunit  
2.48 % 1 55.87  4.09  
Neutral alpha-glucosidase AB  2.44 % 1 57.91  3.53  
Microtubule-associated protein 4  2.34 % 1 20.13  5.50  
Complement C1s subcomponent  2.33 % 1 47.04  9.58  
Afamin  2.17 % 1  2.22  
Coatomer subunit beta  2.10 % 1 97.14  6.95  
General vesicular transport factor p115  2.08 % 1 22.12  4.63  
Filamin-B  1.96 % 2 33.23  7.62  
Protein KIAA0368  1.90 % 1  0.00  
N-alpha-acetyltransferase 15, NatA auxiliary subunit  1.85 % 1 25.05  5.97  
Importin-5  1.73 % 1 79.90  9.58  
Apolipoprotein B-100  1.71 % 5 176.50  18.15  
Eukaryotic translation initiation factor 5B  1.64 % 1 78.59  5.50  
Band 3 anion transport protein  1.43 % 1 49.60  3.05  
Kininogen-1  1.40 % 1 33.98  0.00  
DNA-dependent protein kinase catalytic subunit  1.17 % 2  4.51  
Filamin-A  1.02 % 1 23.70  2.59  
E3 ubiquitin-protein ligase HUWE1 (Fragment)  0.56 % 1  4.10  
Kinesin-like protein KIF1C  0.54 % 1  0.00  
Cytoplasmic dynein 1 heavy chain 1  0.50 % 1  0.00  
Spectrin beta chain, erythrocytic  0.47 % 1 28.21  0.00  
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Protein description 
Present replicate 
1 
Y/N 
Present replicate 
2 
Y/N 
Present 
replicate 3 
Y/N 
14-3-3 protein theta  Y N N 
Actin, cytoplasmic 1  Y Y Y 
Actin, gamma-enteric smooth muscle  N Y N 
Adenylate kinase isoenzyme 1  Y N N 
Alpha-1-acid glycoprotein 1  Y Y Y 
Alpha-1-antichymotrypsin  Y Y Y 
Alpha-1-antitrypsin  Y Y Y 
Alpha-1B-glycoprotein  Y Y Y 
Alpha-2-HS-glycoprotein  Y N Y 
Alpha-2-macroglobulin  Y Y Y 
Alpha-enolase Y Y N 
Alpha-synuclein  Y Y N 
Angiotensinogen  Y N N 
Annexin A2  N Y Y 
Antithrombin-III  N Y Y 
AP-2 complex subunit beta  N Y N 
Apolipoprotein A-I  Y Y Y 
Apolipoprotein A-II  Y Y Y 
Apolipoprotein A-IV  Y N Y 
Apolipoprotein B-100  Y Y N 
Apolipoprotein C-I  Y N Y 
Apolipoprotein C-II Y N Y 
Apolipoprotein C-III  Y Y Y 
Apolipoprotein D  N Y Y 
Apolipoprotein E  Y N N 
Apolipoprotein-L1  Y N N 
Arginase-1  Y Y N 
Astrotactin-1  N N Y 
Bisphosphoglycerate mutase  Y N Y 
Calmodulin-like protein 5  N Y Y 
Carbonic anhydrase 1  Y Y Y 
Carbonic anhydrase 2  Y Y Y 
Catalase  Y Y Y 
Cathepsin B  N Y N 
Ceruloplasmin  Y Y Y 
Clusterin  Y Y Y 
Cofilin-1  Y N N 
Coiled-coil domain-containing protein 27  N N Y 
Complement C1s subcomponent  Y N N 
Complement C3  Y Y Y 
Complement C4-A  N Y N 
Complement C4-B  Y N Y 
Complement component C9  Y N N 
Complement factor B  Y Y Y 
Complement factor H  Y N N 
Cystatin-A  N Y Y 
Delta-aminolevulinic acid dehydratase  Y N N 
Dermcidin  Y Y Y 
Desmoglein-1  N Y Y 
Desmoplakin  N Y N 
Extracellular glycoprotein lacritin  N N Y 
Fatty acid-binding protein, epidermal  N Y Y 
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Protein description 
Present replicate 
1 
Y/N 
Present replicate 
2 
Y/N 
Present 
replicate 3 
Y/N 
Fatty acid-binding protein, liver  N Y N 
Fibrinogen alpha chain  Y Y Y 
Fibrinogen beta chain  Y Y Y 
Fibrinogen gamma chain  Y Y Y 
Fibroblast growth factor 2  Y Y Y 
Filaggrin-2  N Y N 
Flavin reductase Y Y Y 
FRAS1-related extracellular matrix protein 2  N Y N 
Fructose-bisphosphate aldolase A  Y N Y 
Gelsolin  Y N Y 
Glutathione S-transferase A1 Y Y N 
Glyceraldehyde-3-phosphate dehydrogenase  Y Y Y 
GTP-binding nuclear protein Ran  Y N Y 
Haptoglobin  Y Y Y 
Heat shock 70 kDa protein 1A/1B  N Y N 
Heat shock protein beta-1  Y Y N 
Heat shock-related 70 kDa protein 2  Y Y Y 
Hemoglobin subunit alpha Y Y Y 
Hemoglobin subunit beta  Y Y Y 
Hemoglobin subunit delta  Y Y Y 
Hemoglobin subunit gamma-1  Y Y Y 
Hemopexin  Y Y Y 
Heparin cofactor 2  Y N Y 
Histidine-rich glycoprotein  Y Y Y 
Histone H2A type 1-H  Y Y Y 
Hornerin  N N Y 
Ig alpha-1 chain C region  Y Y Y 
Ig gamma-1 chain C region Y Y Y 
Ig gamma-2 chain C region  Y N Y 
Ig gamma-3 chain C region  Y Y N 
Ig heavy chain V-III region TEI  N Y Y 
Ig kappa chain C region  Y Y Y 
Ig kappa chain V-I region Lay  Y Y Y 
Ig kappa chain V-III region SIE  Y Y Y 
Ig lambda chain V-I region WAH  N N Y 
Ig lambda chain V-III region LOI  Y N N 
Ig lambda-7 chain C region  Y Y Y 
Ig mu heavy chain disease protein  Y N N 
Inter-alpha-trypsin inhibitor heavy chain H1  Y Y Y 
Inter-alpha-trypsin inhibitor heavy chain H2  Y Y Y 
Inter-alpha-trypsin inhibitor heavy chain H4  Y N Y 
Junction plakoglobin N Y N 
Kallikrein-7  N Y N 
Keratin, type I cytoskeletal 10  Y Y Y 
Keratin, type I cytoskeletal 13  Y N N 
Keratin, type I cytoskeletal 14 Y Y Y 
Keratin, type I cytoskeletal 16  N Y N 
Keratin, type I cytoskeletal 17  N Y Y 
Keratin, type I cytoskeletal 9  Y Y Y 
Keratin, type II cytoskeletal 1  Y N Y 
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Protein description 
Present 
replicate 1 
Y/N 
Present replicate 
2 
Y/N 
Present 
replicate 3 
Y/N 
Keratin, type II cytoskeletal 2 epidermal  Y Y Y 
Keratin, type II cytoskeletal 2 oral  Y Y N 
Keratin, type II cytoskeletal 5 Y Y Y 
Keratin, type II cytoskeletal 6A  Y Y Y 
Keratin, type II cytoskeletal 6C  N Y Y 
Kininogen-1  Y Y Y 
Lactotransferrin  Y Y Y 
Lethal(3)malignant brain tumor-like protein 2  N Y N 
Lipocalin-1  N Y Y 
Liver carboxylesterase 1  Y Y Y 
Lumican  Y N N 
Lysozyme C  Y Y Y 
Mammaglobin-B  N N Y 
Mucin-like protein 1  Y Y Y 
N-acetylmuramoyl-L-alanine amidase  N Y N 
Nesprin-1 N Y N 
Nicotinate phosphoribosyltransferase  N Y Y 
Nucleoside diphosphate kinase A  Y N N 
Peptidyl-prolyl cis-trans isomerase A  Y N N 
Peroxiredoxin-1  Y N N 
Peroxiredoxin-2  Y Y Y 
Peroxiredoxin-6  Y Y N 
Phosphoglycerate kinase 1  Y Y N 
Plasma kallikrein  Y N N 
Plasma protease C1 inhibitor  Y Y Y 
Plasminogen  Y Y Y 
Plastin-2  N Y N 
Polymeric immunoglobulin receptor  N N Y 
Polyubiquitin-C  Y Y Y 
Prolactin-inducible protein  N Y Y 
Proline-rich protein 4  N N Y 
Protein disulfide-isomerase A2  Y N N 
Protein DJ-1  Y Y N 
Protein S100-A4  N N Y 
Protein S100-A6 OS=Homo sapiens  Y N N 
Protein S100-A7  N Y Y 
Protein S100-A8  Y Y Y 
Protein S100-A9  Y Y Y 
Prothrombin  Y Y Y 
Purine nucleoside phosphorylase  Y N N 
Purine nucleoside phosphorylase  N N Y 
Putative lipocalin 1-like protein 1  N Y N 
Rab GDP dissociation inhibitor beta OS=Homo 
sapiens  
Y N N 
Rab-related protein Rab-14  Y N N 
Retinal dehydrogenase 1  Y N N 
Secretoglobin family 1D member 2  N Y N 
Semenogelin-1  Y Y Y 
Semenogelin-2  Y Y N 
Serotransferrin  Y Y Y 
Serpin B3  Y Y Y 
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Protein description 
Present replicate 
1 
Y/N 
Present replicate 
2 
Y/N 
Present 
replicate 3 
Y/N 
Serum albumin  Y Y Y 
Serum amyloid A-4 protein  Y N N 
Serum amyloid P-component  N N Y 
Serum paraoxonase/arylesterase 1  Y N Y 
Sialic acid-binding Ig-like lectin 16  N Y N 
Testis-specific serine/threonine-protein kinase 4  N Y Y 
Thioredoxin  Y N N 
Transketolase  N Y N 
Transthyretin  N Y Y 
Trypsin-1  Y Y N 
Uncharacterized protein UNQ773/PRO1567  N Y N 
Vitamin D-binding protein  Y Y Y 
Vitronectin  Y Y Y 
Zinc finger protein 611  Y N N 
Zinc-alpha-2-glycoprotein  Y Y Y 
Zymogen granule protein 16 homolog B  Y N N 
Appendix 4.5 Proteins identified from LC MS/MS run of automated  surface sampling based digestion of dried blood 
spot.   
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Appendix 5 
Protein description Present replicate 1 
Y/N 
Present replicate 2 
Y/N 
Present replicate 
3 
Y/N 
14-3-3 protein theta  Y N N 
60 kDa heat shock protein, mitochondrial  Y N N 
Actin, cytoplasmic 1  Y Y Y 
ADP-ribosylation factor 5  N N Y 
Alpha-1-acid glycoprotein 1  Y Y Y 
Alpha-1-acid glycoprotein 2  N Y N 
Alpha-1-antichymotrypsin  Y Y Y 
Alpha-1-antitrypsin  Y Y Y 
Alpha-1B-glycoprotein  Y Y Y 
Alpha-2-HS-glycoprotein  N Y N 
Alpha-2-macroglobulin  Y Y Y 
Alpha-enolase  N Y N 
Alpha-synuclein  Y Y Y 
Angiotensinogen  N Y N 
Apolipoprotein A-I  Y Y Y 
Apolipoprotein A-II  Y Y Y 
Apolipoprotein A-IV  Y Y Y 
Apolipoprotein B-100  Y N Y 
Apolipoprotein C-III  Y Y Y 
Apolipoprotein D  Y Y Y 
Band 3 anion transport protein  Y Y Y 
Beta-actin-like protein 2  N Y N 
Bisphosphoglycerate mutase  Y Y Y 
Carbonic anhydrase 1  Y Y Y 
Carbonic anhydrase 2  Y Y Y 
Catalase  Y Y Y 
Ceruloplasmin  Y N Y 
Clusterin  N Y N 
Complement C3  Y Y Y 
Complement C4-A  Y N N 
Complement factor B  Y N Y 
Delta-aminolevulinic acid dehydratase Y Y Y 
Flavin reductase  Y Y Y 
Fructose-bisphosphate aldolase A Y Y Y 
Glyceraldehyde-3-phosphate 
dehydrogenase  
Y Y Y 
GTP-binding nuclear protein Ran  Y Y Y 
Haptoglobin  Y Y Y 
Heat shock-related 70 kDa protein 2  Y N N 
Hemoglobin subunit alpha  Y Y Y 
Hemoglobin subunit beta  Y Y Y 
Hemoglobin subunit delta  Y Y Y 
Hemoglobin subunit gamma-1 Y Y Y 
Hemoglobin subunit gamma-2  Y Y Y 
Hemopexin  Y Y Y 
Heparin cofactor 2 N Y N 
Hermansky-Pudlak syndrome 1 protein  N Y N 
Histidine-rich glycoprotein  Y N N 
Ig alpha-1 chain C region  Y Y Y 
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Protein description Present replicate 1 
Y/N 
Present replicate 2 
Y/N 
Present replicate 
3 
Y/N 
Ig alpha-2 chain C region Y Y Y 
Ig gamma-1 chain C region  Y Y Y 
Ig gamma-2 chain C region  Y Y Y 
Ig heavy chain V-III region GAL  Y Y Y 
Ig heavy chain V-III region TEI  N Y Y 
Ig kappa chain V-I region Lay  N Y N 
Ig kappa chain V-III region B6  N Y N 
Ig kappa chain V-III region SIE  Y N Y 
Ig kappa chain V-III region VG (Fragment)  Y Y Y 
Ig kappa chain V-IV region Len  N N Y 
Ig lambda chain V-I region WAH  Y Y Y 
Ig lambda chain V-III region LOI  N Y Y 
Ig lambda-1 chain C regions  N Y Y 
Ig lambda-7 chain C region  Y Y Y 
Ig mu heavy chain disease protein  Y Y Y 
Inter-alpha-trypsin inhibitor heavy chain 
H1  
N Y Y 
Inter-alpha-trypsin inhibitor heavy chain 
H2  
N Y N 
Inter-alpha-trypsin inhibitor heavy chain 
H4  
N N Y 
Keratin, type II cytoskeletal 1  N N Y 
Kininogen-1  Y Y Y 
L-lactate dehydrogenase B chain  N Y Y 
Mucin-16  Y N N 
Nuclear transport factor 2  N Y N 
Nucleoside diphosphate kinase A  Y N N 
Peroxiredoxin-1  N Y Y 
Peroxiredoxin-2  Y Y Y 
Peroxiredoxin-6  Y Y Y 
Phosphoglycerate kinase 1  Y N N 
Plasma protease C1 inhibitor  Y Y Y 
Polyubiquitin-C  Y Y Y 
Protein S100-A4  Y Y Y 
Protein S100-A6  Y Y Y 
Protein S100-A8 N Y Y 
Prothrombin  N N Y 
Purine nucleoside phosphorylase  Y Y N 
Putative uncharacterized protein C19orf81  N Y N 
Retinal dehydrogenase 1  Y Y N 
Selenium-binding protein 1 Y Y Y 
Serotransferrin  Y Y Y 
Serum albumin  Y Y Y 
Spectrin alpha chain, erythrocyte  Y Y Y 
Spectrin alpha chain, erythrocytic 1  N Y N 
Superoxide dismutase [Cu-Zn]  Y Y Y 
Thioredoxin  Y N N 
Transthyretin  Y Y Y 
Triosephosphate isomerase  N Y Y 
UDP-glucuronosyltransferase 1-9  Y N N 
Vitamin D-binding protein  Y Y Y 
Zinc-alpha-2-glycoprotein Y N N 
Appendix 5.1 Proteins identified from LC MS/MS analysis of a DBS digest with a digestion time of 30 minutes 
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Protein description 
Present replicate 
1 
Y/N 
Present replicate 
2 
Y/N 
Present 
replicate 3 
Y/N 
14-3-3 protein theta  Y Y Y 
60 kDa heat shock protein, mitochondrial  Y Y N 
Actin, cytoplasmic 1 Y Y Y 
ADP-ribosylation factor 5  N N Y 
Alpha-1-acid glycoprotein 1  Y Y Y 
Alpha-1-antichymotrypsin  Y Y Y 
Alpha-1-antitrypsin  Y Y Y 
Alpha-1B-glycoprotein Y Y Y 
Alpha-2-HS-glycoprotein  Y N N 
Alpha-2-macroglobulin  Y Y Y 
Alpha-enolase Y Y Y 
Alpha-synuclein  Y Y Y 
Angiotensinogen  Y N Y 
Apolipoprotein A-I  Y Y Y 
Apolipoprotein A-II  Y Y Y 
Apolipoprotein A-IV  Y Y Y 
Apolipoprotein B-100  Y N Y 
Apolipoprotein C-III  Y Y Y 
Apolipoprotein D Y Y Y 
Band 3 anion transport protein  Y Y Y 
Beta-actin-like protein 2  N N Y 
Bisphosphoglycerate mutase  Y Y Y 
Calcium-dependent secretion activator 2  Y N N 
Carbonic anhydrase 1  Y Y Y 
Carbonic anhydrase 2  Y Y Y 
Catalase  Y Y Y 
Ceruloplasmin  Y Y Y 
Clusterin  Y Y Y 
Complement C3  Y Y Y 
Complement C4-A  Y Y N 
Complement factor B  N N Y 
D-dopachrome decarboxylase N Y N 
Delta-aminolevulinic acid dehydratase  Y Y Y 
DNA mismatch repair protein Mlh1  N N Y 
Ecto-ADP-ribosyltransferase 5 N N Y 
Flavin reductase Y Y Y 
Fructose-bisphosphate aldolase A  Y Y Y 
Glyceraldehyde-3-phosphate dehydrogenase  Y Y Y 
GTP-binding nuclear protein Ran Y Y Y 
Haptoglobin  Y Y Y 
Hemoglobin subunit alpha  Y Y Y 
Hemoglobin subunit beta  Y Y Y 
Hemoglobin subunit delta  Y Y Y 
Hemoglobin subunit gamma-1  Y Y Y 
Hemoglobin subunit gamma-2  Y Y Y 
Hemopexin  Y Y Y 
Heparin cofactor 2  N Y Y 
High affinity cAMP-specific and IBMX-insensitive 
3',5'-cyclic phosphodiesterase 8A  
N Y N 
Histidine-rich glycoprotein  Y Y N 
Ig alpha-1 chain C region Y Y Y 
Ig alpha-2 chain C region  Y Y Y 
Ig heavy chain V-III region  Y N N 
Ig heavy chain V-III region GAL  Y Y Y 
Ig heavy chain V-III region VH26  Y N Y 
Ig kappa chain C region  Y Y Y 
Ig kappa chain V-I region  Y N N 
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Protein description 
Present replicate 
1 
Y/N 
Present replicate 
2 
Y/N 
Present 
replicate 3 
Y/N 
Hemoglobin subunit alpha  Y Y Y 
Hemoglobin subunit beta  Y Y Y 
Hemoglobin subunit delta  Y Y Y 
Hemoglobin subunit gamma-1  Y Y Y 
Hemoglobin subunit gamma-2  Y Y Y 
Hemopexin  Y Y Y 
Heparin cofactor 2  N Y Y 
High affinity cAMP-specific and IBMX-insensitive 
3',5'-cyclic phosphodiesterase 8A  
N Y N 
Histidine-rich glycoprotein  Y Y N 
Ig alpha-1 chain C region Y Y Y 
Ig alpha-2 chain C region  Y Y Y 
Ig heavy chain V-III region  Y N N 
Ig heavy chain V-III region GAL  Y Y Y 
Ig heavy chain V-III region VH26  Y N Y 
Ig kappa chain C region  Y Y Y 
Ig kappa chain V-I region  Y N N 
Ig kappa chain V-I region Lay  N N Y 
Ig kappa chain V-III region SIE  Y Y Y 
Ig kappa chain V-III region VG (Fragment) Y Y Y 
Ig kappa chain V-IV region Len  N N Y 
Ig lambda chain V-I region WAH N Y Y 
Ig lambda chain V-III region LOI  Y Y Y 
Ig lambda-1 chain C regions  N N Y 
Ig lambda-7 chain C region  Y Y Y 
Ig mu heavy chain disease protein Y Y Y 
Inter-alpha-trypsin inhibitor heavy chain H1  Y Y Y 
Inter-alpha-trypsin inhibitor heavy chain H2  Y Y Y 
Inter-alpha-trypsin inhibitor heavy chain H4  Y Y Y 
Interleukin-7 receptor subunit alpha  Y Y N 
Keratin, type II cytoskeletal 1  N N Y 
Kininogen-1  Y Y Y 
L-lactate dehydrogenase B chain  Y Y Y 
Malate dehydrogenase, cytoplasmic  N Y N 
Nucleoside diphosphate kinase A  Y Y N 
Peptidyl-prolyl cis-trans isomerase A  N Y N 
Peroxiredoxin-1  N Y Y 
Peroxiredoxin-2  Y Y Y 
Peroxiredoxin-6  Y Y Y 
Phosphoglycerate kinase 1 O Y Y N 
Plasma protease C1 inhibitor  Y Y Y 
Polycystin-2  N N Y 
Polyubiquitin-C  Y Y Y 
Proteasome activator complex subunit 1  N N Y 
Protein S100-A4  Y Y N 
Protein S100-A6  Y Y N 
Protein S100-A8  N Y Y 
Protein S100-A9 N Y N 
Purine nucleoside phosphorylase  Y Y Y 
Putative protein FAM10A4  N N Y 
Putative uncharacterized protein C19orf81  N N Y 
Rab GDP dissociation inhibitor beta  N Y N 
Retinal dehydrogenase 1 Y Y Y 
Selenium-binding protein 1  Y Y Y 
Serotransferrin  Y Y Y 
Serum albumin  Y Y Y 
Serum amyloid P-component  N Y Y 
Spectrin alpha chain, erythrocyte  Y N N 
Spectrin alpha chain, erythrocytic 1 N Y Y 
Spectrin beta chain, erythrocytic  Y Y Y 
StAR-related lipid transfer protein 3  Y N N 
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Protein description 
Present replicate 
1 
Y/N 
Present replicate 
2 
Y/N 
Present 
replicate 3 
Y/N 
Superoxide dismutase Y Y Y 
Thioredoxin  Y N Y 
Transthyretin  Y Y Y 
Triosephosphate isomerase  N N Y 
Ubiquitin conjugation factor E4 A N N Y 
Vitamin D-binding protein  Y N Y 
Appendix 5.2 Proteins identified from LC MS/MS analysis of a DBS digest with a digestion time of 1 hour. 
 
 
Protein description 
Present replicate 
1 
Y/N 
Present replicate 
2 
Y/N 
Present 
replicate 3 
Y/N 
14-3-3 protein theta  Y Y Y 
60 kDa heat shock protein, mitochondrial  Y N N 
Actin, alpha cardiac muscle 1  Y Y N 
Actin, cytoplasmic 1  Y Y Y 
Agmatinase, mitochondrial  Y N N 
Alpha-1-acid glycoprotein 1  Y Y Y 
Alpha-1-acid glycoprotein 2  Y Y Y 
Alpha-1-antichymotrypsin  Y Y Y 
Alpha-1-antitrypsin  Y Y Y 
Alpha-1B-glycoprotein  Y Y Y 
Alpha-2-HS-glycoprotein  Y Y N 
Alpha-2-macroglobulin  Y Y Y 
Alpha-synuclein  Y Y Y 
Ankyrin-1  Y N N 
Apolipoprotein A-I  Y Y Y 
Apolipoprotein A-II  Y Y Y 
Apolipoprotein A-IV  Y Y Y 
Apolipoprotein C-III  Y Y Y 
Apolipoprotein D  Y Y Y 
Band 3 anion transport protein  Y Y N 
Beta-actin-like protein 2  N Y N 
Bisphosphoglycerate mutase  Y Y Y 
Carbohydrate sulfotransferase 8  Y N N 
Carbonic anhydrase 1  Y Y Y 
Carbonic anhydrase 2  Y Y Y 
Catalase  Y Y Y 
Ceruloplasmin  Y Y Y 
Clusterin  Y Y N 
Complement C3  Y Y Y 
Complement C4-A  Y N N 
Complement C4-B  N Y Y 
Complement factor B  N Y N 
Complement factor H  N N Y 
D-dopachrome decarboxylase  N Y N 
Delta-aminolevulinic acid dehydratase Y Y Y 
Fibulin-2  Y N N 
Flavin reductase  Y Y Y 
Fructose-bisphosphate aldolase A  Y Y Y 
Gamma-enolase  Y N N 
General transcription factor 3C polypeptide 1  N Y N 
Glyceraldehyde-3-phosphate dehydrogenase  Y Y Y 
GTP-binding nuclear protein Ran  N Y Y 
Haptoglobin  Y Y Y 
Hemoglobin subunit alpha  Y Y Y 
Hemoglobin subunit beta  Y Y Y 
Hemoglobin subunit delta  Y Y Y 
Hemoglobin subunit gamma-1  Y Y Y 
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Protein description Present replicate 
1 
Y/N 
Present replicate 
2 
Y/N 
Present 
replicate 3 
Y/N 
Hemoglobin subunit gamma-2  Y Y Y 
Hemopexin  Y Y Y 
Heparin cofactor 2  Y N N 
Hermansky-Pudlak syndrome 1 protein  N N Y 
Histidine-rich glycoprotein  N N Y 
Ig heavy chain V-III region TEI N N Y 
Ig kappa chain C region  Y Y Y 
Ig kappa chain V-I region CAR  N N Y 
Ig kappa chain V-I region DEE  Y Y N 
Ig kappa chain V-III region SIE  Y Y Y 
Ig kappa chain V-III region VG (Fragment)  N Y Y 
Ig lambda chain V-I region WAH  Y N Y 
Ig lambda chain V-III region LOI  N N Y 
Ig lambda-7 chain C region  Y Y Y 
Ig mu chain C region  Y Y N 
Ig mu heavy chain disease protein  N N Y 
Inter-alpha-trypsin inhibitor heavy chain H4  N N Y 
Keratin, type I cytoskeletal 10  Y N Y 
Keratin, type I cytoskeletal 9  N Y Y 
Keratin, type II cytoskeletal 1  Y Y Y 
Kininogen-1  Y Y Y 
Leucine-rich repeat neuronal protein 2  Y N N 
L-lactate dehydrogenase B chain  N Y Y 
Malate dehydrogenase, cytoplasmic  N Y N 
Mitogen-activated protein kinase-binding protein 1  N Y N 
Nucleoside diphosphate kinase A  Y Y N 
Paired box protein Pax-1  Y N N 
Peptidyl-prolyl cis-trans isomerase A  Y Y N 
Peroxiredoxin-2 Y Y Y 
Peroxiredoxin-1  N Y Y 
Peroxiredoxin-6  Y Y Y 
Phosphatidylinositol 4,5-bisphosphate 3-kinase 
catalytic subunit alpha isoform 
Y N N 
Phosphoglycerate kinase 1  Y Y Y 
Plasma protease C1 inhibitor  Y Y Y 
Polyubiquitin-C  Y Y Y 
Protein S100-A4  Y Y Y 
Protein S100-A6  Y Y Y 
Protein S100-A8  Y Y Y 
Protein S100-A9 N N Y 
Protein TANC2  N N Y 
Purine nucleoside phosphorylase  Y Y Y 
Putative uncharacterized protein C19orf81  N Y Y 
Retinal dehydrogenase 1  N Y Y 
Rotatin  Y N N 
Sal-like protein 3  Y N N 
Selenium-binding protein 1  Y Y Y 
Serotransferrin  Y Y Y 
Serum albumin  Y Y Y 
Serum amyloid P-component  Y Y Y 
Solute carrier organic anion transporter family 
member 1A2  
N N Y 
Spectrin alpha chain, erythrocyte  Y Y Y 
Spectrin beta chain, erythrocyte  N Y Y 
Superoxide dismutase Y Y Y 
Thiamin pyrophosphokinase 1  Y N N 
Thioredoxin  Y N N 
Transthyretin  Y Y Y 
Triosephosphate isomerase  N N Y 
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Protein description Present replicate 
1 
Y/N 
Present replicate 
2 
Y/N 
Present 
replicate 3 
Y/N 
Ubiquitin-conjugating enzyme E2 variant 2  N N Y 
Uncharacterized protein C6orf163  N Y N 
Vitamin D-binding protein  Y Y Y 
Vitronectin  N N Y 
Zinc-alpha-2-glycoprotein  Y N N 
 
 
Appendix 5.3 Proteins identified from LC MS/MS analysis of a DBS digest with a digestion time of 2 hours. 
 
 
 
 
 
 
 
 
 
Protein description Present replicate 
1 
Y/N 
Present replicate 
2 
Y/N 
Present 
replicate 3 
Y/N 
14-3-3 protein theta  N Y N 
Actin, cytoplasmic 1 Y Y Y 
Alpha-1-acid glycoprotein 1  Y Y Y 
Alpha-1-antichymotrypsin  Y Y Y 
Alpha-1-antitrypsin  Y Y Y 
Alpha-1B-glycoprotein  Y Y Y 
Alpha-2-HS-glycoprotein  Y Y Y 
Alpha-2-macroglobulin  Y Y Y 
Alpha-synuclein  Y Y N 
Ankyrin-1  N Y N 
Apolipoprotein A-I  Y Y Y 
Apolipoprotein A-II  Y Y Y 
Apolipoprotein A-IV  Y Y Y 
Apolipoprotein C-III  Y Y Y 
Apolipoprotein D  N Y Y 
Bisphosphoglycerate mutase  Y Y Y 
Carbonic anhydrase 1  Y Y Y 
Carbonic anhydrase 2  Y Y Y 
Catalase  Y Y Y 
Ceruloplasmin  Y Y N 
Clusterin  N Y N 
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Protein description Present replicate 
1 
Y/N 
Present replicate 
2 
Y/N 
Present 
replicate 3 
Y/N 
Complement C3  Y Y Y 
Complement C4-B  N Y N 
Complement factor B  Y N N 
Delta-aminolevulinic acid dehydratase  Y Y N 
Ensconsin  N Y N 
Exportin-1 Y Y N 
Flavin reductase  Y Y Y 
Fructose-bisphosphate aldolase A  Y Y Y 
Glyceraldehyde-3-phosphate dehydrogenase  Y Y Y 
GTP-binding nuclear protein Ran  Y Y Y 
Haptoglobin  Y Y Y 
Hemoglobin subunit alpha  Y Y Y 
Hemoglobin subunit beta  Y Y Y 
Hemoglobin subunit delta  Y Y Y 
Hemoglobin subunit gamma-1  Y Y Y 
Hemoglobin subunit gamma-2  Y Y Y 
Hemopexin  Y Y Y 
Ig alpha-1 chain C region  Y Y Y 
Ig gamma-1 chain C region  Y Y Y 
Ig gamma-2 chain C region  Y Y Y 
Ig kappa chain C region  Y Y Y 
Ig kappa chain V-I region CAR  N Y N 
Ig kappa chain V-I region DEE  Y Y Y 
Ig kappa chain V-III region SIE Y Y Y 
Ig kappa chain V-III region VG (Fragment)  N Y Y 
Ig lambda chain V-I region WAH  N Y N 
Ig lambda chain V-III region LOI  N Y N 
Ig lambda-7 chain C region  Y Y Y 
Ig mu chain C region  Y Y N 
Immunity-related GTPase family Q protein  Y Y N 
Inter-alpha-trypsin inhibitor heavy chain H2  N Y N 
Interleukin-7 receptor subunit alpha  N Y N 
Katanin p60 ATPase-containing subunit A1  Y Y N 
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Protein description Present replicate 
1 
Y/N 
Present replicate 
2 
Y/N 
Present 
replicate 3 
Y/N 
Keratin, type I cytoskeletal 10  Y N Y 
Keratin, type II cytoskeletal 1 Y Y Y 
Kininogen-1  Y Y Y 
L-amino-acid oxidase  Y Y N 
Methyltransferase-like protein 7B  Y Y N 
N-glycosylase/DNA lyase  Y Y N 
Nucleoside diphosphate kinase A Y Y N 
Paired box protein Pax-1  Y Y N 
Peptidyl-prolyl cis-trans isomerase A  N Y N 
Peroxiredoxin-1  N Y N 
Peroxiredoxin-2  Y Y Y 
Peroxiredoxin-6  Y Y N 
Phosphatidylinositol 4,5-bisphosphate 3-kinase 
catalytic subunit alpha isoform 
N Y N 
Polyubiquitin-C  Y Y Y 
Protein S100-A4  Y Y N 
Protein S100-A9  N Y N 
Protein unc-80 homolog  N Y N 
Purine nucleoside phosphorylase  N Y N 
Putative sodium-coupled neutral amino acid 
transporter 10  
Y Y N 
Putative uncharacterized protein C19orf81  N N Y 
Receptor-type tyrosine-protein phosphatase F  Y N N 
Retinal dehydrogenase 1  N Y N 
Selenium-binding protein 1  N Y N 
Serotransferrin  Y Y Y 
Serum albumin  Y Y Y 
Spectrin alpha chain, erythrocyte  Y Y N 
Spectrin alpha chain, erythrocytic 1  N N Y 
Spectrin beta chain, erythrocytic  N Y N 
Superoxide dismutase [Cu-Zn]  Y Y Y 
Tetratricopeptide repeat protein 40  Y N N 
TGF-beta-activated kinase 1 and MAP3K7-binding 
protein 3  
Y N N 
Thioredoxin  Y Y Y 
Transient receptor potential cation channel 
subfamily M member 3  
Y N N 
Transthyretin  Y Y Y 
Vitamin D-binding protein  N Y N 
Vitronectin  N Y N 
Zinc finger protein 470  N Y N 
Zinc finger protein 638  N Y Y 
 
Appendix 5.4 Proteins identified from LC MS/MS analysis of a DBS digest with a digestion time of 4 hours. 
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Protein description Present replicate 
1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
60 kDa heat shock protein, mitochondrial  Y N N 
Actin, cytoplasmic 1  Y Y Y 
Alpha-1-acid glycoprotein 1  N Y Y 
Alpha-1-acid glycoprotein 2  N Y N 
Alpha-1-antitrypsin  Y Y Y 
Alpha-2-macroglobulin  Y Y Y 
Apolipoprotein A-I  Y Y Y 
Apolipoprotein C-III  Y Y Y 
Carbonic anhydrase 1  Y Y Y 
Carbonic anhydrase 2  Y Y Y 
Catalase  Y Y Y 
CD166 antigen  Y N N 
Complement C3  Y Y Y 
Complement factor B  N N Y 
Disrupted in schizophrenia 1 protein Y N N 
EF-hand domain-containing family member A1  Y N N 
Flavin reductase  Y Y Y 
Fructose-bisphosphate aldolase A  Y N Y 
Fructose-bisphosphate aldolase B  Y N N 
Glutathione reductase, mitochondrial  Y N N 
Glyceraldehyde-3-phosphate dehydrogenase  Y Y Y 
Haptoglobin Y Y Y 
HEAT repeat-containing protein 1 Y N N 
Hemoglobin subunit alpha Y Y Y 
Hemoglobin subunit beta  Y Y Y 
Hemoglobin subunit delta  Y Y Y 
Hemoglobin subunit gamma-1  Y Y Y 
Hemopexin  Y Y N 
Ig alpha-1 chain C region  Y Y Y 
Ig gamma-1 chain C region  Y Y Y 
Ig gamma-2 chain C region  Y Y Y 
Ig kappa chain C region  Y Y Y 
Ig kappa chain V-I region DEE  Y N Y 
Ig lambda-7 chain C region  Y Y Y 
Ig mu chain C region  Y N Y 
Long-chain fatty acid transport protein 6  N N Y 
N-glycosylase/DNA lyase  Y Y N 
Paired box protein Pax-1  N Y N 
Peroxiredoxin-1 Y N N 
Peroxiredoxin-2  Y Y Y 
Peroxiredoxin-6  Y Y N 
Polyubiquitin-C  Y Y Y 
Protein RIC1 homolog  N Y Y 
Purine nucleoside phosphorylase  Y N N 
Retrotransposon-like protein 1 Y N N 
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Protein description Present replicate 
1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
Serotransferrin  Y Y Y 
Serum albumin  Y Y Y 
Spectrin alpha chain, non-erythrocytic 1  Y N N 
Superoxide dismutase [Cu-Zn]  Y Y Y 
Thioredoxin  Y N N 
Transthyretin  Y Y Y 
Uncharacterized protein KIAA1958 Y N N 
Voltage-dependent L-type calcium channel 
subunit alpha-1 
N N Y 
Appendix 5.5 Proteins identified from LC MS/MS analysis of a DBS digest with a digestion time of 8 hours. 
 
 
 
Protein description Present replicate 
1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
14-3-3 protein theta  N N Y 
Actin, cytoplasmic 1  N N Y 
Alpha-1-acid glycoprotein 1  Y N Y 
Alpha-1-antichymotrypsin  Y Y N 
Alpha-1-antitrypsin  Y Y Y 
Alpha-1B-glycoprotein  Y Y Y 
Alpha-2-HS-glycoprotein  Y N Y 
Alpha-2-macroglobulin  Y N N 
Alpha-enolase  Y Y N 
Alpha-mannosidase 2C1 (Fragment)  N N Y 
Alpha-synuclein  N N Y 
Antithrombin-III  N Y Y 
Apolipoprotein A-I  N N Y 
Apolipoprotein A-IV  N N Y 
Apolipoprotein C-III  N N Y 
Bisphosphoglycerate mutase  N N Y 
Calmodulin  Y Y N 
Calmodulin-like protein 5  Y Y N 
Calpastatin  N N Y 
Carbonic anhydrase 1  Y Y Y 
Carbonic anhydrase 2  Y Y Y 
Caspase-14  N Y N 
Catalase  Y Y N 
Cell division cycle protein 20 homolog B  N Y N 
Ceruloplasmin  Y Y Y 
Cofilin-1  N N Y 
Complement factor B  Y N N 
Cyclic AMP-responsive element-binding protein 3-
like protein  
Y N Y 
D-dopachrome decarboxylase  N N Y 
Delta-aminolevulinic acid dehydratase  N N Y 
Dermcidin  Y N N 
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Protein description Present replicate 
1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
Elongation factor 1-alpha 1  Y N N 
Flavin reductase  N Y N 
Flavin reductase (NADPH)  Y N Y 
Fructose-bisphosphate aldolase  N N Y 
Glyceraldehyde-3-phosphate dehydrogenase  Y Y Y 
Haptoglobin  Y Y Y 
Hemoglobin subunit alpha  Y Y Y 
Hemoglobin subunit beta  Y Y Y 
Hemoglobin subunit delta  Y Y Y 
Hemoglobin subunit gamma-1  Y Y Y 
Hemopexin  Y Y Y 
Histidine-rich glycoprotein  N N Y 
Ig gamma-2 chain C region  Y N N 
Ig kappa chain C region  Y N N 
Importin subunit beta-1  N N Y 
Importin-13  N N Y 
Isoform 2 of Rab GDP dissociation inhibitor beta  N N Y 
Keratin, type I cytoskeletal 10  Y Y N 
Keratin, type I cytoskeletal 13  Y Y N 
Keratin, type I cytoskeletal 14  Y Y N 
Keratin, type I cytoskeletal 16  Y Y N 
Keratin, type I cytoskeletal 9  Y Y N 
Keratin, type II cytoskeletal 4  Y Y N 
Keratin, type II cytoskeletal 5  Y Y N 
Keratin, type II cytoskeletal 6A  Y Y N 
Keratin, type II cytoskeletal 6B Y N N 
L-lactate dehydrogenase B chain  N N Y 
MORC family CW-type zinc finger protein 1  N Y N 
Nucleoside diphosphate kinase A (Fragment)  N N Y 
Olfactory receptor 10K2  N N Y 
Peptidyl-prolyl cis-trans isomerase A  Y Y Y 
Peroxiredoxin-2  Y N Y 
Phosphoglycerate kinase 1  N N Y 
Phosphoglycerate mutase 2  N N Y 
Polyubiquitin-C  N Y Y 
ProSAP-interacting protein 1  Y N N 
Protein 4.1  N Y N 
Protein disulfide-isomerase A2  Y Y N 
Protein DJ-1  N Y N 
Protein fantom  N N Y 
Protein S100-A4  N N Y 
Prothrombin  Y Y N 
Purine nucleoside phosphorylase  N N Y 
Putative uncharacterized protein C19orf81  Y N N 
Retinal dehydrogenase 1  N N Y 
Retinol-binding protein 4 Y N N 
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Protein description Present replicate 
1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
Ribose-5-phosphate isomerase  N N Y 
RNA-binding motif, single-stranded-interacting 
protein 1 (Fragment)  
N N Y 
Selenium-binding protein 1  Y Y N 
Serine/threonine-protein kinase LMTK2  Y N N 
Serotransferrin  Y N N 
Serum albumin  Y Y N 
Sickle tail protein homolog  N Y N 
Spectrin beta chain, erythrocytic  N N Y 
Superoxide dismutase Y Y Y 
Thioredoxin  N N Y 
Transthyretin  N Y N 
Triosephosphate isomerase  Y Y N 
Tropomyosin alpha-3 chain  N Y N 
Trypsin-3  Y N N 
Uncharacterized protein C6orf163  N Y N 
Vitamin D-binding protein  Y Y N 
Vitronectin  N N Y 
Zinc finger protein 616  N N Y 
Zinc-alpha-2-glycoprotein  Y Y N 
 
Appendix 5.6 Proteins identified from LC MS/MS analysis of a DBS digest depleted of the top 12 plasma proteins. 
Sample digested for 1 hour. 
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Protein description Present 
replicate 1 Y/N 
Present 
replicate 2 Y/N 
Present 
replicate 3 Y/N 
45 kDa calcium-binding protein  Y N N 
Actin, cytoplasmic 1  Y N N 
Alpha-1-acid glycoprotein 1  Y Y N 
Alpha-1-antitrypsin  Y Y Y 
Alpha-synuclein  Y Y Y 
Apolipoprotein A-I  Y Y Y 
Apolipoprotein A-II  N N Y 
Apolipoprotein A-IV  N Y Y 
Apolipoprotein C-III  Y Y Y 
Arf-GAP with GTPase, ANK repeat and PH domain-
containing protein 11  
N N Y 
Bifunctional methylenetetrahydrofolate 
dehydrogenase/cyclohydrolase, mitochondrial  
N N Y 
Bisphosphoglycerate mutase  Y N Y 
Calpastatin  Y N N 
Carbonic anhydrase 1  Y Y Y 
Carbonic anhydrase 2  Y Y Y 
Catalase  Y Y Y 
Ceruloplasmin Y N Y 
Cofilin-1  N N Y 
Complement C3  Y Y Y 
Complement factor B  Y Y N 
C-type mannose receptor 2  Y N N 
Cyclic AMP-responsive element-binding protein 3-
like protein 4  
N N Y 
Cytochrome P450 1B1  N N Y 
Delta-aminolevulinic acid dehydratase  Y Y Y 
DNA polymerase subunit gamma-2, mitochondrial  N Y N 
EIF2AK2 protein (Fragment)  N N Y 
Endothelial protein C receptor  N N Y 
Euchromatic histone-lysine N-methyltransferase 2  N N Y 
Flavin reductase (NADPH)  Y Y Y 
Glyceraldehyde-3-phosphate dehydrogenase  Y Y Y 
Golgi integral membrane protein 4  N N Y 
GS homeobox 1  N Y N 
Hemoglobin subunit alpha  Y Y Y 
Hemoglobin subunit beta  Y Y Y 
Hemoglobin subunit delta  Y Y Y 
Hemoglobin subunit gamma-1  Y Y Y 
Hemoglobin subunit gamma-2  Y Y Y 
Hemopexin  Y Y Y 
Importin subunit beta-1  Y N Y 
Importin-13  Y N N 
Inactive caspase-12  N N Y 
Insulin receptor-related protein  N N Y 
Inter-alpha-trypsin inhibitor heavy chain H4  N Y N 
Isoform 2 of Alpha-1B-glycoprotein  N N Y 
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Protein description Present 
replicate 1 Y/N 
Present 
replicate 2 Y/N 
Present 
replicate 3 Y/N 
Isoform 2 of Coiled-coil domain-containing protein 
34  
N N Y 
Isoform 2 of Cytochrome P450 4V2  N N Y 
Isoform 2 of Delta-aminolevulinic acid dehydratase  N N Y 
Isoform 2 of Glioma tumor suppressor candidate 
region gene 1 protein 
N Y N 
Isoform 2 of GPI inositol-deacylase  N N Y 
Isoform 2 of Sodium bicarbonate transporter-like 
protein 11  
N N Y 
Isoform 2 of Vacuolar protein sorting-associated 
protein 13B  
N N Y 
Isoform 3 of Perilipin-3  N Y N 
Isoform 3 of Up-regulator of cell proliferation  N N Y 
Isoform 4 of Polypyrimidine tract-binding protein 3  N N Y 
Isoform 7 of Protein LAP2  N N Y 
Keratin, type I cytoskeletal 10  Y Y Y 
Keratin, type I cytoskeletal 9 Y N Y 
Keratin, type II cytoskeletal 1  Y Y Y 
Keratin, type II cytoskeletal 2 epidermal  N N Y 
Keratin, type II cytoskeletal 4  N N Y 
Keratin, type II cytoskeletal 6B  N N Y 
Lipopolysaccharide-responsive and beige-like 
anchor protein  
N Y N 
L-lactate dehydrogenase B chain  Y Y N 
NADH-cytochrome b5 reductase-like  N N Y 
N-alpha-acetyltransferase 50  N N Y 
Neuroendocrine convertase 1  Y N N 
Nucleoside diphosphate kinase A  Y Y Y 
Peptidyl-prolyl cis-trans isomerase A  Y Y N 
Peroxiredoxin-2  Y Y Y 
Phosphatidylinositol 4,5-bisphosphate 3-kinase 
catalytic subunit alpha isoform  
Y N N 
Phosphoglycerate kinase  N N Y 
Plasminogen  N N Y 
Polyubiquitin-C  Y Y Y 
POTE ankyrin domain family member F  N N Y 
Protein ARMCX6  N N Y 
Protein CNPPD1 (Fragment)  N N Y 
Protein FAM180A  N N Y 
Protein fantom  N N Y 
Protein RRP5 homolog  N N Y 
Protein S100-A4  Y Y Y 
Protein S100-A6  Y Y Y 
Protocadherin Fat 2  N N Y 
Purine nucleoside phosphorylase  Y N Y 
Regulator of microtubule dynamics protein 2  Y N N 
Retinal dehydrogenase 1  Y Y Y 
Ribose-5-phosphate isomerase  N N Y 
Selenium-binding protein 1  Y N Y 
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Sodium-coupled monocarboxylate transporter 1  N N Y 
Solute carrier family 22 member 8 N N Y 
Splicing factor 45 (Fragment)  N Y N 
Superoxide dismutase [Cu-Zn]  Y Y Y 
Synembryn-B (Fragment)  N N Y 
Tau-tubulin kinase 1 N N Y 
Thioredoxin  Y Y Y 
Titin  N Y N 
Transcription initiation factor TFIID subunit 10  N N Y 
Transmembrane protein PVRIG  Y N N 
Triosephosphate isomerase  N Y N 
Uncharacterized protein  Y N N 
Uncharacterized protein KIAA1841  N N Y 
Vitamin D-binding protein  Y N Y 
Voltage-dependent L-type calcium channel subunit 
alpha-1F  
N N Y 
Zinc finger protein 566 (Fragment) N Y N 
Zinc-alpha-2-glycoprotein  Y N N 
 
Appendix 5.7 Proteins identified from LC MS/MS analysis of a DBS digest depleted of the top 12 plasma proteins. 
Sample digested for 8 hours. 
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Protein description Present replicate 
1 Y/N 
Present replicate 
2 Y/N 
Present replicate 
3 Y/N 
14-3-3 protein beta/alpha  Y y Y 
14-3-3 protein epsilon  Y Y Y 
14-3-3 protein gamma  Y Y Y 
14-3-3 protein theta  Y Y N 
14-3-3 protein zeta/delta  Y Y Y 
A disintegrin and metalloproteinase with 
thrombospondin motifs 13  
N N Y 
Actin, alpha cardiac muscle 1  N Y N 
Actin, cytoplasmic 1  Y Y Y 
Actin, gamma-enteric smooth muscle  Y N Y 
Adenylate cyclase type 9  N Y N 
Adenylate kinase isoenzyme 1  Y Y Y 
Afamin  Y Y Y 
Alpha-1-acid glycoprotein 1  Y Y Y 
Alpha-1-acid glycoprotein 2 Y Y Y 
Alpha-1-antichymotrypsin  Y Y Y 
Alpha-1-antitrypsin  Y Y Y 
Alpha-1B-glycoprotein  Y Y Y 
Alpha-2-antiplasmin  Y Y Y 
Alpha-2-HS-glycoprotein  Y Y Y 
Alpha-2-macroglobulin Y Y Y 
Alpha-hemoglobin-stabilizing protein  Y Y Y 
Alpha-synuclein  Y Y Y 
AMBP protein  Y Y Y 
Angiotensinogen  Y Y Y 
ANKRD26-like family C member 1A  N Y N 
Ankyrin-1  Y Y Y 
Antithrombin-III  Y Y Y 
Apolipoprotein A-I  Y Y Y 
Apolipoprotein A-II  Y Y Y 
Apolipoprotein A-IV  Y Y Y 
ATP synthase subunit alpha, mitochondrial  N Y N 
ATP synthase subunit beta, mitochondrial  N Y N 
Band 3 anion transport protein  Y Y Y 
Beta-2-glycoprotein 1  Y Y Y 
Bisphosphoglycerate mutase  Y Y Y 
Calmodulin  Y Y Y 
Calpastatin  Y Y Y 
Carbonic anhydrase 1  Y Y Y 
Carbonic anhydrase 2  Y Y Y 
Catalase  Y Y Y 
Ceruloplasmin  Y Y Y 
Charged multivesicular body protein 5  N N Y 
Clusterin  Y Y Y 
Cofilin-1  Y Y Y 
Collagen alpha-1(IX) chain  N Y N 
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Protein description Present replicate 
1 Y/N 
Present replicate 
2 Y/N 
Present replicate 
3 Y/N 
Complement C1q subcomponent subunit A  Y Y N 
Complement C1q subcomponent subunit B  Y N N 
Complement C3  Y Y Y 
Complement C4-B  Y Y Y 
Complement C5  N N Y 
Complement component C6  N Y N 
Complement component C9  N N Y 
Complement factor B  Y Y Y 
Complement factor H  Y Y Y 
Complement factor I  Y N Y 
CUB domain-containing protein 1  Y N N 
Cystic fibrosis transmembrane conductance 
regulator  
N Y N 
Cytochrome b5  Y Y Y 
Delta-aminolevulinic acid dehydratase  Y Y Y 
Deoxyribonucleoside 5'-monophosphate N-
glycosidase  
N Y N 
Eukaryotic translation initiation factor 4B  N N Y 
Eukaryotic translation initiation factor 5A-1  Y Y Y 
Fibrinogen alpha chain  Y N Y 
Fibrinogen beta chain  N N Y 
Fibronectin type-III domain-containing protein 3A  N N Y 
Flavin reductase  Y Y Y 
Gelsolin  Y Y N 
Glyceraldehyde-3-phosphate dehydrogenase  Y Y Y 
Glycophorin-A  Y Y Y 
Guanine nucleotide-binding protein alpha-12 
subunit  
N N Y 
Haptoglobin  Y Y Y 
Haptoglobin-related protein  N N Y 
Heat shock 70 kDa protein 1 N Y N 
Heat shock cognate 71 kDa protein  Y Y Y 
Heat shock protein HSP 90-alpha  N Y N 
Hemoglobin subunit alpha  Y Y Y 
Hemoglobin subunit beta  Y Y Y 
Hemoglobin subunit delta  Y Y Y 
Hemoglobin subunit gamma-1  Y Y Y 
Hemopexin  Y Y Y 
High affinity cAMP-specific and IBMX-insensitive 
3',5'-cyclic phosphodiesterase 8A  
Y N N 
Histidine-rich glycoprotein  Y Y Y 
Histone H2A.Z  N Y N 
Histone H2B type 1-K  N Y N 
Ig alpha-1 chain C region  Y Y Y 
Ig alpha-2 chain C region  Y Y Y 
Ig gamma-1 chain C region  Y Y Y 
Ig gamma-2 chain C region  Y Y Y 
Ig gamma-3 chain C region  Y Y Y 
Ig gamma-4 chain C region  Y Y Y 
Ig heavy chain V-III region GAL  N Y N 
Ig heavy chain V-III region TEI  Y Y Y 
Ig heavy chain V-III region TIL Y N Y 
Ig heavy chain V-III region VH26  Y N N 
Ig kappa chain C region  Y Y Y 
Ig kappa chain V-I region CAR  Y N N 
Ig kappa chain V-I region DEE  Y Y Y 
Ig kappa chain V-I region Lay  Y Y N 
Ig kappa chain V-II region TEW  Y Y Y 
Ig kappa chain V-III region SIE Y Y Y 
Ig kappa chain V-III region VG   Y N N 
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Protein description Present replicate 
1 Y/N 
Present replicate 
2 Y/N 
Present replicate 
3 Y/N 
Ig kappa chain V-IV region Len  Y Y Y 
Ig lambda chain V-III region LOI Y N Y 
Ig lambda chain V-III region SH  Y N Y 
Ig lambda chain V-IV region Hil  Y Y N 
Ig lambda-1 chain C regions  Y Y Y 
Ig mu chain C region  Y N Y 
Ig mu heavy chain disease protein  N Y N 
Inactive carboxypeptidase-like protein X2  N Y N 
Inactive caspase-12  Y N N 
Inter-alpha-trypsin inhibitor heavy chain H1  Y Y Y 
Inter-alpha-trypsin inhibitor heavy chain H2  Y Y Y 
Inter-alpha-trypsin inhibitor heavy chain H4  Y Y Y 
Keratin, type I cytoskeletal 10  Y Y Y 
Keratin, type I cytoskeletal 14  N Y N 
Keratin, type I cytoskeletal 9  Y Y Y 
Keratin, type II cytoskeletal 1  Y Y Y 
Keratin, type II cytoskeletal 2 epidermal  Y Y Y 
Keratin, type II cytoskeletal 4  N N Y 
Keratin, type II cytoskeletal 5  N Y Y 
Kininogen-1  Y Y Y 
Leucine-rich alpha-2-glycoprotein  Y N Y 
Leucine-rich repeat neuronal protein 4  Y N N 
Leucine-rich repeat-containing protein 9  N Y N 
L-lactate dehydrogenase B chain Y Y Y 
Nck-associated protein 1  N Y N 
NEDD4-binding protein 2  N Y N 
NSFL1 cofactor p47  Y Y Y 
Nucleoside diphosphate kinase A  Y Y Y 
Peroxiredoxin-1  Y Y Y 
Peroxiredoxin-2  Y Y Y 
Peroxiredoxin-6  Y Y Y 
Peroxisomal NADH pyrophosphatase NUDT12  N N Y 
Plasma protease C1 inhibitor  Y Y Y 
Plasminogen  Y Y Y 
Platelet basic protein  Y Y Y 
Polyubiquitin-C  N N Y 
Pre-rRNA-processing protein TSR1 homolog  Y N N 
Proteasome activator complex subunit 1  N Y N 
Proteasome subunit alpha type-1  N N Y 
Proteasome subunit alpha type-2  N N Y 
Proteasome subunit beta type-4  N N Y 
Proteasome subunit beta type-7  Y Y Y 
Protein 4.1  Y Y Y 
Protein DDI1 homolog 2  N Y N 
Protein DJ-1  Y N N 
Protein FAM10A4  Y N Y 
Protein FAM20A  N Y N 
Protein S100-A10  N Y N 
Protein S100-A12  Y Y Y 
Protein S100-A4  Y Y Y 
Protein S100-A6  Y Y Y 
Protein S100-A9  N N Y 
Prothrombin  Y Y Y 
Protocadherin beta-15  N N Y 
PTB domain-containing engulfment adapter 
protein  
N Y N 
Purine nucleoside phosphorylase  Y Y Y 
Putative tropomyosin alpha-3 chain-like protein N N Y 
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Protein description Present replicate 
1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
Selenium-binding protein 1  Y Y Y 
Serotransferrin  Y Y Y 
Serum albumin  Y Y Y 
Serum paraoxonase/arylesterase 1  Y N N 
SH3 domain-binding glutamic acid-rich-like protein 
3  
Y N N 
Small ubiquitin-related modifier 2  Y N N 
Spectrin alpha chain, erythrocyte  Y Y Y 
Spectrin beta chain, erythrocyte  Y Y Y 
S-phase kinase-associated protein 1  Y Y N 
Superoxide dismutase  Y Y Y 
Taste receptor type 2 member 30  Y N N 
Thioredoxin  Y Y Y 
Thyroxine-binding globulin  Y N Y 
Transaldolase  N Y Y 
Transitional endoplasmic reticulum ATPase  N N Y 
Transthyretin  Y Y Y 
Triosephosphate isomerase  Y Y Y 
Tropomyosin alpha-3 chain  Y Y Y 
Tubulin alpha-3C/D chain  N Y N 
Tubulin beta chain  N Y N 
Tubulin-specific chaperone A  Y N N 
Ubiquitin-associated domain-containing protein 1  N Y N 
Ubiquitin-conjugating enzyme E2 N  N Y N 
Uncharacterized protein C9orf40  Y Y Y 
UV excision repair protein RAD23 homolog A  Y Y Y 
Vacuolar fusion protein MON1 homolog A  N N Y 
Vitamin D-binding protein  Y Y Y 
Vitronectin  Y Y Y 
X-ray repair cross-complementing protein 6  Y N N 
Zinc finger CCHC domain-containing protein 5  N Y N 
Zinc-alpha-2-glycoprotein  Y Y N 
 
Appendix 5.8 Proteins identified from LC MS/MS analysis of a DBS digest depleted of haemoglobin. Sample digested 
for 1 hour. 
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Protein description Present replicate 
1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
14-3-3 protein beta/alpha  Y Y Y 
14-3-3 protein epsilon  Y Y Y 
14-3-3 protein gamma  N Y Y 
14-3-3 protein zeta/delta  N Y Y 
Actin, cytoplasmic 1  Y Y Y 
Adenylate kinase isoenzyme 1  N Y N 
Afamin  Y Y Y 
Alpha-1-acid glycoprotein 1  Y Y Y 
Alpha-1-acid glycoprotein 2  Y Y Y 
Alpha-1-antichymotrypsin  Y Y Y 
Alpha-1-antitrypsin  Y Y Y 
Alpha-1B-glycoprotein  Y Y Y 
Alpha-2-HS-glycoprotein Y Y Y 
Alpha-2-macroglobulin  Y Y Y 
Alpha-hemoglobin-stabilizing protein  Y Y Y 
Alpha-synuclein  Y Y Y 
Angiotensin-2  N N Y 
Angiotensinogen  N Y N 
Ankyrin repeat and BTB/POZ domain-containing 
protein 1  
N N Y 
Ankyrin-1  Y Y Y 
Antithrombin-III  Y Y Y 
Apolipoprotein A-I  Y Y Y 
Apolipoprotein A-II  Y Y Y 
Apolipoprotein A-IV  Y Y Y 
Apolipoprotein C-III  Y Y Y 
Band 3 anion transport protein  Y Y Y 
B-cell receptor CD22  Y Y N 
Beta-2-glycoprotein 1  Y N Y 
Beta-actin-like protein 2  N N Y 
Beta-adducin  Y Y N 
Beta-galactosidase-1-like protein 3  N Y N 
BH3-interacting domain death agonist  N N Y 
Bisphosphoglycerate mutase  Y Y Y 
BPI fold-containing family B member 1  N Y Y 
Calmodulin  Y Y Y 
Calpastatin  Y Y Y 
Carbonic anhydrase 1  Y Y Y 
Carbonic anhydrase 2  N Y Y 
Catalase  Y Y Y 
Ceruloplasmin  Y Y Y 
Chromosome 1 open reading frame 123 Y N N 
Clusterin  Y Y Y 
Cofilin-1  Y Y Y 
Collagen alpha-1(XVIII) chain (Fragment)  N Y N 
Complement C3  Y Y Y 
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Protein description Present replicate 
1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
Complement C4-B  Y Y Y 
Complement factor B  Y Y Y 
Complement factor H  Y Y Y 
Complement factor I  Y Y N 
Copper chaperone for superoxide dismutase  Y Y Y 
Corticosteroid-binding globulin  N N Y 
Cyclin-Y-like protein 2 (Fragment)  Y N N 
Cytochrome b5  Y Y Y 
Cytochrome P450 2B6  N Y Y 
D-dopachrome decarboxylase  N Y Y 
Delta-aminolevulinic acid dehydratase  Y Y Y 
Dematin  Y N N 
Dipeptidyl peptidase 3  N N Y 
Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-
mannosyltransferase (Fragment)  
N Y N 
Dynein heavy chain 9, axonemal (Fragment)  N Y N 
Eukaryotic translation initiation factor 4B  N N Y 
Eukaryotic translation initiation factor 5A-1  N Y Y 
Eukaryotic translation initiation factor 5A-2  Y N N 
Fibrinogen alpha chain  Y Y Y 
Flavin reductase (NADPH)  Y Y Y 
Glyceraldehyde-3-phosphate dehydrogenase  Y Y Y 
Glycophorin Erik I-IV (Precursor)  N N Y 
Glycophorin-A  N Y N 
Haptoglobin  Y Y Y 
Heat shock 70 kDa protein 1A/1B  N N Y 
Heat shock cognate 71 kDa protein  Y Y Y 
Hemoglobin subunit alpha  Y Y Y 
Hemoglobin subunit beta  Y Y Y 
Hemoglobin subunit delta  Y Y Y 
Hemoglobin subunit delta (Fragment) N N Y 
Hemoglobin subunit gamma-1  Y Y Y 
Hemopexin Y Y Y 
Histidine triad nucleotide-binding protein 1 Y N Y 
Histidine-rich glycoprotein  Y y Y 
Hsc70-interacting protein  N Y N 
Hyaluronan and proteoglycan link protein 3  N N Y 
Ig alpha-1 chain C region  Y Y Y 
Ig alpha-2 chain C region  Y Y Y 
Ig gamma-1 chain C region  Y Y Y 
Ig gamma-2 chain C region  Y Y Y 
Ig gamma-3 chain C region  Y Y Y 
Ig gamma-4 chain C region  Y Y Y 
Ig heavy chain V-III region TEI  Y Y Y 
Ig heavy chain V-III region TIL  Y N Y 
Ig kappa chain C region  Y Y Y 
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Protein description Present replicate 
1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
Ig kappa chain V-I region DEE  Y Y Y 
Ig kappa chain V-I region Lay  Y Y Y 
Ig kappa chain V-III region SIE  Y Y Y 
Ig kappa chain V-IV region Len  Y N Y 
Ig lambda chain V-III region LOI  Y Y Y 
Ig lambda-1 chain C regions  Y Y Y 
Ig lambda-2 chain C regions  N Y Y 
Ig lambda-6 chain C region  Y N N 
Ig mu chain C region  Y Y Y 
Inactive caspase-12  N N Y 
Inter-alpha-trypsin inhibitor heavy chain H4  Y Y Y 
Isoform 1 of Rho GTPase-activating protein 7  N N Y 
Isoform 2 of Hydroxyacyl-coenzyme A 
dehydrogenase, mitochondrial  
N Y N 
Isoform 2 of Leucine-rich repeat-containing 
protein 9  
N N Y 
Isoform 2 of PRELI domain-containing protein 2  N N Y 
Isoform 2 of Proteasome subunit alpha type-7  Y N N 
Isoform 2 of Three prime repair exonuclease 1  N N Y 
Isoform 3 of Interleukin-12 receptor subunit beta-
1  
N Y N 
Isoform 3 of Magnesium-dependent phosphatase 
1  
N N Y 
Isoform 4 of Lipid phosphate phosphatase-related 
protein type 3  
N Y N 
Kelch-like protein 30  N Y N 
Keratin, type I cytoskeletal 10  Y Y Y 
Keratin, type I cytoskeletal 17  Y N N 
Keratin, type I cytoskeletal 9  Y Y Y 
Keratin, type II cytoskeletal 1  Y Y Y 
Keratin, type II cytoskeletal 2 epidermal  Y Y Y 
Keratin, type II cytoskeletal 6B Y N N 
Kinetochore-associated protein 1  Y N Y 
Kininogen-1  Y Y Y 
Lactoylglutathione lyase  N Y Y 
Laminin subunit alpha-5  N Y N 
L-lactate dehydrogenase A chain Y Y Y 
L-lactate dehydrogenase B chain  Y Y Y 
Mediator of RNA polymerase II transcription 
subunit  
Y N N 
Myotrophin  N N Y 
NSFL1 cofactor p47  Y Y Y 
Nuclear transport factor 2 (Fragment)  Y N N 
Nucleoside diphosphate kinase A  Y Y Y 
Nucleoside diphosphate kinase B  N Y N 
Peptidyl-prolyl cis-trans isomerase A  Y Y Y 
Peroxiredoxin-1  Y Y Y 
Peroxiredoxin-2  Y Y Y 
Peroxiredoxin-6  Y Y Y 
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Protein description Present replicate 
1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
Phosphoglycerate mutase 1  N Y Y 
Phospholysine phosphohistidine inorganic 
pyrophosphate phosphatase  
N Y Y 
Pigment epithelium-derived factor  Y Y Y 
Plasma protease C1 inhibitor  Y Y Y 
Plasminogen N Y Y 
Plasminogen (Fragment)  Y N N 
Platelet basic protein  Y Y Y 
Polyubiquitin-C  N Y N 
Proteasome activator complex subunit 1  Y Y Y 
Proteasome subunit alpha type  Y N N 
Proteasome subunit alpha type-1  N N Y 
Proteasome subunit alpha type-2  N Y N 
Proteasome subunit alpha type-4  Y N Y 
Proteasome subunit alpha type-5 N Y N 
Proteasome subunit alpha type-6  N Y Y 
Proteasome subunit beta type-7  N Y Y 
Protein 4.1  Y Y Y 
Protein AMBP  N Y Y 
Protein DDI1 homolog 2 Y Y N 
Protein RRP5 homolog  N Y N 
Protein S100-A12  N N Y 
Protein S100-A4 Y Y Y 
Protein S100-A6  Y Y Y 
Protein S100-A7  N N Y 
Protein S100-A8  N Y N 
Protein unc-13 homolog B  Y N N 
Prothrombin  Y Y Y 
Purine nucleoside phosphorylase  Y Y Y 
Putative protein FAM10A4  Y N Y 
Radixin  Y Y Y 
Ran-specific GTPase-activating protein  N N Y 
Retinol-binding protein 4  Y Y Y 
SAGA-associated factor 29 homolog  N N Y 
Selenium-binding protein 1  Y Y Y 
Serine palmitoyltransferase 2  N N Y 
Serotransferrin  Y Y Y 
Serum albumin  Y Y Y 
Serum amyloid P-component  Y Y Y 
SH3 domain-binding glutamic acid-rich-like protein 
3  
Y Y Y 
Small ubiquitin-related modifier 2  Y Y Y 
Spectrin alpha chain, erythrocytic 1 Y Y Y 
Spectrin beta chain, erythrocytic  Y Y Y 
S-phase kinase-associated protein 1  N Y Y 
Stress-induced-phosphoprotein 1  N Y N 
Superoxide dismutase [Cu-Zn]  Y Y Y 
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Protein description Present replicate 
1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
Syntaxin-1B (Fragment)  N Y N 
Thioredoxin  Y Y Y 
Thioredoxin domain-containing protein 17  Y N N 
Transaldolase  Y Y Y 
Transgelin-2  N Y N 
Transthyretin  Y Y Y 
Triosephosphate isomerase  Y Y Y 
Tropomyosin 3  Y Y Y 
Tubulin-specific chaperone A  Y N Y 
Tyrosine--tRNA ligase, mitochondrial (Fragment)  N N Y 
Ubiquitin-associated domain-containing protein 1 N Y N 
Ubiquitin-conjugating enzyme E2 N  Y Y Y 
Uncharacterized protein  Y N N 
Uncharacterized protein C9orf40  N Y Y 
Uncharacterized protein KIAA0240  N N Y 
UV excision repair protein RAD23 homolog A  Y Y Y 
Vitamin D-binding protein  Y Y Y 
Vitronectin  N Y Y 
Voltage-dependent R-type calcium channel 
subunit alpha-1E  
Y N N 
WD repeat-containing protein 17 (Fragment)  N Y N 
Xaa-Pro dipeptidase  Y N N 
YTH domain family protein 1  Y N N 
Zinc finger CCHC domain-containing protein 5  N Y Y 
Zinc-alpha-2-glycoprotein  Y Y Y 
 
Appendix 5.9 Proteins identified from LC MS/MS analysis of a DBS digest depleted of haemoglobin. Sample digested 
for 8 hours. 
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Protein description Present 
replicate 1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
14-3-3 protein epsilon  N Y Y 
14-3-3 protein zeta/delta  N Y N 
26S proteasome non-ATPase regulatory subunit 9  Y N Y 
3-hydroxyanthranilate 3,4-dioxygenase  Y N N 
60 kDa heat shock protein, mitochondrial  Y N N 
Acidic leucine-rich nuclear phosphoprotein 32 
family member C  
Y N N 
Actin, cytoplasmic 1  N Y N 
Actin-related protein 2/3 complex subunit 2  Y N N 
Acylamino-acid-releasing enzyme  Y N Y 
ADP-sugar pyrophosphatase  N Y N 
Afamin  Y N Y 
Aflatoxin B1 aldehyde reductase member 3  Y N N 
Alcohol dehydrogenase 1B  Y N N 
Aldo-keto reductase family 1 member C4  Y N N 
Alpha-1-acid glycoprotein 1  Y Y Y 
Alpha-1-acid glycoprotein 2  Y Y Y 
Alpha-1-antichymotrypsin  Y Y Y 
Alpha-1-antitrypsin  Y Y Y 
Alpha-1B-glycoprotein  N N Y 
Alpha-2-HS-glycoprotein  Y Y Y 
Alpha-2-macroglobulin  Y Y Y 
Alpha-amylase 1  N Y N 
Alpha-enolase  Y N N 
Alpha-hemoglobin-stabilizing protein  Y N Y 
Alpha-synuclein Y N Y 
AMBP protein  N Y N 
Angiotensinogen  Y N Y 
Ankyrin-1  Y N Y 
Antithrombin-III  Y Y Y 
Apolipoprotein A-I  N Y N 
Apolipoprotein C-III  Y N Y 
Attractin  Y N Y 
Band 3 anion transport protein  N Y N 
Beta-adducin  Y N Y 
Betaine--homocysteine S-methyltransferase 1  Y N N 
Bile salt sulfotransferase  Y N N 
Bisphosphoglycerate mutase  N Y N 
Bleomycin hydrolase  Y N Y 
C-1-tetrahydrofolate synthase, cytoplasmic  Y N N 
Calmodulin  Y N N 
Calmodulin-like protein 5  Y N N 
Calpastatin  Y N Y 
Carbamoyl-phosphate synthase [ammonia], 
mitochondrial  
Y N N 
Carbonic anhydrase 1  Y Y Y 
Carbonic anhydrase 2  Y N Y 
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Protein description Present 
replicate 1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
Catalase  Y Y Y 
CD44 antigen  Y N N 
Ceruloplasmin  Y Y Y 
Chromosome 1 open reading frame 123  Y N N 
Clusterin  N N Y 
Coagulation factor V  N N Y 
Cofilin-1  N Y N 
Colorectal mutant cancer protein  N Y N 
Complement C1q subcomponent subunit A  N Y N 
Complement C3  Y Y Y 
Complement C4-A  N Y N 
Complement C4-B  N N Y 
Complement factor B  N N Y 
Complement factor H  N Y N 
Complement factor I  N Y N 
Copper chaperone for superoxide dismutase  Y N Y 
Cystatin-S  N N Y 
Cytochrome b5  Y N Y 
Delta-1-pyrroline-5-carboxylate dehydrogenase, 
mitochondrial  
Y N N 
Delta-aminolevulinic acid dehydratase  Y N Y 
Dematin  N N Y 
Dematin (Fragment)  Y N N 
Dermcidin  Y N Y 
Dihydropteridine reductase  N N Y 
Dipeptidyl peptidase 3  Y N N 
Dynactin subunit 2  N N Y 
Elongation factor 1-alpha 1 N Y N 
Endoplasmin  Y N N 
Enoyl-CoA hydratase, mitochondrial  Y N N 
Eukaryotic translation initiation factor 5A-1  N Y N 
Fatty acid synthase  Y N N 
Fatty acid-binding protein, liver  Y N N 
Flavin reductase (NADPH)  N N Y 
G2/M phase-specific E3 ubiquitin-protein ligase 
(Fragment)  
Y N N 
Gamma-enolase  Y N Y 
GDP-L-fucose synthase  Y N N 
GDP-L-fucose synthase (Fragment)  N N Y 
Glutathione S-transferase A1  Y N Y 
Glutathione synthetase  Y N Y 
Glyceraldehyde-3-phosphate dehydrogenase  Y Y N 
Glycophorin-A  N Y N 
Haptoglobin  Y Y Y 
Heat shock cognate 71 kDa protein  N N Y 
Hemoglobin subunit alpha  Y Y Y 
Hemoglobin subunit beta  Y Y Y 
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Protein description Present 
replicate 1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
Hemoglobin subunit delta  Y Y Y 
Hemoglobin subunit delta (Fragment)  N Y Y 
Hemoglobin subunit gamma-1  N Y Y 
Hemopexin  Y Y Y 
Histidine-rich glycoprotein  Y Y Y 
Ig alpha-1 chain C region  N Y N 
Ig gamma-1 chain C region  N Y N 
Ig gamma-2 chain C region  N Y N 
Ig kappa chain C region  N Y N 
Ig kappa chain V-III region SIE  N Y N 
Ig lambda-1 chain C regions  N Y N 
Inter-alpha-trypsin inhibitor heavy chain H1  N Y N 
Inter-alpha-trypsin inhibitor heavy chain H2  N Y N 
Inward rectifier potassium channel 16  N Y N 
Isoform 2 of 14 kDa phosphohistidine 
phosphatase  
N N Y 
Isoform 2 of Aldo-keto reductase family 1 member 
C2  
Y N N 
Isoform 2 of Hydroxymethylglutaryl-CoA synthase, 
mitochondrial  
Y N N 
Isoform 2 of Proteasome subunit alpha type-4  Y N N 
Isoform 2 of Tropomyosin alpha-1 chain  Y N Y 
Isoform 5 of EF-hand calcium-binding domain-
containing protein 6  
N N Y 
Keratin, type I cuticular Ha3-II  N Y N 
Keratin, type I cytoskeletal 10  Y Y Y 
Keratin, type I cytoskeletal 14 N Y N 
Keratin, type I cytoskeletal 16  N Y N 
Keratin, type I cytoskeletal 17  N Y N 
Keratin, type I cytoskeletal 19  N N Y 
Keratin, type I cytoskeletal 9  Y Y Y 
Keratin, type II cuticular Hb4  N Y N 
Keratin, type II cytoskeletal 1 Y Y Y 
Keratin, type II cytoskeletal 2 epidermal  Y Y Y 
Keratin, type II cytoskeletal 5  N Y N 
Keratin, type II cytoskeletal 6A  N Y N 
Keratin, type II cytoskeletal 6B  N Y N 
Keratin-associated protein 3-1  N Y N 
Ketohexokinase  Y N N 
Kininogen-1  Y Y Y 
Leucine-rich alpha-2-glycoprotein  Y N N 
Leucine-rich repeat neuronal protein 4  N Y N 
LIM and SH3 domain protein 1  N N Y 
LisH domain and HEAT repeat-containing protein 
KIAA1468  
N Y N 
L-lactate dehydrogenase A chain  Y N Y 
L-lactate dehydrogenase B chain  Y N Y 
Lysosome-associated membrane glycoprotein 2  N N Y 
Lysozyme C  N Y N 
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Protein description Present 
replicate 1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
Nostrin  N Y N 
NSFL1 cofactor p47  Y N Y 
Nucleoside diphosphate kinase  Y N N 
Peptidyl-prolyl cis-trans isomerase A  N N Y 
Peroxiredoxin-2  Y Y Y 
PH domain leucine-rich repeat-containing protein  Y N N 
Phosphatidate phosphatase LPIN2  N N Y 
Phosphoacetylglucosamine mutase  Y N N 
Phosphoenolpyruvate carboxykinase [GTP], 
mitochondrial  
Y N Y 
Pigment epithelium-derived factor  Y N Y 
PITH domain-containing protein 1  Y N Y 
Plasma protease C1 inhibitor Y Y Y 
Plasminogen  Y N Y 
Platelet basic protein  Y N Y 
Platelet glycoprotein Ib alpha chain  N N Y 
Polyubiquitin-C  Y N Y 
Probable ATP-dependent RNA helicase DDX41 
(Fragment)  
N N Y 
Prolactin-inducible protein  Y N N 
Proteasome subunit alpha type-1  Y N Y 
Proteasome subunit alpha type-3  Y N Y 
Proteasome subunit alpha type-5  N N Y 
Proteasome subunit alpha type-6  Y N Y 
Proteasome subunit alpha type-7  Y N N 
Proteasome subunit beta type-1  Y N Y 
Proteasome subunit beta type-2  Y N Y 
Proteasome subunit beta type-6  Y N N 
Protein 4.1  Y Y Y 
Protein AMBP  Y N N 
Prothrombin  Y Y Y 
Putative nucleoside diphosphate kinase  N N Y 
Ran-specific GTPase-activating protein (Fragment)  N N Y 
Retinal dehydrogenase 1  Y N N 
Retinol-binding protein 4  Y Y Y 
Selenium-binding protein 1  N N Y 
Serine hydroxymethyltransferase, cytosolic  Y N N 
Serotransferrin  Y Y Y 
Serum albumin  Y Y Y 
Serum amyloid P-component  Y N Y 
Serum deprivation-response protein  N N Y 
Small ubiquitin-related modifier 2  Y N N 
SMT3 suppressor of mif two 3 homolog 1 (Yeast), 
isoform CRA_b  
N N Y 
Spectrin beta chain, erythrocyte (Fragment)  N N Y 
S-phase kinase-associated protein 1  Y N Y 
Superoxide dismutase  Y Y Y 
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Protein description Present 
replicate 1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
Syntaxin-3  N Y N 
Thioredoxin  Y Y Y 
Thymidine phosphorylase  Y N N 
Thyroxine-binding globulin  Y N Y 
TPR and ankyrin repeat-containing protein 1  Y N N 
Transaldolase  Y N Y 
Transcription elongation factor SPT6  N Y N 
Transmembrane 9 superfamily member 4  N Y N 
Transthyretin  Y Y Y 
Tropomyosin 3  Y N Y 
Tropomyosin alpha-4 chain  Y Y Y 
Tubulin-specific chaperone A  N N Y 
Uncharacterized protein C6orf163  Y N Y 
UPF0587 protein C1orf123  N N Y 
UTP--glucose-1-phosphate uridylyltransferase  Y N N 
UV excision repair protein RAD23 homolog A  Y N Y 
UV excision repair protein RAD23 homolog B  Y N N 
Vitamin D-binding protein  Y N Y 
Vitronectin  Y N N 
WD repeat-containing protein 1  N N Y 
Xaa-Pro dipeptidase  N N Y 
Zinc-alpha-2-glycoprotein  Y N Y 
Appendix 5.10 Proteins identified from LC MS/MS analysis of a DBS digest depleted of the top 12 plasma proteins 
and haemoglobin. Sample digested for 1 hours. 
 
Protein description Present 
replicate 1 Y/N 
Present 
replicate 2 Y/N 
Present 
replicate 3 Y/N 
14-3-3 protein beta/alpha  N N Y 
14-3-3 protein epsilon  Y Y Y 
14-3-3 protein zeta/delta  Y Y Y 
26S proteasome non-ATPase regulatory subunit 4  Y N N 
26S proteasome non-ATPase regulatory subunit 9  N Y Y 
Acidic leucine-rich nuclear phosphoprotein 32 
family member A  
Y Y N 
Acylamino-acid-releasing enzyme  Y Y Y 
Acyl-CoA:lysophosphatidylglycerol acyltransferase 
1  
N N Y 
Adapter molecule crk Y Y N 
Afamin  Y Y Y 
Alpha-1-acid glycoprotein 1  Y Y Y 
Alpha-1-acid glycoprotein 2  Y Y Y 
Alpha-1-antichymotrypsin  Y Y Y 
Alpha-1-antitrypsin  Y Y Y 
Alpha-1B-glycoprotein  Y Y Y 
Alpha-2-HS-glycoprotein  Y Y Y 
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Protein description Present 
replicate 1 Y/N 
Present 
replicate 2 Y/N 
Present 
replicate 3 Y/N 
Alpha-2-macroglobulin  Y Y Y 
Alpha-enolase  Y Y Y 
Alpha-hemoglobin-stabilizing protein  Y Y Y 
Alpha-synuclein  Y Y Y 
Angiotensinogen  Y Y Y 
Ankyrin-1 Y N N 
Antithrombin-III  Y Y Y 
Apolipoprotein B-100  N N Y 
Apolipoprotein C-III  N N Y 
Attractin  Y Y Y 
Band 3 anion transport protein  Y Y Y 
Beta-adducin  Y Y Y 
Bleomycin hydrolase  Y Y Y 
BolA-like protein 2  N Y Y 
Calcineurin-like phosphoesterase domain-
containing protein 1  
N Y Y 
Calmodulin  Y Y Y 
Calmodulin-like protein 5  Y Y Y 
Calpastatin  Y Y Y 
Carbonic anhydrase 1  Y Y Y 
Carbonic anhydrase 2  N Y N 
Catalase  Y Y Y 
CD44 antigen Y Y Y 
Ceruloplasmin  Y Y Y 
Charged multivesicular body protein 4a 
(Fragment)  
N N Y 
Clusterin  Y N N 
Clusterin alpha chain (Fragment)  N Y Y 
Complement C3  Y Y Y 
Complement C4-B  Y Y Y 
Complement factor H  Y Y Y 
Copper chaperone for superoxide dismutase  Y Y y 
Cytochrome b5  Y Y Y 
Dedicator of cytokinesis protein 11  N Y N 
Delta-aminolevulinic acid dehydratase  Y Y Y 
Dematin  Y Y Y 
Dipeptidyl peptidase 3  Y Y Y 
DNA damage-binding protein  Y Y Y 
Dynactin subunit 2  Y N N 
Epithelial discoidin domain-containing receptor 1 
(Fragment)  
N N Y 
Eukaryotic translation initiation factor 5A-1  Y Y Y 
Flavin reductase (NADPH)  Y Y Y 
Gamma-enolase  Y Y Y 
GDP-L-fucose synthase  Y Y Y 
Glutathione synthetase  Y Y Y 
Glyceraldehyde-3-phosphate dehydrogenase  Y Y Y 
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Protein description Present 
replicate 1 Y/N 
Present 
replicate 2 Y/N 
Present 
replicate 3 Y/N 
Haptoglobin  Y Y Y 
Hemoglobin subunit alpha  Y Y Y 
Hemoglobin subunit beta  Y Y Y 
Hemoglobin subunit delta  Y Y Y 
Hemoglobin subunit delta (Fragment)  Y N Y 
Hemoglobin subunit gamma-1  Y Y Y 
Hemopexin  Y Y Y 
Hepatoma-derived growth factor  Y N N 
Histidine-rich glycoprotein  Y Y Y 
Ig gamma-1 chain C region  Y Y Y 
Ig heavy chain V-III region TEI  Y Y Y 
Ig kappa chain C region  Y Y Y 
Ig kappa chain V-I region Lay  N Y Y 
Ig kappa chain V-III region NG9 (Fragment)  Y N N 
Ig lambda-1 chain C regions  Y N N 
Ig lambda-7 chain C region  N Y N 
Ig mu chain C region  N Y Y 
Ig mu heavy chain disease protein  Y N N 
Importin subunit beta-1  Y Y N 
Insulin-like growth factor-binding protein complex 
acid labile subunit  
Y Y Y 
Isoform 2 of Forkhead box protein K1  N N Y 
Isoform 2 of Lysine-specific histone demethylase 
1B  
N Y N 
Isoform 2 of NIF3-like protein 1 N N Y 
Isoform 2 of Solute carrier family 35 member  N N Y 
Isoform 2 of Spectrin alpha chain, erythrocyte  N N Y 
Isoform 2 of Tropomyosin alpha-1 chain  Y Y Y 
Isoform 3 of Magnesium-dependent phosphatase 
1  
N N Y 
Isoform Er3 of Ankyrin-1  N Y Y 
Keratin, type I cytoskeletal 10  Y Y Y 
Keratin, type I cytoskeletal 14  Y Y Y 
Keratin, type I cytoskeletal 15  N Y Y 
Keratin, type I cytoskeletal 9  Y Y Y 
Keratin, type II cytoskeletal 1  Y Y Y 
Keratin, type II cytoskeletal 5  N N Y 
Keratin, type II cytoskeletal 6A N N Y 
Keratin, type II cytoskeletal 6B  Y Y N 
Kininogen-1  Y Y Y 
Leucine-rich alpha-2-glycoprotein  Y N Y 
Leucine-rich repeat-containing protein 72  Y Y N 
LIM and SH3 domain protein 1  Y Y Y 
L-lactate dehydrogenase B chain  Y Y Y 
Lysosome-associated membrane glycoprotein 2  N Y Y 
Mediator of DNA damage checkpoint protein 1  N Y N 
Myeloma-overexpressed gene 2 protein  N Y Y 
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Protein description Present 
replicate 1 Y/N 
Present 
replicate 2 Y/N 
Present 
replicate 3 Y/N 
NIF3-like protein 1  N Y N 
NSFL1 cofactor p47 Y Y Y 
Nucleoredoxin  Y N N 
Nucleoside diphosphate kinase A  Y Y Y 
Peptidyl-prolyl cis-trans isomerase A  Y Y Y 
Peroxiredoxin-2  Y Y Y 
Phosphatidylinositol 4-kinase type 2 beta  N N Y 
Pigment epithelium-derived factor  Y Y Y 
PITH domain-containing protein 1 Y Y Y 
Plasma protease C1 inhibitor  Y Y Y 
Plasminogen  Y Y N 
Platelet basic protein  Y Y Y 
Platelet glycoprotein Ib alpha chain  Y Y Y 
Polyubiquitin-C  Y Y Y 
Programmed cell death protein 5  Y Y Y 
Prolactin-inducible protein  Y Y Y 
Proteasome subunit alpha type-1  Y Y Y 
Proteasome subunit alpha type-2  Y Y Y 
Proteasome subunit alpha type-3  N Y Y 
Proteasome subunit alpha type-4  Y Y Y 
Proteasome subunit alpha type-5  Y N Y 
Proteasome subunit alpha type-6  Y Y Y 
Proteasome subunit alpha type-7 Y Y Y 
Proteasome subunit beta type-1  Y Y Y 
Proteasome subunit beta type-2  N Y Y 
Proteasome subunit beta type-3  Y Y Y 
Proteasome subunit beta type-4  Y Y Y 
Proteasome subunit beta type-6  N N Y 
Proteasome subunit beta type-7  N Y Y 
Protein 4.1  Y Y Y 
Protein AMBP  Y Y Y 
Protein LZIC  Y Y Y 
Protein phosphatase 1 regulatory subunit 7  N N Y 
Protein S100-A6  Y Y Y 
Prothrombin  Y Y Y 
Putative Polycomb group protein ASXL3  N Y N 
Ran-specific GTPase-activating protein  Y Y Y 
Retinol-binding protein 4  Y Y Y 
Selenium-binding protein 1  Y Y Y 
Serotransferrin  Y Y Y 
Serum albumin  Y Y Y 
Serum amyloid P-component  Y Y Y 
Serum deprivation-response protein  Y Y Y 
SH3 domain-binding glutamic acid-rich-like protein 
3  
Y Y Y 
Small ubiquitin-related modifier 1  N Y N 
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Protein description Present 
replicate 1 Y/N 
Present 
replicate 2 Y/N 
Present 
replicate 3 Y/N 
Solute carrier family 25 member 53  N N Y 
Spectrin beta chain, erythrocytic  Y Y Y 
S-phase kinase-associated protein 1  Y Y Y 
Stathmin  N N Y 
Superoxide dismutase [Cu-Zn]  Y Y Y 
Thioredoxin  Y Y Y 
Thioredoxin reductase 1, cytoplasmic (Fragment)  N N Y 
Thrombospondin-1  N Y N 
Thyroxine-binding globulin  Y Y Y 
Transaldolase  Y Y Y 
Transthyretin  Y Y Y 
Triosephosphate isomerase  N N Y 
Tropomodulin-1  Y Y Y 
Tropomyosin 3  Y Y Y 
Tropomyosin alpha-4 chain  Y Y Y 
Tubulin-specific chaperone A  Y Y Y 
Tyrosine--tRNA ligase, mitochondrial (Fragment)  Y N N 
Ubiquitin-conjugating enzyme E2 variant 2  N Y Y 
Uncharacterized protein  N N Y 
Uncharacterized protein C9orf40  Y Y Y 
UPF0587 protein C1orf123  Y Y Y 
UV excision repair protein RAD23 homolog A  Y Y Y 
UV excision repair protein RAD23 homolog B  N N Y 
Vitamin D-binding protein  Y Y Y 
Vitronectin  N N Y 
WD repeat-containing protein 1 Y N Y 
Zinc-alpha-2-glycoprotein  Y Y Y 
 
Appendix 5.11 Proteins identified from LC MS/MS analysis of a DBS digest depleted of the top 12 plasma proteins 
and haemoglobin. Sample digested for 8 hours. 
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Protein description Present replicate 
1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
26S proteasome non-ATPase regulatory subunit 9  N Y Y 
Actin, cytoplasmic 1, N-terminally processed  N N Y 
Adenosylhomocysteinase  N N Y 
Afamin  Y Y Y 
Alpha-1-acid glycoprotein 1  Y Y Y 
Alpha-1-acid glycoprotein 2 Y Y Y 
Alpha-1-antichymotrypsin  Y Y N 
Alpha-1-antitrypsin Y Y Y 
Alpha-1B-glycoprotein  Y Y Y 
Alpha-2-HS-glycoprotein  Y Y Y 
Alpha-2-macroglobulin  Y Y Y 
Alpha-adducin  Y Y Y 
Alpha-hemoglobin-stabilizing protein  Y Y Y 
Alpha-L-iduronidase  N Y N 
Alpha-synuclein  Y Y Y 
Antithrombin-III  Y Y Y 
Apolipoprotein A-I  Y Y Y 
Apolipoprotein A-II  Y Y Y 
Apolipoprotein A-IV  Y Y Y 
Apolipoprotein C-I  Y Y Y 
Apolipoprotein C-II  Y N N 
Apolipoprotein C-III  Y Y Y 
Apolipoprotein D  Y Y Y 
Apolipoprotein E  Y Y Y 
Attractin  Y Y Y 
Beta-2-glycoprotein 1  Y Y Y 
Beta-actin-like protein 2 Y N N 
Beta-adducin  Y Y Y 
Bleomycin hydrolase  Y Y Y 
C4b-binding protein alpha chain Y Y Y 
C4b-binding protein beta chain  Y Y N 
Calmodulin  Y Y Y 
Calmodulin-like protein 5  Y N N 
Calpastatin  Y Y Y 
Carbonic anhydrase 1  Y Y Y 
Carbonic anhydrase 2  N Y Y 
Catalase  Y Y Y 
CD44 antigen  Y Y Y 
Centrosomal protein of 192 kDa  N Y N 
Ceruloplasmin  Y Y Y 
Clusterin  Y Y Y 
Complement C3  Y Y Y 
Complement C4-B  Y N N 
Complement factor B  Y Y Y 
Complement factor H  N Y Y 
Complement factor I  N Y Y 
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Protein description Present replicate 
1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
Cystatin-A  Y N Y 
Cystatin-S  N Y N 
Cytochrome b5  Y Y Y 
Delta-aminolevulinic acid dehydratase  Y Y Y 
Dematin  Y N Y 
Dermcidin  Y Y Y 
Eukaryotic translation initiation factor 4B  Y N N 
FGA protein  N Y Y 
Fibrinogen alpha chain  Y N N 
Fibrinogen beta chain  Y N N 
Fibrinogen gamma chain  Y Y Y 
Flavin reductase (NADPH)  Y Y Y 
GDP-L-fucose synthase  Y Y Y 
Haptoglobin  Y Y Y 
Hemoglobin subunit alpha  Y Y Y 
Hemoglobin subunit beta  Y Y Y 
Hemoglobin subunit delta  Y Y Y 
Hemoglobin subunit delta (Fragment)  Y Y N 
Hemoglobin subunit gamma-1  Y Y Y 
Hemopexin  Y Y Y 
Histidine-rich glycoprotein  Y Y N 
Hsc70-interacting protein  Y Y Y 
Ig alpha-1 chain C region  Y Y Y 
Ig alpha-2 chain C region  N N Y 
Ig gamma-1 chain C region  Y Y Y 
Ig kappa chain C region  Y Y Y 
Ig kappa chain V-III region NG9 (Fragment)  Y Y Y 
Ig lambda chain V-III region LOI  N Y N 
Ig lambda-7 chain C region  N Y N 
Ig mu chain C region  Y Y Y 
Immunoglobulin J chain  Y Y Y 
Importin subunit beta-1  N Y Y 
Insulin-like growth factor-binding protein complex 
acid labile subunit  
Y Y Y 
Isoform 2 of 14 kDa phosphohistidine 
phosphatase  
Y N Y 
Isoform 2 of Haloacid dehalogenase-like hydrolase 
domain-containing protein 2  
Y N Y 
Isoform 2 of Sushi domain-containing protein 3  Y N N 
Keratin, type I cytoskeletal 10  Y Y Y 
Keratin, type I cytoskeletal 14  Y Y Y 
Keratin, type I cytoskeletal 9  Y Y Y 
Keratin, type II cytoskeletal 1 Y Y Y 
Keratin, type II cytoskeletal 2 epidermal  Y Y Y 
Keratin, type II cytoskeletal 5  Y Y Y 
Keratin, type II cytoskeletal 6A N Y Y 
Kininogen-1  Y Y Y 
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Protein description Present replicate 
1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
Lactotransferrin  Y N Y 
Leucine-rich alpha-2-glycoprotein  Y Y Y 
LIM and SH3 domain protein 1  Y N N 
L-lactate dehydrogenase A chain  Y Y Y 
L-lactate dehydrogenase B chain  Y Y Y 
Low affinity immunoglobulin gamma Fc region 
receptor III-A  
Y N N 
Low affinity immunoglobulin gamma Fc region 
receptor III-A (Fragment)  
N Y N 
L-selectin  Y Y Y 
Lysosome-associated membrane glycoprotein 2  Y Y N 
Lysozyme C  Y Y Y 
Malate dehydrogenase, cytoplasmic  Y N N 
Mitogen-activated protein kinase kinase kinase 14  N Y N 
Myeloperoxidase  Y N N 
Myomegalin  Y N N 
NSFL1 cofactor p47  Y Y Y 
Peptidyl-prolyl cis-trans isomerase A  Y Y N 
Peroxiredoxin-1  N Y Y 
Peroxiredoxin-2  Y Y Y 
Peroxiredoxin-6 N N Y 
Phosphatidylinositol-glycan-specific phospholipase 
D  
N Y N 
Pigment epithelium-derived factor  Y Y N 
Plasma protease C1 inhibitor  Y Y N 
Plasminogen  Y Y Y 
Platelet basic protein  Y Y Y 
Platelet glycoprotein Ib alpha chain  Y Y Y 
Polyubiquitin-C Y N Y 
Probable ATP-dependent RNA helicase DDX60-like 
(Fragment)  
N N Y 
Prolactin-inducible protein  Y Y Y 
Protein 4.1  Y Y Y 
Protein AMBP  Y Y N 
Protein S100-A4  Y Y Y 
Protein S100-A7  Y Y Y 
Protein S100-A8  Y Y N 
Protein S100-A9  Y N N 
Prothrombin  Y Y Y 
Putative nucleoside diphosphate kinase  N Y N 
Quinone oxidoreductase PIG3  Y Y N 
RAD23 homolog B (S. cerevisiae), isoform CRA_a  Y N N 
Ran-specific GTPase-activating protein  Y Y Y 
Retinol-binding protein 4  Y Y Y 
Secretoglobin family 1D member 2  N Y N 
Selenium-binding protein 1  Y Y Y 
Serotransferrin  Y Y Y 
Serum albumin  Y Y Y 
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Protein description Present replicate 
1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
Serum deprivation-response protein  Y Y Y 
SH3 domain-binding glutamic acid-rich-like protein 
3  
Y Y Y 
Spectrin alpha chain, erythrocytic 1  Y Y Y 
Spectrin beta chain, erythrocyte  Y N N 
Spectrin beta chain, erythrocyte (Fragment)  N N Y 
Stathmin  Y Y N 
Stathmin (Fragment)  N N Y 
Stress-induced-phosphoprotein 1  Y N N 
Superoxide dismutase  Y Y Y 
Tetranectin  Y N N 
Thioredoxin  Y Y Y 
Thrombospondin-1  Y N N 
Thyroxine-binding globulin  Y Y Y 
Transaldolase  Y Y Y 
Transthyretin  Y Y Y 
Triosephosphate isomerase  Y Y Y 
Tropomyosin 3  Y N Y 
Tropomyosin alpha-1 chain  N Y Y 
Tubulin-specific chaperone A  Y Y Y 
Uncharacterized protein C13orf33  N Y N 
Uncharacterized protein C9orf40  Y N N 
UPF0587 protein C1orf123  Y Y N 
UV excision repair protein RAD23 homolog A  N Y Y 
Vitamin D-binding protein  Y Y N 
Vitamin K-dependent protein S  N Y N 
Vitronectin  Y N N 
WD repeat-containing protein 1  N Y N 
Xaa-Pro dipeptidase  N N Y 
 
Appendix 5.12 Proteins identified from LC MS/MS analysis of a DBS digest depleted of haemoglobin and the top 12 
plasma proteins. Sample digested for 1 hour. 
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Protein description Present 
replicate 1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
26S proteasome non-ATPase regulatory subunit 9  N Y Y 
Actin, cytoplasmic 1, N-terminally processed  N Y N 
Adenylate kinase 7, isoform CRA_e  Y N N 
Afamin  Y Y Y 
Alpha-1-acid glycoprotein 1  Y Y Y 
Alpha-1-acid glycoprotein 2  Y Y Y 
Alpha-1-antichymotrypsin  Y Y Y 
Alpha-1-antitrypsin  Y Y Y 
Alpha-1B-glycoprotein  Y Y Y 
Alpha-2-HS-glycoprotein  Y Y Y 
Alpha-2-macroglobulin  Y Y Y 
Alpha-adducin  Y Y N 
Alpha-enolase  Y Y Y 
Alpha-hemoglobin-stabilizing protein  Y Y Y 
Alpha-synuclein  Y Y Y 
Ankyrin-1  Y Y Y 
Antithrombin-III  Y Y Y 
Apolipoprotein A-I  Y Y Y 
Apolipoprotein A-II  Y Y Y 
Apolipoprotein A-IV  Y Y Y 
Apolipoprotein C-I  N Y N 
Apolipoprotein C-III  Y Y Y 
Apolipoprotein D  Y Y Y 
Apolipoprotein E  Y Y Y 
Apolipoprotein M  N N Y 
Aspartate aminotransferase, cytoplasmic  N N Y 
Attractin  Y Y Y 
Beta-2-glycoprotein 1  Y Y Y 
Beta-adducin  Y Y Y 
Bleomycin hydrolase  Y Y Y 
Brevican core protein  N Y N 
C4b-binding protein beta chain  Y Y Y 
Calcium-regulated heat stable protein 1  N Y N 
Calmodulin  Y Y Y 
Calmodulin-like protein 5  Y Y Y 
Carbonic anhydrase 1  Y Y Y 
Carbonic anhydrase 2  Y N N 
Caspase-14  N Y N 
Catalase  Y Y Y 
CD44 antigen  Y N N 
Ceruloplasmin  Y Y Y 
Chromodomain-helicase-DNA-binding protein 1-
like  
Y N N 
Clusterin  Y Y Y 
Complement C3  Y Y Y 
Complement C4-B  Y N Y 
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Protein description Present 
replicate 1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
Complement factor B  Y Y Y 
Complement factor I  N N Y 
Cystatin-A  Y Y Y 
Cytochrome b5  Y Y Y 
Delta-aminolevulinic acid dehydratase  Y Y Y 
Dematin  N N Y 
Dermcidin  Y Y Y 
E3 ubiquitin-protein ligase UBR3  N Y N 
Eukaryotic translation initiation factor 4B  Y N Y 
Eukaryotic translation initiation factor 5A-1  Y Y Y 
Fibrinogen alpha chain  Y Y Y 
Fibrinogen beta chain  N Y Y 
Fibrinogen gamma chain  N Y Y 
Filaggrin-2  Y N Y 
Flavin reductase (NADPH)  Y Y Y 
GDP-L-fucose synthase  Y Y Y 
Glyceraldehyde-3-phosphate dehydrogenase  Y Y Y 
Haptoglobin  Y Y Y 
Heat shock protein beta-1  N Y N 
Hemoglobin subunit alpha  Y Y Y 
Hemoglobin subunit beta  Y Y Y 
Hemoglobin subunit delta  Y Y Y 
Hemoglobin subunit delta (Fragment)  Y Y Y 
Hemoglobin subunit gamma-1  Y Y Y 
Hemopexin  Y Y Y 
Histidine-rich glycoprotein  Y Y Y 
Ig alpha-2 chain C region  Y N Y 
Ig gamma-1 chain C region  Y Y Y 
Ig gamma-2 chain C region  Y Y Y 
Ig kappa chain C region  Y Y Y 
Ig kappa chain V-III region NG9 (Fragment)  Y Y Y 
Ig lambda chain V-III region LOI Y Y Y 
Ig lambda-1 chain C regions  Y Y Y 
Ig mu chain C region  Y Y Y 
Ig mu heavy chain disease protein  Y Y Y 
Insulin-like growth factor-binding protein complex 
acid labile subunit  
Y Y Y 
Integrin alpha-IIb light chain, form 1 N Y N 
Inter-alpha-trypsin inhibitor heavy chain H4  N Y N 
Isoform 2 of 14 kDa phosphohistidine 
phosphatase  
Y Y Y 
Isoform 2 of Cullin-associated NEDD8-dissociated 
protein 2  
N Y N 
Isoform 2 of Dipeptidyl peptidase 3  N Y N 
Isoform 2 of Nuclear receptor corepressor 1  N Y N 
Isoform 2 of Spectrin alpha chain, erythrocyte  N N Y 
Isoform 5 of cAMP-specific 3',5'-cyclic 
phosphodiesterase 4A  
N N Y 
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Protein description Present 
replicate 1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
Isoform Short of Laminin subunit gamma-2  N Y N 
Junction plakoglobin  Y N N 
Keratin, type I cytoskeletal 10  Y Y Y 
Keratin, type I cytoskeletal 14 Y Y Y 
Keratin, type I cytoskeletal 16  N Y N 
Keratin, type I cytoskeletal 17  Y Y N 
Keratin, type I cytoskeletal 9  Y Y Y 
Keratin, type II cytoskeletal 1  Y Y Y 
Keratin, type II cytoskeletal 2 epidermal  Y Y Y 
Keratin, type II cytoskeletal 5  Y Y Y 
Keratin, type II cytoskeletal 6A  N Y Y 
Keratin, type II cytoskeletal 6B  Y N N 
Mesoderm induction early response protein 2  N Y N 
Nebulin  N N Y 
NIF3-like protein 1 N Y N 
NSFL1 cofactor p47 Y Y Y 
Peptidyl-prolyl cis-trans isomerase A  N Y Y 
Peroxiredoxin-2  Y Y Y 
Phospholysine phosphohistidine inorganic 
pyrophosphate phosphatase  
Y Y Y 
Plasma protease C1 inhibitor  Y N N 
Plasminogen  Y Y Y 
Platelet basic protein  Y Y Y 
Platelet glycoprotein Ib alpha chain  Y Y Y 
Polyubiquitin-C  Y Y N 
Prolactin-inducible protein  Y Y Y 
Proteasome activator complex subunit 1 Y N N 
Proteasome activator complex subunit 1 
(Fragment)  
N N Y 
Protein 4.1  Y Y Y 
Protein AMBP  Y Y Y 
Protein LZIC  Y N N 
Protein RRP5 homolog  N N Y 
Protein S100-A4  Y Y Y 
Protein S100-A6  Y Y Y 
Protein S100-A7  Y Y Y 
Protein S100-A8  N Y N 
Protein S100-A9  Y Y N 
Prothrombin  Y Y Y 
Putative unconventional myosin-XVB  Y N Y 
Quinone oxidoreductase PIG3  Y N N 
Radixin  N Y N 
Retinol-binding protein 4  Y Y Y 
Roundabout homolog 2  Y N N 
Secretoglobin family 1D member 2 Y Y Y 
Selenium-binding protein 1  Y Y Y 
Serotransferrin  Y Y Y 
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Protein description Present 
replicate 1 Y/N 
Present replicate 
2 Y/N 
Present 
replicate 3 Y/N 
Serum albumin  Y Y Y 
Serum amyloid A-4 protein  N Y N 
Serum deprivation-response protein  Y Y Y 
SH3 domain-binding glutamic acid-rich-like protein 
3  
Y Y Y 
Sialic acid-binding Ig-like lectin 16  Y N Y 
Sodium/potassium/calcium exchanger 3  N N Y 
Solute carrier family 2, facilitated glucose 
transporter member 1  
N Y N 
Spectrin alpha chain, erythrocytic 1  Y Y N 
S-phase kinase-associated protein 1  Y Y Y 
Stathmin  N N Y 
Superoxide dismutase  Y Y Y 
Thioredoxin  Y Y Y 
Thioredoxin domain-containing protein 17  Y N N 
Thyroxine-binding globulin  Y Y Y 
Transaldolase  Y Y Y 
Transthyretin  Y Y Y 
Triosephosphate isomerase  Y Y Y 
Tropomyosin 3  Y N N 
Tropomyosin alpha-3 chain  N Y Y 
Tyrosine-protein kinase FRK  Y N N 
Ubiquitin (Fragment)  N N Y 
Uncharacterized protein C9orf40  Y Y Y 
UPF0587 protein C1orf123  Y Y Y 
UV excision repair protein RAD23 homolog A  Y Y Y 
Vitamin D-binding protein  Y Y Y 
Vitamin K-dependent protein S Y N N 
Vitronectin  N Y Y 
WD repeat-containing protein 1 (Fragment)  N N Y 
Xaa-Pro dipeptidase  Y N N 
Zinc-alpha-2-glycoprotein  Y Y Y 
Zyxin  N Y N 
Appendix 5.13 Proteins identified from LC MS/MS analysis of a DBS digest depleted of haemoglobin and the top 12 
plasma proteins. Sample digested for 8 hours. 
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Appendix 6  
Replicate 1 
MPSSVSWGIL LLAGLCCLVP VSLAEDPQGD AAQKTDTSHH DQDHPTFNKI TPNLAEFAFS  
 
LYRQLAHQSN STNIFFSPVS IATAFAMLSL GTKADTHDEI LEGLNFNLTE IPEAQIHEGF  
 
QELLRTLNQP DSQLQLTTGN GLFLSEGLKL VDKFLEDVKK LYHSEAFTVN FGDTEEAKKQ 
 
INDYVEKGTQ GKIVDLVKEL DRDTVFALVN YIFFKGKWER PFEVKDTEEE DFHVDQVTTV  
 
KVPMMKRLGM FNIQHCKKLS SWVLLMKYLG NATAIFFLPD EGKLQHLENE LTHDIITKFL 
 
ENEDRRSASL HLPKLSITGT YDLKSVLGQL GITKVFSNGA DLSGVTEEAP LKLSKAVHKA  
 
VLTIDEKGTE AAGAMFLEAI PMSIPPEVKF NKPFVFLMIE QNTKSPLFMG KVVNPTQK 
Replicate 2 
MPSSVSWGIL LLAGLCCLVP VSLAEDPQGD AAQKTDTSHH DQDHPTFNKI TPNLAEFAFS  
 
LYRQLAHQSN STNIFFSPVS IATAFAMLSL GTKADTHDEI LEGLNFNLTE IPEAQIHEGF  
 
QELLRTLNQP DSQLQLTTGN GLFLSEGLKL VDKFLEDVKK LYHSEAFTVN FGDTEEAKKQ 
 
INDYVEKGTQ GKIVDLVKEL DRDTVFALVN YIFFKGKWER PFEVKDTEEE DFHVDQVTTV  
 
KVPMMKRLGM FNIQHCKKLS SWVLLMKYLG NATAIFFLPD EGKLQHLENE LTHDIITKFL 
 
ENEDRRSASL HLPKLSITGT YDLKSVLGQL GITKVFSNGA DLSGVTEEAP LKLSKAVHKA  
 
VLTIDEKGTE AAGAMFLEAI PMSIPPEVKF NKPFVFLMIE QNTKSPLFMG KVVNPTQK 
Replicate 3 
MPSSVSWGIL LLAGLCCLVP VSLAEDPQGD AAQKTDTSHH DQDHPTFNKI TPNLAEFAFS  
 
LYRQLAHQSN STNIFFSPVS IATAFAMLSL GTKADTHDEI LEGLNFNLTE IPEAQIHEGF  
 
QELLRTLNQP DSQLQLTTGN GLFLSEGLKL VDKFLEDVKK LYHSEAFTVN FGDTEEAKKQ 
 
INDYVEKGTQ GKIVDLVKEL DRDTVFALVN YIFFKGKWER PFEVKDTEEE DFHVDQVTTV  
 
KVPMMKRLGM FNIQHCKKLS SWVLLMKYLG NATAIFFLPD EGKLQHLENE LTHDIITKFL 
 
ENEDRRSASL HLPKLSITGT YDLKSVLGQL GITKVFSNGA DLSGVTEEAP LKLSKAVHKA  
 
VLTIDEKGTE AAGAMFLEAI PMSIPPEVKF NKPFVFLMIE QNTKSPLFMG KVVNPTQK 
Appendix 6.1 Sequence coverage of A1AT protein obtained from LC MS/MS analysis of DBS digestions from healthy 
human controls. 
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SZ1 
MPSSVSWGIL LLAGLCCLVP VSLAEDPQGD AAQKTDTSHH DQDHPTFNKI TPNLAEFAFS  
 
LYRQLAHQSN STNIFFSPVS IATAFAMLSL GTKADTHDEI LEGLNFNLTE IPEAQIHEGF  
 
QELLRTLNQP DSQLQLTTGN GLFLSEGLKL VDKFLEDVKK LYHSEAFTVN FGDTEEAKKQ 
 
INDYVEKGTQ GKIVDLVKEL DRDTVFALVN YIFFKGKWER PFEVKDTEEE DFHVDQVTTV  
 
KVPMMKRLGM FNIQHCKKLS SWVLLMKYLG NATAIFFLPD EGKLQHLENE LTHDIITKFL 
 
ENEDRRSASL HLPKLSITGT YDLKSVLGQL GITKVFSNGA DLSGVTEEAP LKLSKAVHKA  
 
VLTIDEKGTE AAGAMFLEAI PMSIPPEVKF NKPFVFLMIE QNTKSPLFMG KVVNPTQK 
SZ2 
MPSSVSWGIL LLAGLCCLVP VSLAEDPQGD AAQKTDTSHH DQDHPTFNKI TPNLAEFAFS  
 
LYRQLAHQSN STNIFFSPVS IATAFAMLSL GTKADTHDEI LEGLNFNLTE IPEAQIHEGF  
 
QELLRTLNQP DSQLQLTTGN GLFLSEGLKL VDKFLEDVKK LYHSEAFTVN FGDTEEAKKQ  
 
INDYVEKGTQ GKIVDLVKEL DRDTVFALVN YIFFKGKWER PFEVKDTEEE DFHVDQVTTV  
 
KVPMMKRLGM FNIQHCKKLS SWVLLMKYLG NATAIFFLPD EGKLQHLENE LTHDIITKFL 
 
ENEDRRSASL HLPKLSITGT YDLKSVLGQL GITKVFSNGA DLSGVTEEAP LKLSKAVHKA  
 
VLTIDEKGTE AAGAMFLEAI PMSIPPEVKF NKPFVFLMIE QNTKSPLFMG KVVNPTQK 
SZ3 
MPSSVSWGIL LLAGLCCLVP VSLAEDPQGD AAQKTDTSHH DQDHPTFNKI TPNLAEFAFS  
 
LYRQLAHQSN STNIFFSPVS IATAFAMLSL GTKADTHDEI LEGLNFNLTE IPEAQIHEGF  
 
QELLRTLNQP DSQLQLTTGN GLFLSEGLKL VDKFLEDVKK LYHSEAFTVN FGDTEEAKKQ  
 
INDYVEKGTQ GKIVDLVKEL DRDTVFALVN YIFFKGKWER PFEVKDTEEE DFHVDQVTTV  
 
KVPMMKRLGM FNIQHCKKLS SWVLLMKYLG NATAIFFLPD EGKLQHLENE LTHDIITKFL 
 
ENEDRRSASL HLPKLSITGT YDLKSVLGQL GITKVFSNGA DLSGVTEEAP LKLSKAVHKA  
 
VLTIDEKGTE AAGAMFLEAI PMSIPPEVKF NKPFVFLMIE QNTKSPLFMG KVVNPTQK 
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ZZ1 
MPSSVSWGIL LLAGLCCLVP VSLAEDPQGD AAQKTDTSHH DQDHPTFNKI TPNLAEFAFS  
 
LYRQLAHQSN STNIFFSPVS IATAFAMLSL GTKADTHDEI LEGLNFNLTE IPEAQIHEGF  
 
QELLRTLNQP DSQLQLTTGN GLFLSEGLKL VDKFLEDVKK LYHSEAFTVN FGDTEEAKKQ  
 
INDYVEKGTQ GKIVDLVKEL DRDTVFALVN YIFFKGKWER PFEVKDTEEE DFHVDQVTTV  
 
KVPMMKRLGM FNIQHCKKLS SWVLLMKYLG NATAIFFLPD EGKLQHLENE LTHDIITKFL 
 
ENEDRRSASL HLPKLSITGT YDLKSVLGQL GITKVFSNGA DLSGVTEEAP LKLSKAVHKA  
 
VLTIDEKGTE AAGAMFLEAI PMSIPPEVKF NKPFVFLMIE QNTKSPLFMG KVVNPTQK 
ZZ2 
MPSSVSWGIL LLAGLCCLVP VSLAEDPQGD AAQKTDTSHH DQDHPTFNKI TPNLAEFAFS  
 
LYRQLAHQSN STNIFFSPVS IATAFAMLSL GTKADTHDEI LEGLNFNLTE IPEAQIHEGF  
 
QELLRTLNQP DSQLQLTTGN GLFLSEGLKL VDKFLEDVKK LYHSEAFTVN FGDTEEAKKQ  
 
INDYVEKGTQ GKIVDLVKEL DRDTVFALVN YIFFKGKWER PFEVKDTEEE DFHVDQVTTV  
 
KVPMMKRLGM FNIQHCKKLS SWVLLMKYLG NATAIFFLPD EGKLQHLENE LTHDIITKFL 
 
ENEDRRSASL HLPKLSITGT YDLKSVLGQL GITKVFSNGA DLSGVTEEAP LKLSKAVHKA  
 
VLTIDEKGTE AAGAMFLEAI PMSIPPEVKF NKPFVFLMIE QNTKSPLFMG KVVNPTQK 
ZZ3 
MPSSVSWGIL LLAGLCCLVP VSLAEDPQGD AAQKTDTSHH DQDHPTFNKI TPNLAEFAFS  
 
LYRQLAHQSN STNIFFSPVS IATAFAMLSL GTKADTHDEI LEGLNFNLTE IPEAQIHEGF  
 
QELLRTLNQP DSQLQLTTGN GLFLSEGLKL VDKFLEDVKK LYHSEAFTVN FGDTEEAKKQ  
 
INDYVEKGTQ GKIVDLVKEL DRDTVFALVN YIFFKGKWER PFEVKDTEEE DFHVDQVTTV  
 
KVPMMKRLGM FNIQHCKKLS SWVLLMKYLG NATAIFFLPD EGKLQHLENE LTHDIITKFL 
 
ENEDRRSASL HLPKLSITGT YDLKSVLGQL GITKVFSNGA DLSGVTEEAP LKLSKAVHKA  
 
VLTIDEKGTE AAGAMFLEAI PMSIPPEVKF NKPFVFLMIE QNTKSPLFMG KVVNPTQK 
 
Appendix 6.2. Sequence coverage of A1AT from SZ and ZZ genotype DBS digestions obtained from untargeted data 
dependent LC MS/MS analysis 
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